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Abstract
Introduction
Cambodia suffers very high rates of tuberculosis (TB). In 1994, Hospital Direct Observed 
Treatment (DOT), as recommended by WHO, was introduced. In 2002 ambulatory or 
health center DOT (HC-DOT) was implemented, requiring patients to come to the HC to 
take medicine with HC staff during the intensive phase. In 2005, community-based DOT 
(CDOT), using health volunteers in their own community, was implemented in some 
areas. This study compares CDOT and HC-DOT in terms of treatment success, case 
notification and acceptability.
Methods
This thesis includes a systematic review and meta-analysis of studies comparing CDOT to 
HC-DOT and Family-DOT; a controlled before-after quantitative study of the 
introduction of CDOT (1067 participants in 48 HCs with all TB forms were surveyed at 
the baseline in 2002/2003, as were 1297 in 2006/2007 two years after its introduction); 
and a qualitative study assessing its strengths, weaknesses and acceptability to HC staff, 
patients and CDOT watchers.
Results
The meta-analysis from the systematic review shows that CDOT was at least as effective 
as HC-DOT (RR=1.05, Cl: 1.01-1.10), and treatment of smear-positive patients treated by 
CDOT is clearly better than for family-DOT (OR=1.33, Cl: 1.20-1.48)
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The quantitative study shows that in Cambodia the treatment success rates of patients 
treated with CDOT and HC-DOT are similar (OR=1.26, 95% Cl: 0.56-2.82). In the 
CDOT areas, the death rate among all TB patients was significantly reduced after its 
implementation (OR=0.37, 95%CI: 0.15-0.92)
Most participants in the qualitative study felt CDOT was helpful particularly for very sick 
patients, and because it reduced travel costs and allowed patients to continue working. 
There was significant involvement of family members in both approaches.
Conclusion
CDOT is as effective as HC-DOT for treatment success and case finding. Both 
approaches are well accepted. There remain problems which need to be addressed in 
order to improve outcomes.
3
Doctorate in Public Health Integrating Statement
The research degree Doctorate in Public Health (Dr.PH) at London School of Hygiene 
and Tropical Medicines (LSHTM) aims to provide candidates with access to a wide range 
of skills and experience in various disciplines related to public health management and 
research. There are three components which are required for Dr.PH candidates.
1. Taught courses on leadership and management, systematic reviews, research 
methodologies, how to transfer policies into practice and various study units selected by 
individual candidate. All are examined.
2. A Professional Attachment (PA) in an institution related to the candidate’s 
particular interest. The purpose of the PA is to provide the candidate with understanding 
of leadership and management, the organizational structures in public health 
organizations, and in particular to show that the candidate has developed an extensive 
understanding as a public health person as well as a policy maker. The PA is 
accomplished with a marked report.
3. The final component is a research project that leads to a dissertation. This is 
designed to contribute to knowledge of the topic through the individual candidate’s 
thought and analysis.
This dissertation continues from my Master thesis on “how to improve TB case detection 
rates in Cambodia” at Boston University, United States. My main interest is in TB and in 
particular how to extend TB treatment to patients who live in remote areas. The taught 
courses, including on systematic reviews, research methodology and design, and getting 
results into policy and practice, allowed me to understand the fundamentals of research.
4
The course in public health leadership and management provided me with the abilities 
and instruments for my personal management development.
Between September 2005 and March 2006 I carried out a Professional Attachment (PA) 
to the Cambodian National Public Health Promotion Department in Phnom Penh, 
Cambodia. The aim of the PA was to identify the organizational structure, and to examine 
how staff are organized and how decisions are made in the context of public health. For 
the PA I used qualitative methods including both formal and informal interviews with 
staff at all levels, and observation of interactions during meetings between staff within all 
units. By analyzing the transcripts of interviews and notes from the observation, I gained 
new skills in methods of qualitative data and analysis. The PA enabled me to expand my 
knowledge and perspective of organizational management, leadership and the process of 
decision making, in a public health organisation.
During my PA, I discussed many issues relating to health activities and programmes with 
staff at the Ministry of Health. Between 2005 and 2006 the NTP started to implement 
CDOT with the main purpose of increasing TB case detection rates and maintaining 
treatment success rates, and in particular improving patients’ adherence to treatment. I 
was interested to know how effective of the new CDOT was compared with the existing 
ambulatory DOT in Cambodia. In developing the methodology for my research, it was 
interesting for me to conduct the systematic review to see how the effectiveness of CDOT 
compared to alternative DOT options in different settings. I also carried out the 
qualitative study in this research, because I wanted to explore what patients, staff, and 
DOT watchers think of CDOT and ambulatory DOT, in particular how both DOT 
approaches work in the field.
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Working for the Dr.PH degree has been very important to me; it has brought me new 
skills such as leadership and management in the public health field, and expanded my 
understanding of public health within the academic scientific structure. In particular it is 
enabling me to take a role in policy and decision making.
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Definition of terms
•  Hospitalized DOT (this is neither CDOT nor HC-DOT): treatment in which patients 
swallow TB drugs in the hospital under the direct observation of health workers (HWs) 
during the intensive phase of treatment.
•  Ambulatory DOT (HC-DOT): treatment in which non-hospitalized patients swallow 
TB drugs at the health facility under direct observation of HWs. Patients attend the health 
facility every morning during the intensive phase of treatment.
•  DOT at home: this is a type of community based DOT in which treatment takes place 
at the patient’s house under the direct observation of HWs or an instructed person during 
the intensive phase of treatment. DOT at home is sub-divided into “DOT at home by 
health worker” and “DOT at home by community member” called Community DOTS.
•  Community DOT (CDOT): forms part of DOT at home, whereby TB patients stay in 
their community during treatment and receive DOT from a person selected from the 
community, who is not a health worker. These individuals are called DOT watchers or 
DOT observers.
•  Multi-drug resistant patient: a patient resistant to at least two TB drugs which are 
Rifampicine and Isoniazide
Source: Guidelines on Community DOTS Implementation. NTP, Cambodia
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1 CHAPTER 1: Background and Rational
This chapter introduces the international recommended strategy for TB control known as 
DOTS, and discusses the effectiveness of directly observed treatment (DOT), and the 
contribution of the community in TB care. It also describes the background for the 
research in the context of the epidemiology of TB, the impact of TB, the health care 
system and the national TB control programme in Cambodia.
1.1 Global tuberculosis burden
Tuberculosis (TB) is one of the leading causes of adult mortality (Dye C and al 1999). It 
is estimated that 32% of the world’s population has been infected with TB (Borgdorff 
MW, Nagelkerke NJ et al. 1999), and between 8.5-9.2 million TB cases were estimated in 
2010 (WHO 2011). It is estimated that globally around 1.1 million deaths caused by TB, 
it was equivalent to 15 deaths per 100 000 population in 2010 (WHO 2011).
More than 90% of these global TB cases and deaths occur in the developing world, where 
75% of cases are found among the most economically productive age group (15-54 
years). Each year, about 80% of all new cases occur in Africa and Southeast Asia (Dye C 
and al 1999). Because HIV significantly increases the risk of developing TB (Narain JP, 
Raviglione MC et al. 1992), the number of TB cases will be larger in countries with a 
high prevalence of both diseases (Msamanga GI and Fawzi WW 1997). According to 
WHO, in 2010 there were around 0.35 million deaths among people who were HIV­
positive (WHO 2011).
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In addition, multi-drug resistance TB (MDR-TB), which is exacerbated or caused partly 
by poorly managed TB treatment, is a growing problem in many countries (Dye C and al 
1999) . In 2010, 650 000 cases of MDR-TB were reported among the world’s 12.0 
million prevalent TB cases (WHO 2011)
1.2 DOTS TB control strategy
Recognizing an urgent need to deal with these problems, in 1993 the World Health 
Organization (WHO) declared TB to be a global emergency and developed a cost- 
effective health intervention to fight the disease (WHO 1994; WHO 2002), the DOTS TB 
control strategy (Enarson D A, Rieder H L et al. 2000). This strategy has been reported to 
be successful in both developed and developing countries including the United States 
(Bayer R, Stayton C et al. 1998), Bangladesh (Chowdhury A M R  1997), China 
(Programme 1996), and South Africa (Wikinson D 1994). In addition, DOTS has been 
shown to be highly cost-effective (Baltussen R 2005).
DOTS combines five elements that must be fully implemented to achieve effective TB 
control: 1) A government commitment to sustained TB control activities; 2) Case 
detection through bacteriological examinations of patients with respiratory symptoms 
attending primary health care units; 3) A standardized treatment regime of six to eight 
months for at least all sputum smear positive cases, with directly observed therapy (DOT) 
for at least the initial two months; 4) Securing a regular, uninterrupted supply of all 
essential anti-TB drugs; and 5) A standardized recording and reporting system, allowing 
monitoring and evaluation of treatment results (WHO 2006). The DOTS strategy focuses 
on two operational targets which are promoted by WHO: detection of at least 70% of the 
new smear-positive TB cases and cure of at least 85% of these cases (WHO 1994;
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Enarson D A, Rieder H L et al. 2000; WHO 2002). According to WHO estimates, with 
direct observation of treatment it is anticipated that the number of contacts infected would 
be reduced by 40%, and 80% of deaths attributed to TB worldwide would be prevented 
(Myer CS 1996). By the end of 2004, 83% of the world’s population lived in the countries 
covered by DOTS (WHO 2006), and today more than 30 million patients with TB have 
been treated with DOTS, resulting in cure rates of more than 80%. However, case 
detection has remained low at 42% in 2003 (Dye C 2003), but has increased steadily over 
the years. By the end of 2006, the case detection rate for new-smear positive cases 
reached 61% (WHO 2008), and it is estimated that it will reach the target of 70% in 2012 
if all national TB control programmes (NTPs) are fully implementing DOTS (Dye C 
2002; Dye C 2003).
However, a key problem in TB control still remains, which is how to encourage patients’ 
adherence to treatment. Adherence requires many components such as appropriate health 
care, including diagnosis and information about their disease, accessible health care, 
including drugs supply and help to complete the treatment (CDC 1993).
1.3 The effectiveness of Directly Observed Therapy (DOT)
Directly Observed Therapy (DOT) as already stated above aims to decrease the risk of TB 
infection by increasing treatment adherence and thus cutting the chain of transmission, 
reducing morbidity and mortality, and preventing the development of drug resistance 
(Dye C 1998; Enarson D A, Rieder H L et al. 2000). Initially, DOT was implemented in 
the setting of the hospital or clinic. The advantage of clinical settings is that patients can 
be closely monitored by staff which may encourage adherence (Sumartojo 1993). 
However, the effectiveness of implementation in hospitals and clinics has been
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questioned, especially for those badly affected by HIV-related TB in sub-Saharan Africa 
(WHO 2003). According to the qualitative review by Munro S at al 2007 (Munro S, 
Lewin. S et al. 2007), for patients on DOT who live near to hospitals or clinics, the time 
needed to be present for direct observation for a full course of treatment is not necessarily 
a significant barrier, as clinics are easily accessible to them. However, in areas where 
patients live far from the hospital or clinic, lack of transportation, cost of travel, the 
inconvenience of the treatment time, the challenge of disabilities and travel, and time lost 
from attending daily tasks, were stated as posing barriers. Moreover, other qualitative 
studies have reported that discrimination against TB patients can be a problem, and some 
patients resist going to collect their drug supplies at clinics because of discriminatory staff 
behavior (Steen TW 1999); also women have reported issues of safety while travelling, as 
well as the stigma of visiting a clinic for treatment (Khan M 2005).
The Cochrane systematic review of randomised controlled trials (RCTs) of the 
effectiveness of DOT for TB treatment by Gamer and Volmink showed no significant 
difference between type of DOT and self-supervision at home (Volmink J and Gamer 
2003; Gamer P and Volmink 2007). Garner and Volmink also noted in this review that 
DOT is also often difficult to implement and requires a great deal of effort from both 
patients and health care providers through regular attendance at the health center 
(Volmink J and Gamer 2003). However; in 2007, Noyes and Popay conducted a 
systematic review of qualitative research focusing on lay experiences and perceptions of 
TB treatment (Noyes J and Popay J 2007). They concluded that the effectiveness of TB 
control program cannot be judged by DOT itself. They confirmed reports that barriers to 
accessing and complying with treatment depend on the factors discussed below in section 
1.4, and that DOT could have the most negative impacts on the poorest patients who had
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the most to lose from loss of earnings because of the need to attend for treatment and to 
pay of transport, who had the most to fear from disclosure of the disease, and who were 
most at risk of TB stigmatization. They concluded that DOT was least effective when the 
primary focus was on direct observation itself rather than on the supportive nature of 
treatment (Noyes J and Popay J 2007).
The key challenge of DOT is to implement it well, maximizing the convenience to and 
respectful interaction with patients, recognizing that DOT is necessary both to fulfill 
society’s obligations to care for individual patients effectively, and to protect the rest of 
society by preventing the development and spread of TB, including drug-resistant strains.
1.4 Tuberculosis and adherence to the treatment
Drugs for TB have been available since the 1940s, yet three million people a year 
continue to die from it, with those in low income countries at high risk of death (Netto 
EM 1999). TB treatment is long and intensive, lasting at least six to eight months, and the 
side effects are often severe including vomiting, loss of appetite and insomnia. This can 
lead to poor adherence, with WHO reporting in 2012 that globally about 0.4 million cases 
of diagnosed TB have treatment changed to a retreatment regime, because their previous 
treatment has failed or defaulted (WHO 2012).
The qualitative systematic review by Munro et al in 2007 (Munro S, Lewin. S et al. 2007)
reported poor adherence caused not only by the side effects of drugs, but by other factors
such as problems at health facilities including long waiting times, lack of privacy for
patients, and the absence of staff during patients’ visits. Poor relationships between
patients and staff, inadequate follow-up by staff, and maltreatment by providers resulting
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in non-adherence, has also been reported from different settings (Munro S, Lewin. S et al. 
2007). The distance and availability of transport as well as the physical condition of the 
patient, are key issues for patients’ adherence; patients cannot attend regularly if their 
homes are far from the health center (Munro S, Lewin. S et al. 2007). Poverty and 
disadvantageous circumstances influence the decision to seek and continue treatment. 
Poor patients are less able to give up work or risk the loss their jobs in order to come for 
treatment at health facilities (Noyes J and Popay J 2007). Moreover, the issue of TB 
stigmatization is a key factor resulting in non-adherence; patients say they are reluctant to 
find or come back for treatment, as they wish to keep the diagnosis and treatment secret 
(Munro S, Lewin. S et al. 2007; Noyes J and Popay J 2007). The review by Noyes and 
Popay (Noyes J and Popay J 2007) has stated that poor adherence is also caused by lack 
of financial and social support from family members or friends, and women are more 
likely than men to experience negative family attitudes and are less likely to receive 
financial support. With low adherence, not only does TB remain uncured, but it can cause 
prolonged infectiousness, relapse of TB, multi-drug resistance (MDR-TB) and death. 
Poor adherence not only increases the health risk for the individual, but also for the 
community. In 2010, 290 000 cases of MDR-TB were estimated to exist among patients 
with pulmonary TB world-wide (WHO 2011).
1.5 Community-based direct observation treatment (CDOT)
Because of poor adherence; WHO has recommended expanding DOT from health 
facilities into communities, by engaging members of the community such as health 
workers, health volunteers and neighbors as DOT supporters in providing community- 
based DOT, with the aims of reducing mortality rates due to TB by decreasing the
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distance between providers and patients, and thus removing some of the barriers to 
treatment compliance (Maher D 1999; WHO 2003).
The involvement of the community in TB care can promote access to effective TB 
services by bringing the delivery of health services as close as possible to those who need 
them, and by extending access to TB care to the poor, who need it most, so help reduce 
the TB mortality rate (Maher D 1999; WHO 2003). Community involvement in TB care 
is clearly a contribution to, and not a substitute for other national tuberculosis programme 
activities. Communities have contributed to TB services by supervision of treatment 
under DOT; patient support groups for the support and motivation of patients; and 
community education, so as to increase community awareness of the disease and its 
treatment.
Many non-randomised controlled trials have been conducted especially in developing 
countries including in sub-Saharan Africa, to investigate the community involvement in 
DOT programs. These studies have shown that involvement of the community in DOT 
can encourage patients to complete the treatment and can increase the accountability of 
local health services to the community (Hadley M and Maher 2000; Maher 2003; Maher 
D 2003). Based on these studies WHO encouraged the national TB programs, health care 
providers and communities to work together to increase community involvement in TB 
care, particularly DOT. The Global Plan to Stop TB expected that all developing 
countries, especially countries in Africa, would have scaled up community-based DOT, 
known as CDOT (WHO 2006 PART III).
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The method of implementation of CDOT varies from study to study and between 
countries. Some countries have implemented CDOT to maintain high cure rates and to 
increase case identification, while others have implemented CDOT to improve adherence 
to treatment and to reduce the work load in the health facilities. The CDOT programs also 
vary in other characteristics such as the choice of a community supervisor. Some 
programs use health workers and health volunteers as DOT supporters, while others 
utilize patients’ neighbors or family members. There are questions concerning the choice 
of community supervisors; some programs consider that family members can be DOT 
supervisors, whereas others regard family observation as a seductive but risky concept 
(Frieden TR and Sbarbaro 2007).
This aim of the current study, conducted in Cambodia, was to compare the outcomes of 
health center-DOT and community-based DOT in terms of case finding and treatment 
success, to determine the strengths and weaknesses of each, and to assess the relative 
acceptability of health center and community-based DOT to patients, health center staff 
and DOT watchers. The background for this study is described in the next section.
1.6 Country setting
1.6.1 Cambodia
Cambodia is an agricultural country of 181,035 square kilometers situated on the South­
western Indo-Chinese Peninsula in Southeast Asia. It is bounded by Thailand, Vietnam, 
and Lao People’s Democratic Republic. Cambodia comprises 24 provinces and 
municipalities, 183 districts, 1600 communes, and 13 406 villages. (Figure 1)
35
Figure 1: Map of Cambodia
According to the 2010 census, the total population is about 15 million, with 80% of the 
population living in rural areas and the remaining 20% in urban areas. It is estimated that 
the proportion of children less than 15 years is 42.8% and 51.8% of the population is 
female. The majority of the population is ethnic Khmer by ethnicity and Buddhist by 
religion (NISS2010).
1.6.2 The health care system in Cambodia
Since 1994, the Ministry of Health has been committed to reorganizing the health system, 
placing an emphasis on the district level (MoH 1997). The system reforms, which focus 
on delivering essential health services to rural areas where the majority of the population 
live, have led to the establishment of “Operational health Districts (ODs)” comprising a 
referral hospital (RH) and a network of around 10 health centers (HCs). HCs provide the
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basic health needs of the majority of the population and serve a catchment area of 
approximately 10 000 people living in 2-3 communes of about 5-10 villages each (MoH 
2007).
Each HC provides a basic integrated package of health care services referred to as the 
Minimum Package of Activities (MPAs). These services comprise basic preventive, 
promotive and curative care, including prenatal care, immunization, birth spacing, 
prevention of micronutrient malnutrition, and treatment of diarrhea and acute respiratory 
infection as well as TB. The referral hospital (RH), for its part, receives cases referred 
from the HCs and manages complicated cases, operations, serious illnesses requiring 
admission, and inpatients. These services are called the Complementary Package of 
Activities (CPAs) (MoH 2007).
Based on the 2010 Cambodia MoH report, in 2009, there were 8 national hospitals, 77 
operational districts, 79 referral hospitals, 984 HCs and 111 health posts within the 24 
provinces (MoH 2010).
1.7 TB epidemiological context in Cambodia
Cambodia ranks 21st on the list of 22 countries which have the highest burden of
tuberculosis (TB) in the world (WHO 2002); it is estimated that approximately 64% of
the total population has been infected with TB (WHO 2000) and a substantial number of
cases remain undetected. As of 2010, there were 41,628 new TB cases notified in
Cambodia (WHO 2011); the estimated incidence rate of all forms of TB was 437 cases
per 100,000 population and the prevalence rate of TB was 660/100,000 population (WHO
2011). The mortality rate from TB was 61/100 000 population in 2010 (WHO 2011).
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TB continues to be among the major public health problems in the country mainly due to 
the HIV/AIDS epidemic in Cambodia. The number of notified TB cases increased from 
8,000 in 1982 to about 41,628 in 2010 (MoH 2010). Since the Ministry of Health was re­
established in 1980, TB notification rates slowly increased until about 1991, after which it 
started gradually to rise, especially the notification rates of smear positive TB. The 
current number of TB cases notified is estimated to be at the peak. It should also be noted 
that the increase is partly due to better diagnosis and case reporting. Figure 2 shows the 
TB case notification rates in Cambodia over approximately the past thirty years.
Figure 2: TB case notification (per 100 000 population) from 1982 to 2010
TB Cases Notification, 1982-2011
Source: National Tuberculosis Control Program in Cambodia (MoH 2010)
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1.7.1 HIV-TB Co-infection in Cambodia
As noted, Cambodia is among the countries with a high incidence of combined TB and 
HIV/AIDS. The prevalence of HIV among people with TB increased drastically from 
2.5% in 1995 to 10% in 2005 (MoH 2005), but has since fallen to 7.8% in 2007 and 
6.3% in 2009 (MoH 2010). In 2010, 32,236 TB patients with known HIV status were 
reported (WHO 2011). Figure 3 shows the trend of prevalence of people with HIV among 
TB patients.
Figure 3: The Prevalence of people with HIV/AIDS among TB patients from 1995- 
2009
Trend in HIV Sero-prevalence among TB patients
Source: National Tuberculosis Control Program in Cambodia (MoH 2010)
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1.7.2 Multi-drug Resistance TB (MDR-TB)
MDR-TB is not a significant problem in Cambodia. According to the NTP survey in 
2009, only 1.6% of the new TB cases were MDR-TB. The survey showed that by the end 
of 2010, 136 patients were registered and treated for MDR (MoH 2010).
1.8 The economic impact of TB in Cambodia
According to NTP around 62,000 people were estimated to suffer from TB and almost 
9,000 Cambodians with TB died in 2010 (MoH 2010). The impact of TB on individuals 
includes not only physical health, but also economic, social and mental health. The 
economic impact may include negative effects on households and the country. 
Tuberculosis is considered a chronic disease because it requires at least six months 
treatment. Thus, the disease can drive people into deep poverty especially among 
households with incomes already below the poverty line. On average a TB patient loses 3 
to 4 months of work time during the period of treatment and this may result in the loss of 
up to 20-30% of income in the TB patient’s household income (WHO May, 2002).
This has not only negatively influenced individual families but also communities, and 
even national economic growth is affected due to the loss of output of the country’s 
labour force (Nhem CheaBunly and Myers 2002). Tuberculosis further aggravates 
poverty because it drains national resources to fight it. Furthermore, due to lack of funds, 
Cambodia has to borrow money from outside sources such as from the World Bank. Thus 
TB contributes to creating national debt (Nhem CheaBunly and Myers 2002).
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1.9 The National Tuberculosis (and Leprosy) Programme in Cambodia 
1.9.1 DOTS Strategy
Nearly three decades of chronic internal conflict seriously damaged the health system in 
the country. The number of people with TB increased due to the poor health care system 
and living conditions were often unhygienic during this period. Recognizing an urgent 
need to deal with the catastrophic effects of TB, Cambodia’s government -  through the 
Ministry of Health, the National Tuberculosis Control Program (NTP) was initiated in 
1980 with its main goal being to improve the health of the Cambodian people through the 
reduction in morbidity and mortality rates due to TB. Despite the fact that the NTP was 
fully committed to the TB intervention programme such as increasing TB awareness and 
providing health education to the general population for reducing the death due to TB, the 
NTP was not fully effective; for example in 1980s the cure rate for smear positive cases 
was only 69% and the case detection rate just 44% (MoH 2001).
In 1994, the DOTS strategy was introduced and adopted by the Ministry of Health. The 
treatment approach used at that time was mainly “hospitalization” DOT. Since 1995, the 
NTP has attained and maintained the objective of obtaining more than an 85% cure rate 
of infectious cases. For example, the cure rates for smear positive cases were 85% in 
1995, 89% in 2001, 90% in 2005, 93% in 2007 and 95% in 2010 (MoH 2010). However, 
the case detection rate has remained relatively low (65% in 2010) compared to the 70% 
WHO target, and the prevalence (660/100 000 population) and incidence of TB in 
Cambodia is still among the highest in the world (WHO 2011).
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Over the last decade, the burden of TB has increased in Cambodia due to human 
immunodeficiency virus infection. This could lead to an increased burden on the health 
services because of the associated morbidity and mortality. This may lead to health 
service exhaustion and forces patients to attend health centers often. In Cambodia, 
improving health service coverage and increasing the number of health workers to 
decrease workloads in health centers and reduce patients’ cost seems a distant possibility.
In 2002, the NTP was decentralized into existing HCs supported by a vertical component 
of expertise in management, capacity building, monitoring and evaluation at national and 
provincial level. At the national level there are now three structures: the NTP 
headquarters, the TB referral hospital offering clinical and para-clinical TB services, and 
the National TB reference laboratory. At the provincial level, TB units and HC are 
responsible for program planning and management including training and supervision 
(MoH October, 2006). The structure of TB control in Cambodia is shown in Figure 4.
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Figure 4: Structure of TB control in Cambodia
Source: National Tuberculosis Control Program (NTP), Cambodia (MoH 2010)
1.9.2 DOT implemented in Cambodia
Directly observed therapy for TB is one component of the DOT strategy, which requires 
someone to observe patients taking medicines everyday during the treatment. In 
Cambodia, today, there are three main DOT approaches: 1) Hospitalization DOT which 
requires patients to stay in a hospital for taking medication in the intensive phase, 2)
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Ambulatory DOT which requires patients to come to a health facility to swallow drugs 
during the intensive phase, 3) and DOT at home, including community DOT, which uses 
the patient’s home for observed taking of medication for six months treatment. In 
Cambodia, the ambulatory DOT requires patients to attend the HC taking medicines 
during the intensive phase and allows patients taking medicines with DOT watchers at 
home or community, which is different from the WHO recommendation that requires 
patients to come taking medicines at the HC for six months. More details are shown in the 
definition of terms at the beginning of the thesis. By the end of 2010,75 referral Hospitals 
and 960 HCs were implementing DOT. Moreover, the hospital DOT is still used for about 
10%-20% of all TB patients for re-treatment, and severe and multi-drug resistant patients 
(MoH 2010).
1.9.3 TB case finding and treatment under DOTS in Cambodia
TB diagnosis within the DOT strategy relies on passive case finding in which patients 
present themselves to a hospital or health center once they suspect themselves of having 
symptoms of TB. Every TB suspect is required to provide three sputum samples for TB 
diagnosis. Patients are taken to be tubercular if any of two sputum specimens are positive 
for Acid Fast Bacilli (AFB). Chest X-ray is rarely performed and is only available at a 
few hospitals in the cities due to its high cost. Diagnosis of smear negative and extra- 
pulmonary TB patients follows a clinical algorithm (MoH October, 2006).
TB treatment is mainly through hospitalized DOT and ambulatory DOT within the 
country. The duration for treatment is six months with Rifampicin, Isoniazid, 
Pyrazinamid, as well as Ethambutol during the first two month intensive phase (MoH 
2010).
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Under the ambulatory DOT, TB patients have to come to the health facility daily in the 
morning for two months for direct observation of treatment, supervised by the health 
facility staff. Follow-up of patients is done by checking sputa for AFBs after two months 
of treatment, after five months and at the end of the treatment period (MoH 2001; MoH 
2010; MoH October, 2006).
1.10 Statement of the problem
It is more than eighteen years since the NTP implemented the DOT strategy in Cambodia. 
Experience from this programme implementation for nearly two decades showed the 
following findings. In the first five years, the DOT strategy was delivered mainly through 
hospital DOT. The case detection rate and cure rate increased compared with the previous 
implementation. However, this implementation did not completely reach its target due to 
many patients failing to adhere to treatment.
In 2002, the DOT program expanded from hospitals to HCs which implemented 
ambulatory DOT. This required patients to attend a HC everyday for the intensive phase 
to take TB medication under the observation of HC staff. This approach was more 
acceptable to patients because they could return to their families and continue to work. 
However, it did not completely address the issue of acceptability or affordability for 
people living far from a HC. It also increased the social costs to the patient, and the 
economic burden on the family, and may discourage adherence to treatment (Munro S, 
Lewin. S et al. 2007).
Although the application of the DOT strategy enables Cambodia to achieve and maintain
the treatment success rate of 95% and reduce mortality rate in the country, many issues
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still exist. It is possible that whereas DOT coverage is 100% in the urban areas, the 
problem of accessibility still exists in remote areas, especially for those which are far 
from the city or from health facilities. Information on DOT services in the country is still 
sparse and due to weak health management or minimal information, many TB patients are 
unaware of the services and NTP may be detecting only patients living near the health 
facilities (Suchi M and Tateno 2002).
As recommended by the WHO, community-based DOT has been introduced into 
Cambodia by the NTP in collaboration with Non Governmental Organizations (NGOs) 
and piloted in some rural areas in Cambodia since 2004. Community-based DOT (CDOT) 
was established to improve case finding through referral of TB suspects by communities, 
to improve adherence to treatment, to improve TB case management, and to reduce the 
financial burden for patients and their families. CDOT requires community support by 
volunteer workers who are properly trained and who are regularly supervised by staff 
from the referral health facility and/or staff from the NTP. They also have the task of 
providing medicines and other supplies such as sputum containers, recording and 
reporting material and information on TB knowledge (MoH 2004).
Various community DOT models have been implemented in different settings by using
different types of DOT supervisors to complement health center-based DOT (HC-DOT)
(David W and Geraint 1997; Colvin M 2003; Singh A.A 2004; Wandwalo E 2004; Clarke
M 2005). However, the key question that remains is who is an appropriate and suitable
community DOT supervisor and how can the motivation and sustainability of these
projects in a resource constrained setting be maintained, without compromising the
quality of TB control. Some places have used community health workers and chiefs of the
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village as the DOT supervisors (Becx-Bleumink M 2001; Kironde S and Kahirimbanyi 
2002; Dudley L 2003; Cavalcante S.C 2007) while others have used friends, neighbours, 
family members (Boogaard van den J 2009; Zimbisayi Zvavamwe and Ehlers 2009) and 
former TB patients (Demissie M 2003). There is variation in TB treatment supervision 
from place to place and the challenge remains to determine what sort of supervision is 
best in different settings because it could affect patients’ adherence to treatment.
Since CDOT was established in Cambodia, there have been only two evaluations (Khieu 
K 2007; Frances Daily and Men July, 2004). In 2004, a cross - sectional study of CDOT 
was undertaken in three provinces in Cambodia (Frances Daily and Men July, 2004). The 
study reported that all CDOT pilot areas showed an increase in TB case detection rates 
and that patients were extremely satisfied with the ability to receive treatment within their 
communities. In addition, it reported that in some areas, DOT watchers were involved in 
providing drugs and in observing patients taking their medication only in the first two 
months of treatment (Frances Daily and Men July, 2004). This study did not assess 
treatment outcomes in the areas where CDOT was piloted. Furthermore, the study did not 
show by how much the case detection rate was increased compared to the rate before the 
pilot study. Another 2007 study used a cohort design with retrospective data, and was 
conducted in two ODs in order to compare the results of TB treatment between HC-DOT 
and CDOT (Khieu K 2007). The study suggested that CDOT was as effective as HC- 
DOT: no significant difference in cure rates was found between HC-DOT (90.2%) and 
CDOT (92.5%) for people with smear positive TB. However no description was given of 
how the CDOT was implemented, there was no description of who the DOT watchers 
were, and the methodology of the study has several potential limitations including the 
study design, as the data was collected retrospectively without a control group, and the
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sample size was small (n= 1269 patients). The authors did not report where the data came 
from, and did not include the new TB case finding after CDOT was implemented.
The implementation of CDOT varies between countries, and its operation in Cambodia in 
terms of structure and sponsors has never been studied, particularly in rural areas where 
the infrastructures are weak and resources limited. Thus, there has not been a systematic 
scientific study of how successful the implementation of CDOT is in terms of case 
notification and treatment outcome within the areas of applied CDOT and the concepts 
and experiences of people and community using CDOT.
For this reason, the purpose of this research is to examine how CDOT differs from the 
health facilities approach in terms of their working structures and the results they 
produce, including treatment success and case notification. The research uses two 
approaches. The first is a quantitative study that was designed as a controlled before-after 
introduction of CDOT to compare the outcomes of health center DOT (HC-DOT) and 
CDOT in terms of case finding and treatment success. The second approach is a 
qualitative study to explore how HC-DOT and CDOT are functioning, to determine their 
strengths and weaknesses, and to assess the acceptability of community and health centre 
based DOT to health centre staff, TB patients and DOT watchers.
1.11 Research Team
The author of this study (a Dr.P.H Candidate) was responsible for the research project, 
including the methodology design, the implementation of the research, directing research 
assistants for data collection, conducting in-depth interviews for qualitative study, 
double—checking data entry, and analysis, the documentation and interpretation of the
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findings, the discussion, conclusions and recommendations, as well as the reporting and 
dissemination of the findings.
Ten research assistants were employed to help with the quantitative data collection of the 
main study. One statistician, who works at the National Institute of Statistics in the 
Ministry of Planning, helped with the data cleaning and data entry for the quantitative 
study. In addition, one doctor who works at the National Institute of Public Health 
(NIPH) helped with data re-entry and guided the author for the quantitative analysis. One 
note taker from the NIPH was employed for the in-depth interviews.
The main supervisors from the London School of Hygiene and Tropical Medicine 
(LSHTM), Professor Joy Townsend, Professor Mark Petticrew and Dr. Simon Lewin 
(Norwegian Knowledge Centre for the Health Services, Oslo) provided the author with 
guidance and support throughout the project.
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Picture 1: Author with the research team from the NTP and Dr. Mao Tan Eng
Picture 2: Author with research assistance team: Planning Session
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1.12 Organisation of the thesis
The thesis is divided into ten chapters. Chapter 1 describes the state of global TB, DOTS 
TB control strategy as recommended by WHO, and the effectiveness and limitations of 
DOT, and CDOT. The setting for the study, the epidemiology of TB, National TB control 
programme and implementation of DOT are also described in Chapter 1. Chapter 2 
presents a systematic review of the effectiveness of CDOT compared to alternative DOT 
delivery options for people requiring treatment for clinically active TB, or prevention of 
active disease. The pilot study for the quantitative and qualitative aspects of the project 
including the quality of data are described in Chapter 3. The methods of the quantitative 
study are described in Chapter 4. Chapter 5 presents the results of treatment outcomes 
between CDOT and health centre-based DOT from the quantitative study. Chapter 6 
describes the methods of the qualitative study. The qualitative results relating to the 
implementation of DOT treatment and its administration are presented in Chapter 7. 
Chapter 8 presents the qualitative results relating to the implementation of the CDOT 
program. The qualitative data on the HC-DOT program are presented in Chapter 9. 
Finally, Chapter 10 presents the discussions, recommendations and conclusions of the 
research.
1.13 Timeline of the study
The proposal of this study was reviewed and approved by the committee at LSHTM in 
May, 2008, and the pilot study took place in August 2008. The data collection was 
conducted in January, 2009 for nine months. However, the analysis and present of data 
collection in this study was delayed due to personal and health problems. The author had 
to take an interruption of studies for 2 years during this period; firstly because of two 
sessions of maternity leave and secondly for a period of health treatment. The data
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analysis of this study was therefore completed in 2012, almost three years after the data 
was collected.
52
2 CHAPTER 2: Systematic review and meta-analysis of studies
of effectiveness of CDOT compared to alternative DOT delivery options
This chapter reports the systematic review of the evidence on the effectiveness of 
community-based DOT as delivered through different DOT providers in different 
settings. The objective of the systematic review is to review the effectiveness of CDOT 
compared to alternative DOT delivery options for people requiring treatment for 
clinically active tuberculosis, or prevention of active disease.
2.1 Methods for systematic review
A systematic review of randomised and non-randomised trials examining the 
effectiveness of CDOT was conducted following PRISMA guidelines (Liberati A, 
Altman DG et al. 2009).
2.1.1 Inclusion criteria 
A Type of studies
Randomised control trials (RCTs) and non-randomised control trials (non-RCTs) were 
included in the review. The non-RCTs included case-control studies, prospective, 
retrospective cohort studies and before and after studies that compare two programs, 
CDOT and alternative DOT options.
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People requiring treatment for clinically active TB or on medication for preventing active 
TB were included in the review. However, the review excluded studies of patients with 
multi-drug resistance TB or HIV.
C Type of intervention
As mentioned above, the type of DOT supporters for CDOT programmes varies from one 
country or setting to another, and in some settings CDOT was defined as using 
community health workers or health volunteers, but not family members as DOT 
watchers (Fred L 2003; Eliud W 2004; Singh A.A 2004). In this review, CDOT, the 
intervention group, is defined as routine direct observation by community health workers 
or health volunteers, known as DOT watchers, observing patients taking their anti­
tuberculosis drug in their community, in their home, in the home of the community health 
workers or in a location other than a health facility.
D Type of control group
There were two types of control group. The first DOT control group was the health 
facility- based DOT (HC-DOT) defined as patients observed receiving their treatment at 
health facilities. The second control group was family-based DOT defined as patients 
receiving their treatment at home with family members responsible for observing patients 
taking their medicines. We included the family-DOT as a control group because family 
DOT is another feasible DOT strategy recommended by WHO. Family DOT was used in 
some settings where health volunteers were not available in the community (Pungrassami 
P 2002; Okanurak K., Kitayapom D. et al. 2007)
B Type of participants
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The primary outcome in the review is treatment success among smear positive TB 
patients, which is the sum of cure and treatment completion. WHO standard outcome 
definitions for cure, completion, failure and default were useda. Studies which did not 
provide stratified outcome data for CDOT programs alone were excluded. Moreover, self- 
supervised therapy was excluded from the review because this program is not considered 
as a DOT program (Enarson D A, Rieder H L et al. 2000).
2.1.2 Search methods for the review
A search was carried out to identify randomised and non-randomised studies (with no 
language restriction) using databases PubMed, CINAHL, EMBASE, and the Cochrane 
Central Register of controlled trials Central
(http://onlinelibrarv.wilev.eom/o/cochrane clcentral articles fs.html). The detail of 
combinations of search terms and concepts shows in Appendix 1.
E Type of outcome measures
* “Cured patients” were defined as those with sputum smear positive before starting treatment and confirmed to be 
sputum negative at five (or six) months on at least one occasion. Patients who completed the full course of treatment but 
have had no sputum taken at the end of treatment are defined as “Treatment Completion”. Patients, who remain or 
become smear positive at five (or six) month or later during treatment, are classified as “Treatment Failures”. “Default” 
is defined as patients who fail to collect drugs for more than two consecutive months during treatment.
Source: http://www.stoptb.org/wg/gli/assets/documents/TBcasedefmitions_20110506b.pdf
55
Searches were conducted from 1995 until 2012 because DOT has been fully implemented 
only since 1994. The keys word tuberculosis and TB were combined with keywords 
about, using keywords “tuberculosis, directly observed therapy DOT, community based 
DOT, community involvement, health centre DOT, health facility based DOT, and 
patients’ adherence”. Hand search of the International Journal of Tuberculosis and Lung 
Disease was carried out from 1995 to 2012. Also searched were published bibliographies 
of related topics, and citations in articles which were included in this review.
2.1.3 Selection of RCTs studies
RCTs were selected in this review, studies in which either individual patients or places 
where patients lived were randomly allocated to either the intervention (CDOT) or control 
groups (health facility DOT or family DOT), in order to compare the treatment success 
between these two groups. Because of the nature of the intervention, most RCTs studies 
were unblinded.
2.1.4 Selection of non-RCTs studies
Non-RCTs in this review were defined as studies that included intervention and control 
groups in order to assess the treatment success of the intervention compared with the 
control, but where participants were not randomised. Before and after studies are included 
in this group because they assess the treatment success for participants in the intervention 
areas before and after the CDOT started compared to control areas which only 
implemented health facility DOT or family DOT.
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2.2 Description of studies
In the initial search, 314 studies were identified. Based on the inclusion criteria, this 
number was narrowed down to 22 studies (see Table 1 of studies included in the review).
Twenty two studies in total satisfied the inclusion criteria. Seven studies (Zwarenstein M 
2000; Fred L 2003; Eliud W 2004; Singh A.A 2004; Clarke M 2005; Nirupa C 2005; 
Daniel G. Datiko 2009) were RCTs, comparing the treatment outcomes between CDOT 
and health facility-based DOT. Eleven studies (Becx-Bleumink M 2001; Kironde S and 
Kahirimbanyi 2002; Arora V.K 2003; Demissie M 2003; Dudley L 2003; Cavalcante S.C 
2007; Khieu K 2007; Boogaard van den J 2009; Zimbisayi Zvavamwe and Ehlers 2009; 
Kabongo D and B 2010; André P. Gabriel and Mercado 2011) were non-RCTs. All were 
conducted in low-income or middle-income countries, and evaluated the effectiveness of 
CDOT compare to health facility-based DOT in TB care.
A further four studies, two RCTs (Wright J 2004; Newell JN 2006) and two non-RCTs 
(Mathew A 2005; Anuwatnonthakate A 2008), compared the treatment success between 
CDOT and family-DOT. The period of observation for these was confined to the first two 
months of treatment (intensive phase) in some and in others it was for the full treatment 
period.
Eleven of the studies (Zwarenstein M 2000; Becx-Bleumink M 2001; Demissie M 2003;
Fred L 2003; Singh A.A 2004; Clarke M 2005; Nirupa C 2005; Newell JN 2006; Daniel
G. Datiko 2009; Zimbisayi Zvavamwe and Ehlers 2009; André P. Gabriel and Mercado
2011) included only smear positive pulmonary TB patients, while the others included
patients with all TB forms (smear positive, smear negative and extra-pulmonary TB).
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29,718 participants in total were included in the review. Appendix 2 shows all studies 
included in the review. Appendix 3 shows studies excluded from the review. Figure 5 
shows the flow of studies through the review.
Figure 5: Flowchart showing flow of studies through the review
2.3 Data analysis
This review used meta-analysis methods to synthesise the data. The analysis is organized
into two parts. The first part assessed the treatment success for smear-positive TB of
CDOT compared with the health facility-based DOT. In this part, the analysis was done
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separately for the RCTs and non-RCTs. Outcomes from the seven RCTs were analyzed 
using the risk ratio (RR) while the other ten non-RCTs were analyzed using odds ratios 
(OR), with 95% confidence intervals (Cl) to assess estimated effects. A random-effects 
model was used when there was statistically significant heterogeneity (chi square P<0.1); 
and the fixed-effect model when the heterogeneity was not statistically significant (chi 
square P>0.1) (Senn S 2007).
The second comparison examined treatment success for smear-positive TB of CDOT 
compared with family-DOT. Due to only four studies being included in this review, the 
analysis combined the RCTs and non-RCTs studies by using the OR, with 95% 
confidence intervals (Cl) in order to estimate the overall effects.
2.4 Description of outcomes
This review assessed the effectiveness of implementing CDOT, by comparing the TB 
treatment success for smear-positive TB of CDOT with other DOT alternatives such as 
health facility DOT or family DOT. According to the WHO standard, treatment success 
includes both cure and treatment completion. Other outcomes such as death, failure, 
defaulter and transfer out, are classified as unfavourable outcomes(WHO 2008) in the 
review.
2.5 Characteristics of community-based DOT (CDOT)
Patients treated by CDOT in these studies were supervised by treatment supervisors who 
were former TB lay health workers, health education assistants, community volunteers, or 
community health workers (CHWs) (Zwarenstein M 2000; Dudley L 2003; Fred L 2003; 
Singh A.A 2004; Clarke M 2005; Nirupa C 2005; Cavalcante S.C 2007; Khieu K 2007;
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Boogaard van den J 2009; Daniel G. Datiko 2009; Zimbisayi Zvavamwe and Ehlers 2009; 
Kabongo D and B 2010; André P. Gabriel and Mercado 2011). Treatment supervisors 
were trained to observe drug-taking, to encourage patients to complete treatment, and to 
keep records and collect drugs (Zwarenstein M 2000; Arora V.K 2003; Demissie M 2003; 
Fred L 2003; Singh A.A 2004; Clarke M 2005; Nirupa C 2005; Khieu K 2007; Boogaard 
van den J 2009; Daniel G. Datiko 2009; Kabongo D and B 2010). Patients were observed 
daily taking the medications by treatment supervisors at the patient’s home (Arora V.K 
2003; Demissie M 2003; Singh A.A 2004; Cavalcante S.C 2007; Boogaard van den J 
2009) or the treatment supervisor’s home (Zwarenstein M 2000; Fred L 2003; Wright J 
2004; Mathew A 2005; Nirupa C 2005; Newell JN 2006; Khieu K 2007; Daniel G. Datiko 
2009; Zimbisayi Zvavamwe and Ehlers 2009) for at least two months of the intensive 
phase. Treatment supervisors were responsible for encouraging patients to complete 
treatment by following-up patients who failed to adhere to treatment. In addition, 
treatment supervisors were responsible for referring others in the community with TB- 
like symptoms, to a health facility ((Daniel G. Datiko 2009).
2.6 Characteristics of alternative DOT delivery options
Two DOT delivery options are compared with community-based DOT in the review. The 
first option is health facility-based DOT where patients were observed at least five days 
per week taking the medications by staff at a health facility (Zwarenstein M 2000; Becx- 
Bleumink M 2001; Kironde S and Kahirimbanyi 2002; Arora V.K 2003; Demissie M 
2003; Dudley L 2003; Fred L 2003; Singh A.A 2004; Clarke M 2005; Nirupa C 2005; 
Cavalcante S.C 2007; Khieu K 2007; Boogaard van den J 2009; Daniel G. Datiko 2009; 
Zimbisayi Zvavamwe and Ehlers 2009; Kabongo D and B 2010; André P. Gabriel and 
Mercado 2011). The second comparison is with the family-based DOT; patients were
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supervised by a family member, spouse or partner at home. Family members or carers 
were trained to observe drugs- taking, to keep records, and to collect drugs from the 
health facilities (Wright J 2004; Mathew A 2005; Newell JN 2006; Anuwatnonthakate A 
2008).
2.7 Assessment of study quality 
2.7.1 RCTs study
All RCT studies included in the review were of necessity unblinded with the intervention 
group supervised by community members, while the control consisted of patients assisted 
by staff at health facilities (Zwarenstein M 2000; Fred L 2003; Eliud W 2004; Singh A.A 
2004; Clarke M 2005; Nirupa C 2005; Daniel G. Datiko 2009) or by family members 
(Wright J 2004; Newell JN 2006). Four studies were cluster randomised controlled trials 
((Fred L 2003; Eliud W 2004; Clarke M 2005; Daniel G. Datiko 2009).
Patients’ allocation to treatment group in four studies was randomised by coin
tossing(Eliud W 2004), assigned by medical officers (Singh A.A 2004; Nirupa C 2005)
and computer-generated random sequences(Zwarenstein M 2000). All of the trials were
unblinded (Zwarenstein M 2000; Fred L 2003; Eliud W 2004; Singh A.A 2004; Clarke M
2005; Nirupa C 2005; Daniel G. Datiko 2009). More than 10% of participants were
excluded from the analysis in the study by Fred (Fred L 2003). Three trials did not report
sufficient information on methods of follow up (Singh A.A 2004; Nirupa C 2005; Daniel
G. Datiko 2009). In the remaining RCTs fewer than 10% of participants were lost to
follow up (Zwarenstein M 2000; Eliud W 2004; Clarke M 2005). Reasons for dropout
included discontinuation of CDOT in some health facilities in the intervention group
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(Clarke M 2005), change of treatment methods from CDOT or HC-DOT to self­
supervision (Zwarenstein M 2000) or interruption of treatment (Eliud W 2004).
Four studies (Zwarenstein M 2000; Fred L 2003; Eliud W 2004; Clarke M 2005) were 
analysed by intention to treat (Newell 1992). The baseline characteristics in three trials 
(Zwarenstein M 2000; Eliud W 2004; Clarke M 2005) were similar in that loss to follow­
up was less than 10%, and the selection bias and confounding factors were controlled for 
in their analysis.
Two trials comparing treatment outcomes between CDOT and family DOT (Wright J 
2004; Newell JN 2006), assigned participants to CDOT or family DOT based on random 
selection of papers from a basket; the outcome assessment was blinded, and fewer than 
10% of participants were lost to follow up.
2.7.2 Non-RCTs
Seven of the eleven non-RCTs comparing CDOT and HC-DOT programs, were 
prospective cohort studies (Kironde S and Kahirimbanyi 2002; Arora Y.K 2003; 
Demissie M 2003; Dudley L 2003; Zimbisayi Zvavamwe and Ehlers 2009; Kabongo D 
and B 2010; André P. Gabriel and Mercado 2011), three were retrospective cohort studies 
(Cavalcante S.C 2007; Khieu K 2007; Boogaard van den J 2009), and one study was a 
before and after study (Becx-Bleumink M 2001). Participants were assigned to 
intervention group or control group based on patients’ choice -  i.e whether they wanted to 
be treated with the DOT watcher in the community or staff at the health facility (Kironde 
S and Kahirimbanyi 2002; Arora V.K 2003; Demissie M 2003; Dudley L 2003;
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Cavalcante S.C 2007; Zimbisayi Zvavamwe and Ehlers 2009; André P. Gabriel and 
Mercado 2011).
One study (Becx-Bleumink M 2001) compared the treatment outcomes and TB case­
finding before and after the introduction of CDOT in 1998. The baseline data was 
collected in 1996-1997. The allocation of participants into CDOT or health facility-based 
DOT was based on patients’ choice.
Two studies compared the treatment outcomes between CDOT and family DOT (Mathew 
A 2005; Anuwatnonthakate A 2008). The allocation of patients to CDOT or family DOT 
was based on patients’ choice (Mathew A 2005). The outcome assessment was unblinded 
in all the eleven cohort studies.
2.8 Results
2.8.1 Community-based DOT versus health facility-based DOT 
A Randomised controlled trials (RCTs)
Comparing the seven trials (Zwarenstein M 2000; Fred L 2003; Eliud W 2004; Singh A.A 
2004; Clarke M 2005; Nirupa C 2005; Daniel G. Datiko 2009), there is a very small but 
statistically significant difference in the treatment success for smear-positive TB between 
the CDOT and HC-DOT (RR=1.05, Cl: 1.01-1.10) in the RCTs. There is no significant 
heterogeneity among the seven studies (chi-square=8.27, df=6, p=0.219). See Figure 6.
Pooling only the five RCTs (Fred L 2003; Eliud W 2004; Singh A.A 2004; Nirupa C
2005; Daniel G. Datiko 2009) with a large sample size, there is no statistically significant
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difference in the treatment success for smear-positive TB between the CDOT and HC- 
DOT (RR=1.035 Cl: 0.99-1.08). See Figure 7. It suggests that treatment outcomes for 
smear-positive patients in the CDOT were not better than HC-DOT, but were at least as 
successful as HC-DOT.
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Comparison: Community based DOT versus Health centre based DOT 
Outcome: Treatment success (cure + treatment completion) for smear-positive TB 
Type of study: Randomised control trials
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Comparison: Community based DOT versus Health centre based DOT 
Outcome: Treatment success (cure + treatment completion) for smear-positive TB 
Type of study: Randomised control trials with a large sample-size
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B Non-RCTs
The meta-analysis of non-RCTs found substantial heterogeneity across the eleven studies 
(Becx-Bleumink M 2001; Kironde S and Kahirimbanyi 2002; Arora V.K 2003; Demissie 
M 2003; Dudley L 2003; Cavalcante S.C 2007; Khieu K 2007; Boogaard van den J 2009; 
Zimbisayi Zvavamwe and Ehlers 2009; Kabongo D and B 2010; André P. Gabriel and 
Mercado 2011) (chi-square=36.99, df=10, pO.0001). In contrast with the results of the 
RCTs, the treatment success for smear positive TB for patients treated under CDOT is 
significantly and substantially better than that for HC-DOT (OR=1.63, Cl: 1.45-1.82). See 
Figure 8. It indicates that treatment outcomes for smear-positive patients treated by the 
CDOT was better than for those treated by HC-DOT. This may be biased by patient 
choice of treatment.
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Comparison: Community based DOT versus Health centre based DOT 
Outcome: Treatment success (cure + treatment completion) for smear-positive TB
Figure 8: CDOT versus HC- DOT in non-RCTs
Type of study: non-randomised control trials
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The odds of success for smear-positive patients treated by CDOT was greater than for 
family-based DOT programs (OR=1.33, Cl: 1.20-1.48); but with significant heterogeneity 
among the four studies (chi-square=25.69, df=3, p<0.0001). The results are shown in 
Figure 9. They are strongly influenced by the large study by Anuwatnonthakate 
(Anuwatnonthakate A 2008)
2.8.2 CDOT versus family-based DOT
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Comparison: Community based DOT versus Family-based DOT
Outcome: Treatment success (cure + treatment completion) for smear-positive TB
Type of study: Randomised control trials and non-RCTs
Figure 9: CDOT versus family-based DOT
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2.9 Exploration of risk of publication bias
2.9.1 RCTs
Heterogeneity across the seven studies was not significant (p=0.303) (Zwarenstein M 
2000; Fred L 2003; Eliud W 2004; Singh A.A 2004; Clarke M 2005; Nirupa C 2005; 
Daniel G. Datiko 2009); however, as is known, the size of study could affect the 
treatment estimates. In the forest plot (A.C.Sterne 2009), the confidence-intervals for the 
studies by Zwarenstein M (2000) and by Clark M (2005) were very wide (p=2.78, Cl: 
0.98-7.86, and p=1.70, Cl: 0.94-3.08); these studies had small sample sizes compared to 
the others. (Figure 10 and Figure 11). Figure 10 presents forest plots by the analysis 
according to the year of study; the smallest studies were conducted in 2000 and 2005 to 
compare the difference for smear-positive patients between CDOT and HC-DOT 
(Zwarenstein M 2000; Clarke M 2005) ,the larger studies were published later in 2003, 
2004 and 2009.
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Moreover, the funnel plot test (Figure 11) shows that the standard error for the studies by 
Zwarenstein M (2000) and by Clark M (2005) is large compared to the others with small 
sample sizes.
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Figure 11: Graph of funnel plots in CDOT versus HC- DOT in RCT studies
Funnel plot with pseudo 95% confidence limits
Using Harbord’s modified test to analyse the small sample size studies effect in the
treatment results for smear-positive in RCTs, the estimated bias coefficient is 2.52 with
standard errors of 0.44, giving the p-value 0.002. This shows some evidence of small
study bias by Zwarenstein M (2000) and by Clark M (2005) effect on publication bias in 
the review for RCTs.
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2.9.2 Non-RCTs
The forest plot for eleven studies (Becx-Bleumink M 2001; Kironde S and Kahirimbanyi 
2002; Arora V.K 2003; Demissie M 2003; Dudley L 2003; Cavalcante S.C 2007; Khieu 
K 2007; Boogaard van den J 2009; Zimbisayi Zvavamwe and Ehlers 2009; Kabongo D 
and B 2010; André P. Gabriel and Mercado 2011) comparing the treatment outcomes 
between CDOT and HC-DOT, according to the year of study, the confidence interval of 
study by Arora VK (2003), Demissie M (2003), Zimbisayi Z (2009), Kabongo D (2010), 
and André P. Gabriel (2011) were very wide; it indicates that the sample size of these 
studies was smaller than the others. See Figure 12 and Figure 13.
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The Funnel plot (Figure 13) has also illustrates that the standard error for the studies by 
Arora VK (2003), Demissie M (2003), Zimbisayi Z (2009), Kabongo D (2010), and 
André P. Gabriel (2011) were very large because their sample sizes were very small. 
There appeared to be no association between year of study and study findings.
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Using the Harbord test to analyse the small-study effects in the treatment results for 
smear-positive in non-RCTs studies, the estimated bias coefficient is 0.080 with standard 
errors of 1.13, giving the p-value 0.945. This suggests no evidence that studies by Arora 
VK (2003), Demissie M (2003), Zimbisayi Z (2009), and André P. Gabriel (2011) have a 
significant effect on the results and no evidence publication bias in the review for non- 
RCTs.
2.9.3 CDOT vs Family DOT
Publication bias and small-study size effects for the four studies (Wright J 2004; Mathew 
A 2005; Newell JN 2006; Anuwatnonthakate A 2008), comparing the treatment outcomes
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between CDOT and family DOT in the review were not tested because the studies were 
few and combined both RCTs and non-RCTs.
2.10 Summary of the findings and Discussion
The focus of this review is on the effectiveness of CDOT with the alternative DOT 
options. This review compared the CDOT intervention program separately with HC-DOT 
and with family DOT, but not with self-administration of treatment. We analysed results 
separately for RCTs and non-RCTs, rather than reviewing only RCTs. The synthesis of 
findings from non-RCTs studies in this review has shown a significant difference in 
treatment success rates for smear-positive TB between CDOT compared to other DOT 
options. Patients treated under CDOT were significantly better in combined cure and 
treatment completion rates compared to other DOT options.
The previous reviews by Gamer and Volmink (Garner P and Volmink 2000; Gamer P and 
Volmink 2007) which reviewed only eleven studies of RCTs, showed no difference in 
success rates (cure and treatment completion) for those supervised by community health 
workers compared with staff at health centres or family members. It was noted in the 
review that, “there is no evidence that one form of DOT is better than another” (Gamer P 
and Volmink 2000). However there have been several studies published since these 
reviews which made this updated review necessary.
As we know the RCTs is the most robust study design to determine treatment outcomes
between intervention and control groups. The results of the meta-analysis of seven trials
shows a borderline statistically significant benefit in treatment success for smear-positive
TB patients treated with CDOT compared with HC-DOT (RR=1.05, Cl: 1.01-1.10).
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However, if we analyse only the five studies with large sample size and eliminate the two 
small studies, the result shows no statistically significant difference in the treatment 
success for smear-positive TB between the CDOT and HC-DOT (RR=1.035 Cl: 0.99- 
1.08); this may be due to the lower power to detect a difference. This result is consistent 
with the earlier review by Gamer and Volmink (RR=1.03, Cl: 0.96-1.10). As Gamer and 
Volmink noted in their review, the comparison between CDOT and family DOT with 
HC-DOT did not demonstrate a difference in treatment outcomes. My review also 
indicates that the effectiveness of CDOT is similar to the HC- DOT or family-DOT, but 
with the CDOT appearing to maintain somewhat better treatment outcomes, with 
increased cure or treatment completion.
A review of qualitative evidence by Munro S (Munro S, Lewin. S et al. 2007) reported 
that adherence to TB treatment depends on patients’ access to health facilities, availability 
of health care providers, distance of the patient’s house from the health centre, and 
availability of transportation. CDOT may be particularly useful in developing countries, 
where TB caseloads are often overwhelming, the distances to HCs may be substantial and 
transport facilities limited, and health facility staff and financial resources are limited. As 
well as achieving at least as good treatment outcomes, CDOT can bring the treatment 
closer to the patients’ homes, enabling patients to continue their normal activities (David 
W and Geraint 1997; Nirupa C 2005) and feel comfortable with their DOT supporters 
(Nirupa C 2005). For these reasons, CDOT probably improves patients’ treatment 
adherence.
In additional, several studies of cost-effectiveness of CDOT compared to HC-DOT, not 
included in the review, have shown that CDOT is less expensive and so more cost-
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effective than the HC-DOT (David W and Geraint 1997; Islam AMD 2002; Khan MA 
2002). The cost of using community health workers as DOT supporters has been found to 
be lower than in government facilities for health system (Wandwalo E 2005). CDOT not 
only reduced costs to the health care system, but also reduced costs to patients. A study 
by Wandwalo Eliud (Wandwalo E 2005) showed that CDOT reduced costs by 35%, and 
cost fell by 27% for health services and 72% for patients. The main reason for reduced 
costs to patients was less number of visits to HCs. The cost per patient successfully 
treated with CDOT was USD$128 compared to USD$203 for HC-DOT patient 
(Wandwalo E 2005),
Comparing the treatment outcomes between CDOT and family-DOT, there is also 
evidence that implemented CDOT including family-DOT is still effective and can achieve 
good treatment success in poor settings with limited resources.
2.11 Limitation of the review
A study of this nature has many limitations. Firstly, there were differences between the 
studies in terms of which participants were involved. Some studies included only smear­
positive TB, while others included all TB forms; in which we extracted the outcomes for 
smear-positive TB only. The results from this review have shown only the effectiveness 
of CDOT compared to the other DOT options for smear-positive patients. It may be that 
the results would be different if we include all TB forms.
Secondly, some of the studies were RCTs, while others were non-RCTs. However, to 
minimize the impact on the results, RCTs were reviewed and synthesised separately, 
because the validity of RCTs is better than non-RCTs. Moreover, the results from RCTs
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were analyzed by an intention to treat model, while non-RCTs utilized an explanatory 
model which analyzed outcomes based on the interventions patients actually received and 
which in some cases they had chosen. This could have introduced the selection bias for 
non-RCTs because participants were not randomised in these studies and the confounding 
factors could not control.
Lastly, many of these studies may have been published because they were successful. 
There may be studies that were not published because they did not show the effectiveness 
of CDOT; this could introduce some publication bias.
2.12 Conclusion chapter two
Implications for practice
This review synthesises evidence on the effectiveness of CDOT compared to HC-DOT 
and finds it to be very slightly more effective but similar. CDOT would be useful in rural 
areas where the infrastructure is very poor; especially where the CDOT may help to 
increase patients’ adherence to treatment. However, it should be also considered how to 
implement CDOT and who will be the best person to supervise. It is important to note 
that the CDOT cannot replace the effective health facility in TB control, but can 
complement the service and contribute to better treatment outcomes.
Implications for research
Further research needs to be conducted to evaluate the effectiveness of CDOT in settings 
where resources are limited. In particular as treatment for TB is very costly, it is 
important that more cost effectiveness studies are carried out to indicate, especially for
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low income countries, how best to use their scarce resources for TB treatment. In 
addition, more studies are required to assess the effectiveness of CDOT in other areas 
where the program has already been implemented such as in Cambodia, to compare the 
treatment outcomes before and after CDOT implementation; it is especially important to 
assess the acceptability of implementing CDOT for patients and staff at health facility 
level.
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3 CHAPTER 3: Pilot Study
This chapter describes the pilot study for both the quantitative and qualitative arms of the 
new study which was conducted as part of this Dr.PH. It includes an assessment of the 
quality of data and describes any problems which occurred during the pilot study and how 
they were addressed.
3.1 Purposes of the pilot study
A pilot study of CDOT and HC-DOT in Cambodia was conducted in 2008 after approval 
from the National Ethics Committee for Health Research in Cambodia. This was done in 
collaboration with the Cambodian National Tuberculosis Programme (NTP). The main 
reasons to carry out the pilot study before the main trial were:
a. To examine the feasibility of extracting data from the existing records such as 
patients’ registered book at the HCs and patients’ treatment cards, and check the data 
quality
b. To find out the design effect for the quantitative study, and
c. To pre-test the qualitative study tools, including eliminating or amending questions 
that did not yield useful information
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3.2 Data collection and entry
3.2.1 Data collection for the quantitative study
After receiving the approval from the Cambodian National Committee, quantitative data 
were collected for the pilot study. Data from the NTP indicated that 108 HCs had 
implemented CDOT between 2004 to 2007, and 299 HCs implemented the HC-DOT 
known as ambulatory DOT between 2004 to 2007.
Four HCs were selected for the pilot study; two HCs had implemented CDOT and the 
other two used HC- DOT. The HC was considered as a large HC if the TB case loads 
were more than 15 cases per year. In CDOT, one small HC (14 TB cases in 2007) and 
one large HC (38 cases in 2007) were selected. However, in HC-DOT we could not select 
a small HC, because these two HCs were large centres (>50 TB cases in 2007).
New smear-positive, negative pulmonary and extra-pulmonary TB patients aged 18 and 
over were included in the pilot study. Patients treated in 2002, 2003,2005 and 2006 were 
identified from the patient register book. 544 patients in total were included in the pilot 
study.
3.2.2 Data collection for the qualitative study
Topic guides were developed by the author and agreed with the supervisor and in-depth 
interviews and focus group discussions were conducted to test these topic guides for the 
qualitative study in order to eliminate questions that did not give information for the 
study, and to clarify the instructions and the length of time taken for completion of 
interviews.
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Two focus group discussions were conducted among patients who were treated with 
CDOT and those who were treated with HC-DOT to explore the general issues regarding 
their treatment experiences under the both DOT options. There were 5 to 6 patients in 
each group. In-depth interviews were conducted to gather more detailed information 
about the structure, experiences and patient satisfaction under each DOT approach. Six 
patients (3 females and 3 males), five male TB staff, and three health volunteers (2 males 
and 1 female) were selected for the in-depth interviews.
3.2.3 Data description 
A Quantitative study
A description of the data collected during the pilot study for the quantitative study is 
given below. Six research assistants (three nurses and three doctors who were 
experienced and had been working with NTP and hospitals for at least five years) were 
recruited and trained by the author for the data collection. Data collection involved 
visiting the HCs and extracting data from their records.
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Table 1: Data collection for the quantitative study
Conceptual variables • Operational variables \ \  -
Socio-demographic Sex, age
Examination Date and year treatment started
Type of TB BK+, BK-, EP
Referred patient to HC by Staff, Health volunteer, Family, Neighbour, 
Others (describe)
Type of patient New patient, relapsed, defaulter, 
Transferred-in, multidrug-resistance
Type of DOT Community-based DOT, Hospital DOT, 
ambulatory DOT(health centre-DOT), 
No DOT
Treatment outcomes Cured, treatment completed, defaulted, 
failure, died, transferred-out
The checklist included: 1) Socio-demographic, 2) Type of TB, 3) Type of patient, 4) Type 
of DOT, and 5) Treatment outcomes, for individual patients was translated into the 
Khmer language. The checklist was developed based on the available information from 
the health centre’s patient register.
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B Qualitative study
Interviews were conducted to test the topic guide for the qualitative study for the 
following reasons: to eliminate questions that did not provide enough relevant 
information for the study, and to clarify the instructions and the length of time taken for 
completion o f interview.
The interviews were conducted by the author in Khmer language, and took place at the 
patient’s house, the DOT watcher’s house and the health centre for staff. Each interview 
took between 45 minutes to one hour, and two note takers were trained before the
interviews. The topic guide for the interviews is shown in Appendix 4 and was translated
\
into the Khmer language.
Patients who had been treated for TB during 2006 were selected for the interviews. TB 
staff were selected from the staff list. A list of the DOT watchers was provided by the 
staff and interviewees were randomly selected by the author.
3.2.4 Data entry
The quantitative data were entered and validated in Epi-Info. The statistical package 
STATA version 10.0 was used to estimate the design effect of treatment success based on 
combined cure and treatment completion.
The qualitative data were analysed along general themes including choice of treatment, 
responsibilities of DOT watchers in TB treatment, patients’ experiences with DOT 
treatment, patients’ adherence to treatment, people providing patient motivation and 
support, incentives that patients received during the treatment, and factors influence to
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complete the treatment. The emergent categories and subcategories were identified; the 
relationship between the various categories would be examined to get more detailed 
information for the results.
3.3 Results of the pilot study
3.3.1 Results of the pilot quantitative study
A. Quality of data
The quality of data in the patients’ register at the HC level was not as high as expected. 
The quality depended on the data management of individual HCs; the data management 
between 2002 and 2003 was very poor because this was when DOT was first 
implemented. Approximately 10%-15% of data in 2002 and 2003 were missing from the 
patients’ register but researchers double-checked and supplemented this from patients’ 
treatment cards if they were still kept at the HC. Information on who referred patients to 
the HC was not recorded.
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Picture 3: Peamro Health Center, Prey Veng Province
Picture 4: Patients’ register book at the health centre
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B. Design effect
The design effect for treatment success from the pilot study was very small. For HC with 
CDOT, the design effect was 0.06 and 0.36 for HC without CDOT. After the author 
combined data from both HCs with CDOT and without CDOT, the design effect for 
treatment success from the pilot study was 0.60.
3.3.2 Results of the pilot qualitative study 
A. The HC- DOT
Patients registered with HC-DOT were not 100% treated with the HC-DOT. Two of the 
three interviewees selected from the HC-DOT were found to be in fact non-DOT because 
they took medicines at home without anyone watching them. Their families went to 
collect drugs at the health centre once per week for the first two months and once per 
month for the rest, as reported from interviews below:
Q : W ho w a s  y o u r  D O T  w a tc h e r ?
A : I d i d n ’t  h a v e  o n e .. . .I  s w a l lo w e d  m ed ic in e  a t  h om e b y  m yself. I  w a s  v e r y  sick.
Q : W ho w e n t  to  c o l le c t  m e d ic in e s  f r o m  th e  h ea lth  c e n tre  f o r  y o u ?
A : M y  s o n ..b u t  so m e tim e s  m y  w ife , sh e  s to p p e d  to  c o lle c t  d ru g s  f o r  m e a f te r  sh e  
r e tu r n e d f r o m  th e  m a rk e t. (Patient, male 55 years old)
‘T  c a n ’t  g o  to  th e  h e a lth  c e n tr e  e v e r y  d a y . I  to o k  m e d ic in e s  w ith  s ta f f  o n ly  the f i r s t  tw o  
d a y s .... th en  I  a s k e d  d o c to r  to  ta k e  m e d ic in e s  a t  h o m e b e c a u s e  I  n e e d e d  to  ta k e  c a re  o f  m y  
r ic e  f i e l d  a n d  m y  c h ild re n  h a d  to  g o  to  s c h o o l. . .e v e r y  m o rn in g  I  w a s  v e r y  bu sy ... Then  
d o c to r  a l lo w e d  m e  to  ta k e  m e d ic in e s  a t  h o m e ..B u t h e  t o ld  m e  th a t I  s h o u ld n ’t  te l l  a n y b o d y  
b e c a u se  i t  w a s  a g a in s t  th e ru le . H e  a l lo w e d  m e  to  k e e p  m e d ic in e s  a t  h o m e f o r  1 w e e k  f o r
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th e in itia te  p h a s e .. .a f te r  he b e lie v e d  I  to o k  m e d ic in e s  re g u la r ly , h e le t  m e  k eep  m ed ic in es  
on e  m o n th ” (Patient, female 37 years old).
Patients treated with HC-DOT were required to come to the HC every morning from 
Monday to Friday. During the weekend or on public holidays, patients were allowed to 
keep medicines at home. Treatment flexibility was given to patients treated with the HC- 
DOT.
“ We r e q u ir e  p a t ie n ts  to  co m e  to  H C  f o r  s w a llo w in g  m e d ic in e s  in  f r o n t  o f  o u r s ta f f  e v e r y  
m o rn in g  f r o m  8  to  1 0  am . H o w ever , w e  g iv e  m e d ic in e s  to  th em  d u r in g  th e w e e k e n d  a n d  
h o lid a y . F o r  p a t ie n ts  w h o  h a ve  to  w o r k  o r  a re  a w a y  f r o m  hom e, w e  w i l l  le t  th em  k eep  
m e d ic in e s  f o r  a s  m a n y  d a y s  a s  th e y  h a ve  a s k e d  fo r .. . .H o w e v e r , w e  a lw a y s  en co u ra g e  
p a t ie n ts  to  c o m e  to  ta k e  m e d ic in e s  w ith  o u r  s ta f f  e v e r y  d a y  e s p e c ia lly  f o r  the f i r s t  tw o  
m o n th s  b e c a u s e  i t  is  a  v e r y  im p o r ta n t p e r io d . F o r  th e  c o n tin u o u s p h a s e , w e  a llo w  th em  to  
ta k e  m e d ic in e s  a t  h o m e  f o r  th o se  w h o  liv e  f a r  f r o m  th e  H C  o r  h a ve  th e ir  o w n  re a so n s  w h y  
th e y  c a n ’t  c o m e  h ere , th e y  j u s t  co m e  to  c o lle c t  m ed ic in e s  o n ce  p e r  m o n th  ” (Staff, male 45 
years old).
B. The CDOT
Patients took medicines at the DOT watcher’s house; except for those who were really 
sick or disabled. DOT watchers were allowed to keep medicines for one to two weeks for 
the first phase and for one month for the second phase:
“N o rm a lly , I  w a s  a l lo w e d  to  k e e p  d r u g s  f o r  o n e  w e e k  f o r  th e  f i r s t  tw o  m o n th s....b u t it
d e p e n d s , s o m e tim e s  I  a s k  f o r  tw o  w e e k s  b e c a u se  I  d o n ’t  h a v e  tim e  to  co m e  c o lle c t
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m e d ic in e s  a t  th e  H C ...th e n  d o c to r  a g r e e d ...b u t  so m e tim e s  w h en  th e  d r u g  s to c k  in th e  H C  
is  sh o r t... s t a f f  d o n ’t  a l lo w  m e to  k e e p  lo n g e r  th a n  on e  w e e k ” (DOT watcher, female 39 
years old)
"The f i r s t  tw o  m on th s, i t  is  th e  m o s t d ifficu lt tim e  f o r  p a t ie n ts . . . .s ta f f  d o n ’t  a l lo w  m e to  
k e e p  m e d ic in e s  f o r  p a t ie n ts  a t  h om e lo n g e r  th an  2  w eek s. B u t a f te r  tw o  m on th s, I  am  
a l lo w e d  to  r e f i l l  p a t ie n ts  ’ m e d ic in e s  o n ce  e v e r y  m o n th  f o r  4  m o n th s  ” (DOT watcher, male 
42 years old)
The arrangements for collecting medicines from the HC depended on the time available 
to patients, DOT watchers or staff: “It d ep en d s , s o m e tim e s  s ta f f  c o m e  to  m y  h o u se  a n d  
g iv e  m e  m ed ic in e s , s o m e tim e s  I  c o lle c t  th em  w h en  I  g o  f o r  tra in in g  a t  th e  H C , o r  w h en  I  
a m  b u s y  I  a s k  m y  p a t ie n ts  to  g o  to  H C  f o r  c o lle c t in g  th e ir  m ed ic in es . ” (DOT watcher, 
male 52 years old).
Sputum control in the fifth and six months was rarely done for patients treated with 
CDOT compared to HC-DOT. None of the three patients treated with CDOT had a 
sputum check before they finished their medicines: “I  d id n 't  h a ve  a n y  sp u tu m  ch eck  
b e fo re  I  c o m p le te d  m y  tre a tm e n t. D o c to r  a n d  m y  D O T  w a tc h e r  d i d n ’t  te l l  m e ” (Patient, 
female 55 years old).
“M y  D O T  w a tc h e r  j u s t  t o ld  m e  th a t  1 w o u ld  b e  c u r e d  a f te r  I  to o k  m e d ic in e s  f o r  6  m onths. 
N o  o n e  t o ld  m e to  g o  f o r  th e  te s t  a g a in ” (Patient, male 30 years old).
Visiting patients at home during the treatment by staff at the HC was rarely done, except 
for patients who lived close to staff s house: “N o  o n e  f r o m  th e  h e a lth  c e n tre  c a m e  to  se e
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m e d u r in g  th e  trea tm en t. I f  I  h ave  a n y  p ro b le m , I  j u s t  a s k e d  m y  D O T  w a tc h e r ” (Patient, 
female 55 years old).
The choice of DOT watcher was not given to the patient. The choice was made by staff at 
the HC depending on the availability of DOT watcher either in patient’s commune or 
patient’s village: “M y  D O T  w a tc h e r  w a s  a s s ig n e d  b y  d o c to r  a t  th e  H C . H e  d i d n ’t  l iv e  in  
m y  v il la g e . . . .I  u s e d  to  s e e  h im  b e fo re  I  s ta r te d  th e tre a tm e n t...b u t w e  r a r e ly  ta lk e d ” 
(Patient, female 55 years old)
“ W e d o n ’t  a l lo w  p a t ie n ts  to  s e le c t  th e ir  o w n  D O T  w a tc h e r  b e c a u s e  it  w o u ld  b e  d iff icu lt 
f o r  us to  o r g a n ize  th e w o r k . .b u t  a s  y o u  s e e  o u r  com m u n e i s n ’t  b ig ...S o  e v e ry o n e  k n ow s  
e a c h  o th er, e v e n  th ou gh  th e y  l iv e  in d iffe ren ce  v i l la g e s ” (Staff, male 45 years old)
C. Patient satisfaction
All interviewees reported being satisfied with their treatment. They felt better and 
continued their work as normal after the treatment. They were also happy because the 
treatment was free. Patients were very happy about their choice of DOT, especially the 
non-DOT patients, and the fact that patients were allowed to keep medicines at home 
instead of going to the HC every day.
The selection of the place where patients needed to take medicines depended on staff at 
the HC. However, patients treated with HC- DOT complained about the travel time and 
transportation needed to go to the HC. Encouragement to finish the treatment by family 
members was very important for patients:
“I  a m  v e r y  h a p p y  a n d  s a t i s f i e d  f o r  m y  TB tre a tm e n t b e c a u s e  I  f e e l  m u ch  be tter . I  am  
c u r e d  n ow . B e fo re  th e  tr e a tm e n t I  c o u ld n  t  w ork , 1 f e l t  t i r e d  a n d  1 c o u ld n  ‘t  e ven  w a lk  to
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th e  r ic e  f ie ld .  A f te r  I  to o k  m ed ic in e s  f o r  3 m on th s, I  c o u ld  w o r k  a s  n o rm a l . . .D o n ’t  f e e l
t i r e d  a n y m o re .....B u t g o in g  to  th e H C  e v e r y d a y  a n d  e v e r y  m orn in g , w a s  d iff ic u lt  f o r  m e. I
d o n ’t  h a v e  th e  tra n sp o r ta tio n , so m e tim e s  I  n e e d e d  to  w a lk ..i t  to o k  m e 2 0  m in u tes; a n d  
so m e tim e s  1 n e e d e d  to  b o r r o w  m y  n e ig h b o u r ’s  m o to rb ik e  o r  b icy c le . 1 w a n te d  to  g iv e  
u p ...b u t m y  w ife  a lw a y s  e n c o u ra g e d  m e to  g o  b e c a u se  sh e  d o e s n 't  w a n t th is  d is e a s e  
tr a n s m itte d  to  m y  k id s ” (Patient, male 39 years old).
D. Role of NGOs in CDOT implementation
Most CDOT was implemented by collaboration between the NTP and international or 
local NGOs such as: USAID, Japan International Cooperation Agency (JICA), 
Cambodian Health Committee (CHC), Reproductive and Child Health Alliance 
(RACHA), Partner for Heath and Development (PFHAD), Catholic Relief Service (CRS), 
Save the Children Australia (SCA), and Global Fund to Fight AIDS, Tuberculosis and 
Malaria (GFATM). Some NGOs have provided incentives such as money or materials to 
DOT watchers when their patients completed the treatment.
“ O u r g o v e rn m e n t d o e s n ’t  h a ve  a n y  in cen tive  f o r  co m m u n ity  D O T  w a tc h e r s  b u t C H C  
o rg a n iza tio n  p r o v id e s  U S $ 4  p e r  o n e  p a t ie n t  to  o u r  D O T  w a tch er . T h is m o n e y  is  g iv e n  to  
th e  D O T  w a tc h e r  a t  th e  e n d  o f  th e tre a tm e n t a n d  1  n e e d  to  m ake  su re  th a t  th e p a t ie n t  is 
c u r e d  o r  h a s  c o m p le te d  th e  tr e a tm e n t b y  s e e in g  th e  tre a tm e n t c a rd s .... .  I f  a  p a t ie n t  d ro p s  
th e  tre a tm e n t b e fo re  6  m on th s, th e  D O T  w a tc h e r  c o u ld n ’t  r e c e iv e  th is  m on ey. H o w ever , 
th e  in c e n tiv e  U S $ 4  isn  ’t  r e a l ly  f ix e d ;  i t  d e p e n d s  o n  th e  fu n d in g  f r o m  th e  C H C . F o r  
ex a m p le , la s t  y e a r  th e  C H C  to ld  us th a t  th e y  g a v e  th e  D O T  w a tc h e r  U S $ 4  p e r  p a t ie n t  b u t  
y e s te r d a y  I  j u s t  h e a r d  th a t  th e y  w i l l  c h a n g e  f r o m  U S $ 4  to  U S $ 2  b y  th e  e n d  o f  th is  y e a r . ” 
(Staff, male 45 years old)
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Some NGOs have supported the CDOT by providing free health care services to CDOT 
watchers. “R A C H A  d o e sn  7 p r o v id e  a n y  m o n e y  to  o u r  s ta f f  o r  to  D O T  w a tch ers. B u t w h en  
a  D O T  w a tc h e r ’s  f a m i ly  is  d e liv e r e d  a  b a b y  in th is  H C , th e  h o s p i ta l  f e e  is  f r e e  b e c a u se  
th e  R A C H A  p a y s  th e fe e . ” (Staff, male 50 years old)
E. Focus group discussion
The focus group discussion could not be done in the pilot study due to two reasons. The 
first reason was the location; it was very difficult to gather 5 to 6 patients for the 
interview due to the fact that they do not live in the same village or the same community. 
The second reason was to do with TB stigmatization; the author found out during the 
interviews that even though patients understood TB is an infectious disease, they did not 
want to disclose their disease to anyone else beside their family, as mentioned by patient, 
female 55 years old below that:
A : 1 u n d e r s ta n d  th a t TB i s n ’t  a  g e n e tic  d ise a se  b u t 1 s t i l l  d i d n ’t  w a n t m y  d a u g h te r ’s  
f ia n c é e  f a m i ly  in -la w  to  k n o w  th a t I  to o k  TB  m ed ic in es , s o  l a s h e d  m y  D O T  w a tc h e r  n o t to  
d is c lo s e  in fo rm a tio n  to  a n y o n e  e ls e  b e s id e s  s ta f f  a t  th e  H C .
Q : W hy d id n  7 y o u  w a n t y o u r  d a u g h te r 's f ia n c é e  f a m i ly  in - la w  to  kn ow ?
A : I  w a s n  7 r e a l ly  su re  th a t  h e r  f ia n c é e  ‘s  f a m i ly  in -la w  u n d e r s to o d  th a t TB  is  an  in fec tio u s  
d is e a s e .... I  w a s  a f r a id  h e  w o u ld n  7 w a n t to  m a rr y  m y  d a u g h te r  a n y m o re .....
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Picture 5: The author and research team meeting with patient
3.4 Implication from the pilot study
3.4.1 Quantitative study
According to the results from the pilot study, it was feasible to use a before- and after­
study to compare the treatment success between the CDOT and HC-DOT approaches in 
this research. However, data from the patients’ register book were not complete, and the 
patients’ treatment cards needed to be checked for any missing information cases. Due to 
the facts that between 10% and 15% of data are missing from the register book, the author 
decided to fill in a 10% missing value for the sample size calculation in the main 
research.
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From several meetings between the author and key TB staff during the pilot study, it 
emerged that all parties expected that implementation of CDOT would improve the 
treatment success of smear-positive TB by some 5% compared to the HC-DOT average. 
This point would be used for the sample size calculation in the research.
Findings from the pilot study showed that not all patients who were registered with 
CDOT were treated using this approach, but some of these patients were treated with the 
ambulatory DOT. Similar cases were observed among patients who were registered with 
HC-DOT. So for the main study, only patients treated with CDOT under the HC-CDOT 
approach and those patients who were treated with the ambulatory DOT under HC-DOT 
approach would be selected.
Since there was not sufficient information about patients’ referral -  i.e. who provided 
patients’ references, the author decided that these data would not be used for the main 
research.
3.4.2 Qualitative study
The author decided to exclude the focus group discussion from the main research project 
due to the reasons mentioned above. Since most TB patients had a low-education level, 
the questions needed to be more specific and more structured. The time for the each 
interview would take between one hour to one and a half hour depending on individual 
patient -  i.e. how long it will take the patient to understand and answer questions.
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P ic tu r e  6: A u th o r  a n d  r e s e a rc h  te a m  v is ite d  in p a tie n ts  a t  R e fe r r a l
P ic tu r e  7: A u th o r ,  T B  d o c to r  a n d  r e s e a rc h  te a m  d u r in g  fie ld  v is ite d  in  th e  
c o m m u n ity
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4 CHAPTER 4: Methodology for the Quantitative Study
The research was developed based on two different methodologies: quantitative and 
qualitative methods. The quantitative design of this research was a controlled before-after 
study of the introduction of the CDOT. This chapter presents the objectives and 
methodology used for the quantitative study.
4.1 General objective
This study aims to examine how the CDOT approach differs from HC-DOT in terms of 
its implementation in the field and its impact on TB outcomes, including case notification 
and treatment success in Cambodia.
4.2 Specific objectives
In order to study the difference between CDOT and HC- DOT, the specific objectives of 
the study are as follows:
a. To compare the treatment outcomes of the HC- DOT and the CDOT,
b. To compare the treatment outcomes within the HC before and after implemented 
CDOT, and
c. To compare the TB case finding of HC-DOT and the CDOT.
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4.3 Methodology
4.3.1 The study design
This study was designed as a controlled before-after implementation of the CDOT as 
shown in the diagram below:
Q lxi — Q2ti
Q3t2 — Q4t2
The baseline for this study was the year 2002-2003 (Tl) when CDOT was not yet 
implemented. In Cambodia, CDOT was introduced in 2004 and fully implemented in 
some areas in 2005. The quantitative component of this study was used to collect 
information at baseline (2002-2003, T l) and at two years after CDOT was implemented 
(2006-2007, T2).
Q1 and Q3 indicate the random samples selected from HCs where CDOT has been 
implemented (intervention areas) and Q2 and Q4 indicate the random samples from HC- 
DOT (control areas). T l indicates the time of data collection to be the baseline (2002- 
2003) whereas T2 indicates the time of data collection at two years after CDOT was 
implemented (2006-2007). The dashed line indicates that study participants were not 
randomly assigned to intervention and control groups.
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4.3.2 Study outcome measures
The primary outcome measures for the study are the treatment outcomes for smear­
positive, smear negative and extra-pulmonary TB patients. The outcome measures used 
were: “treatment success”, “death”, “defaulter”, “treatment failure” and “transferred out”. 
“Treatment success” was combined between cured and treatment completion. Cured 
patients were defined as those who were sputum smear-positive before starting treatment 
and were confirmed sputum-negative at five (or 6) months on at least one occasion. 
Treatment completion was defined as completion of the full course of treatment but no 
sputum taken at the end of treatment. Patients, who remained or became smear positive at 
five (or 6) month or later during treatment, were classified as “treatment failures”. 
Patients who died during the treatment due to TB disease or other cause, were recorded in 
the “death” group. “Defaulter” refers to patients who failed to collect drugs for more than 
two consecutive months during treatment. “Transferred out” describes patients who 
transferred to another health centre region.
The secondary outcome was the percentage of TB case finding by year from 2002 until 
2008 in both groups. According to the NTP, case finding is defined as TB suspects who 
had a cough for more than two weeks, and were referred for a sputum test at the HC.
4.3.3 Study sites
HCs which had implemented CDOT over the whole period 2005-2007; were eligible for 
selection for the CDOT group. In contrast, HCs which had only applied regular 
ambulatory DOT since 2004 were eligible to be chosen for the HC-DOT group.
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The NTP report in 2007(NTP 2007), indicated that there were 227 HCs implementing 
CDOT in 2005, in 41 HCs CDOT was withdrawn in 2005 due to lack of funding from the 
NGOs, such as PFHAD, SCA, CRS, RACHA, who had supported the CDOT program. 
Because one province was very difficult to access by road, it was not included in the 
study. In total, 186 HCs within 11 provinces and 21 ODs were eligible for selection for 
the CDOT group.
Between 2004 and 2007, there were 285 HCs within 13 provinces which had not 
implemented CDOT, of these 6 HCs were located in 2 provinces where the infrastructure 
was very difficult to access, especially during the data collection period. The researcher 
therefore decided to exclude those HCs from the study, so 279 HCs in 11 provinces and 
32 ODs were eligible for selection for the HC-DOT group.
4.3.4 Study population
The eligible study population was patients 18 years old and over who were registered for 
treatment in HCs in areas where CDOT was implemented and in areas where it was not, 
during the period from 1st January 2006 until 31st December 2007, and baseline patients 
registered in 2002-2003.
New smear positive and smear negative pulmonary tuberculosis as well as extra- 
pulmonary tuberculosis patients were included in the study. Patients who had been 
previously treated for TB and patients with multi-drug resistance were excluded because 
these groups of patients are required to stay in the hospital for treatment.
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4.3.5 Description of CDOT
The patients in the CDOT selected health centres had been supervised by a DOT watcher. 
There are two categories of DOT watchers: 1) member of the village health support group 
(VHSG); and 2) other community volunteers such as neighbours, former TB patients, 
school teachers and traditional healers. According to the NTP strategy planning reports, 
family members are not used as DOT watchers in Cambodia.
4.3.6 Description of HC-DOT
Patients who had received regular ambulatory DOT at HCs were selected for the HC- 
DOT. Based on the NTP strategy planning, patients treated with HC-DOT have to come 
to HCs every morning during the two months intensive phase to be observed swallowing 
the medication by staff at HCs. During the continuation phase of four months, patients are 
required to come to collect the drug once per week and for clinical evaluation in months 
2, 5 and 6.
Patients who had taken medicines at home without any supervisor were excluded from 
the study because those patients were considered as non-DOT.
4.3.7 Sample size calculation
From the pilot and baseline assessment, the author assumed that CDOT would improve 
the treatment success of smear positive pulmonary TB patients by 5 %  compared to the 
HC-DOT. The sample size calculation, assumed 10% missing values, 25 patients per HC, 
a design effect of the pilot study was 0.60 and a 5% significant level, we needed 27 HCs 
for CDOT and 27 HCs for HC-DOT. We identified approximately 1350 participants for
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the baseline and another 1350 at two years after CDOT was implemented. The details of 
the sample size calculations are given in Appendix 5.
4.3.8 Sampling
A. Sampling for the HC
Based on the TB case notification (2006-2007), HCs which had fewer than 50 TB cases 
for two years (2006-2007) were combined with other HCs in the same operational district 
and within the same province to create one cluster, as those HCs have similar geography 
and share the same OD supervisor. In total, we needed 27 clusters from the HCs where 
CDOT was implemented and 27 clusters from the HC-DOT. Appendix 6 shows the flow 
of selection clusters of HCs in the study. Appendix 7 shows the list of provinces and HCs 
selected into the study.
B. Sampling of patients
The selection of representative patients from each HC was done in four stages. For the 
CDOT, at the first stage patients treated with the CDOT were identified; those patients 
were counted and listed. The second stage selected a number “A” by calculating N/n 
where N= total number of patients treated in the HC, and n= number of CDOT patients to 
be selected as representing the HC (25 patients for each HC). The third stage involved 
selecting a random number “B” which was less than or equal to “A”. The patient in that 
“B” place on the list would be the first representative patient of that HC in the study. The 
next patient was selected as the patient in the position “A+B” on the list (eg. A+B=C:
second patient, C+A=D: third patient......= n), we continued with the same method until
we got the total number of patients “n” that we needed in the HC.
For the HC-DOT, we used the same strategy to select representative patients.
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To ensure a sample size large enough to calculate reliable estimates for all the desired 
elements of the study, it was necessary to control the total number of patients drawn per 
cluster. This was done by selecting 25 patients in every cluster. However, for clusters 
which had more than one HC, we denoted the larger HC “A”, the medium “B” and the 
smaller HC “C”. Then we selected 9 representative patients from the large, 8 from the 
medium and the other 8 patients from the small HC.
4.4 Field preparation
Training took place before the research started (Table 2). The author was responsible for 
gaining access to HCs, recruitment and training of research assistants, making schedules 
with staff at ODs and heads of HCs, arrangement of work and travelling schedule, double 
checking all questionnaires, and analysis of all data.
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Table 2: Field preparation for the quantitative study





•  Director of the NTP
•  Medical officers of 
Health in the NTP
•  Coordinators of TB team 
at ODs level
•  The Author
•  Two Research Assistants
•  Author
•  Two Research Assistants
•  The Author
•  Head of the ODs
•  Two Research Assistants
•  The Author
•Ten Research Assistants
•  One Note taker for the 
qualitative study
Briefing by the 1 day
author on the 
purpose of the 
research and the 
research protocol
•  Confirming about 4 days 
DOT implemented
in HCs included in 
the study
•  Briefing on the 
purpose of the 
research to ODs 
level
•  Informing and 3 days 
briefing by the
author on the 
purpose of the 
research
• Checking the 
record books and 
treatment cards 
available in the ODs 
level




•  Data entry
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Ten research assistants, seven medical doctors and three nurses from the NTP, were 
employed part time for this study. They were familiar with the TB treatment and DOT 
information. They were responsible for collecting and completing data schedules of 
information on participants including sex, type of TB, type of DOT and treatment results 
for the baseline (2002-2003) and two y e a rs  a f te r  C D O T  w a s  im p le m e n te d  (2006-2007). 
They also checked data from patients’ treatment cards when information was missing 
from the TB register. The researcher was with them in almost all HCs to supervise them 
throughout the study period. The descriptions of data collected are given in Appendix 8.
4.5 Data collection for TB case-finding
The research assistants also collected information for TB case-finding from the patient 
register by identifying all new cases including smear-positive TB, smear-negative TB, 
and extra-pulmonary TB from year 2002 to 2008 in every HC selected in the study. 
Appendix 9 describes the data for TB case finding.
4.6 Data processing and analysis
4.6.1 Data processing
All completed questionnaires were checked by the author and two main medical doctors 
(research assistants) at the end of each day to ensure completeness. Incomplete answers 
were considered as missing data. The information was coded and entered using Epi Data 
(Laurit Sen JM and M. 2003) by a statistician from the National Institute of Statistics. 
Data entry began as soon as the field work was finished. Re-entry data was double- 
checked by one doctor from the National Institute of Public Health, supervised by the
author.
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4.6.2 Data analysis 
Treatment outcomes
The author used STATA version 10.0 (College Station, TX) to analyse the treatment 
success data. Cluster effects and sampling weights were taken into account where 
appropriate. First baseline characteristics including age, TB types and treatment success 
were compared between groups and within groups over time, using chi-square test. The 
difference between both groups by gender at the baseline was also analyzed using a t-test. 
Logistic regressions were used to compare treatment success between the two groups and 
within the two groups over time controlling for age, sex, TB type and residence. Odds 
ratios and 95% confidence intervals are reported.
Case-finding
The total number of TB cases from 52 CDOT and HC-DOT reported since 2002 to 2008 
is included in the analysis. First the annual total of TB cases from 26 HCs implemented 
CDOT was calculated and compared with the annual total of TB cases from the 26 HCs- 
DOT. Then two regression lines were used to fit trends of annual total TB cases from 
2002 to 2008.
In order to compare the two regression lines, the difference-in-differences method is used 
(Imbens 2005). All cases reported are tagged with a variable called “post”. The author 
used post=0 to denote the pre-period before CDOT was implemented from 2002-2004 
and post=l to denote the period after CDOT implemented 2005-2008. The outcome is 
total number of TB cases reported. The “treatment” variable is a model variable. The 
difference in differences estimator is the estimate of the coefficient on the interaction 
between the “post” and “treatment” (Larsen February 12,2008).
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4.7 Ethics procedures
All study protocols, consent forms and questionnaires were submitted, reviewed and 
approved by the London School Hygiene and Tropical Medicine ethics committee and the 
National Ethics Committee for Health Research in Cambodia before the research started. 
The baseline and follow-up study of the “evaluation of the effects of CDOT compared to 
HC-DOT” were approved by the Cambodia National Ethics Committee for Health 
Research, Ministry of Health and the Boards of National Tuberculosis for TB control 
Program. The anonymity of all participants approached in the study was guaranteed. It 
was ensured that there was no names of study subjects are shown in the results. The 
questionnaire sheets were locked in a safe place.
4.8 Resources and time frame
This research was funded from personal resources and A&H Fujimoto Foundation 
(private Japanese family fund), which covered expenditure for salaries, transportation, 
food and accommodation for the research assistants. The research project was supported 
by the team from CENAT, staff at the ODs level and as well as from the HCs levels. The 
field work took place from January to July 2009.
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Picture 8: Author with research assistance team: collecting data from the 
registration book at the HC
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5 CHAPTER 5: Results of the Quantitative Study
This chapter presents the quantitative results of the study and compares treatment 
outcomes and TB case finding between CDOT and HC-DOT.
5.1 Participation and distribution
1067 participants were surveyed at baseline in 2002/3 (543 CDOT and 524 HC-DOT) and 
1297(655 CDOT and 642 HC-DOT) at two years after the intervention in 2006/7. In total 
48 HCs were selected in the CDOT and 34 HCs in the HC-DOT areas.
5.2 Socio-demographic characteristics
The author classified ages into three categories (18-39, 40-59, and >60). Table 3 presents 
the distribution of patient characteristics at the baseline assessment and two years after 
CDOT implementation. Both CDOT and HC-DOT populations were similar with respect 
to sex distribution at baseline (50.28% vs 50.19% male, 49.72% vs 49.81 female, p=0.97) 
and two years after CDOT was implemented (50.08% vs 46.73% male, 49.92% vs 
53.27% female, p=0.30). The age distribution did not differ significantly in the two 
groups (p=0.47 for the baseline and p=0.69 two years after the C D O T  was implemented)
The majority of TB patients in both domains were new smear-positive pulmonary TB 
patients. At baseline TB types were similar (p=0.19) in both HCs; however, after two 
years the percentage of smear-positive TB patients was higher in HC-DOT (74.45%) than 
in CDOT (64.12%) patients (p=0.03) and the percentage of smear-negative TB cases was 
lower in HC-DOT (13.08%) compared to CDOT (24.12%). The number of smear-
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negatives increased, particularly for CDOT. No statistically significant difference was
found for residence.
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Table 3: Characteristics of patients at the baseline 2002/3 and at two years after 
CDOT implemented 2006/7
C h a r a c t e r i s t i c
s
B a s e lin e  a s s e s s m e n t 2 0 0 2 /3 2-years a f te r  CD O T 
im plem ented  2006/7
C D O T  
n (% )
H C - 
D O T  
n (% )
T otal 
n  ( % )
C D O T
n ( % )
H C - 






(5 0 .2 8 )
263
(5 0 .1 9 )
536
(5 0 .2 3 )
328
(5 0 .0 8 )
3 0 0
(4 6 .7 3 )
628
(4 8 .4 2 )
Fem ale 2 7 0
(4 9 .7 2 )
261
(4 9 .8 1 )
531
(4 9 .7 7 )
3 2 7
(4 9 .9 2 )
3 4 2
(5 3 .2 7 )
669
(5 1 .5 8 )
p-value 0 .97 0.30
Age g ro u p
18-39 175
(3 2 .2 3 )
171
(3 2 .6 3 )
346
(3 2 .4 3 )
208
(3 1 .7 6 )
221
(3 4 .4 2 )
429
(3 3 .0 8 )
4 0 -5 9 2 3 8
(4 3 .8 3 )
2 1 8
(4 1 .6 0 )
4 5 6
(4 2 .7 4 )
2 6 7
(4 0 .7 6 )
2 6 4
(4 1 .1 2 )
531
(4 0 .9 4 )
6 0 > = 0 130
(2 3 .9 4 )
135
(2 5 .7 6 )
265
(2 4 .8 4 )
180
(2 7 .4 8 )
157
(2 4 .4 5 )
337
(2 5 .9 8 )






(8 4 .7 1 )
411
(7 8 .4 4 )
871
(8 1 .6 3 )
4 2 0
(6 4 .1 2 )
4 7 8
(7 4 .4 5 )
898
(6 9 .2 4 )
Smear 59 62 121 158 84 242
112





(4 .4 2 )
51
(9 .7 3 )
75
(7 .0 3 )
77
(1 1 .7 6 )
80
(1 2 .4 6 )
157
(1 2 .1 0 )
p-value 0 .1 9 0.03








(7 .6 3 )
50
(3 .8 6 )
Battam bang 75
(1 3 .8 1 )
24
(4 .5 8 )
99
(9 .2 8 )
75
(1 1 .4 5 )
25
(3 .8 9 )
100




(1 2 .5 2 )
74
(1 4 .1 2 )
142
(1 3 .3 1 )
124
(1 8 .9 3 )
100
(1 5 .5 8 )
224




(9 .2 1 )
49
(9 .3 5 )
99
(9 .2 8 )
50
(7 .6 3 )
50
(7 .7 9 )
100




(1 3 .8 1 )
75
(7 .0 3 )
75
(1 1 .4 5 )
75




(9 .5 4 )
50
(4 .6 9 )
50
(7 .7 9 )
50
(3 .8 6 )
K am pot 25
(4 .6 )
25
(2 .3 4 )
25
(3 .8 2 )
25
(1 .9 3 )
Kandal 102
(1 9 .4 7 )
102
(9 .5 6 )
142
(2 2 .1 2 )
142




(1 .7 8 )
31
(4 .7 3 )
31
(2 .3 9 )
Phnom  Penh 25
(4 .7 7 )
25
(2 .3 4 )
25
(3 .8 9 )
25
(1 .9 3 )
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5.3 Effectiveness of CDOT
5.3.1 Comparison of treatment outcomes at baseline between CDOT and HC-DOT 
in year 2002-2003
At baseline, data for 550 and 524 patients were collected from CDOT and HC-DOT areas 
respectively. After adjusting for sex, age group and TB types, treatment success was 
similar between CDOT and HC-DOT areas (OR=0.54, 95%CI: 0.27-1.08, p=0.08). The 
treatment success, defined as combination of cure and completion, was successful and 
above 90% for all TB types in both areas (CDOT: 94.29%, HC- DOT: 96.76%). There 
was no statistically significant difference between groups for death or default rates 
(p=0.22 for the death and p=0.91 for defaulter). The results are shown in Table 4.
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Table 4: Comparison of treatment outcomes among all TB patients by type of DOT
in year 2002-2003
T re a tm e n t
ou tcom e











Success* 512 94.29 507 96.76 0.55 0.54 0.27-1.08 0.08
D ied 17 3.13 11 2.1 1.51 1.65 0.72-3.76 0.22
D e fa u lte r 7 1.29 6 1.15 1.13 1.06 0.36-3.07 0.91
F a ilu re 3 0.55 0 - - -










** O dds ratio adjusted for sex, age group and TB type
Tbe °ddS ° f ‘ tfeatment °Utco» e fOT « e a r  positive in boti, areas was also
similar a, baseline (OR=0.54, 95%CI: 0.24-1.18, p=0.12). There was no statistically
significant difference in death rate (OR-1.58, 95%CI: 0.56-4 41 „ -o  ^  ,
l > P or default rate
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(OR=1.06, 95%CI: 0.36-3.06, p-0.91) among smear positive patients between the two 
areas. Table 5 compares treatment outcomes among new-smear positive TB by type of 
DOT at baseline.
Table 5: Comparison of treatment outcomes among new-smear positive TB by type 
of DOT in year 2002-2003
Treatm ent
o u tc o m e
B aseline assessm ent (2002-2003)
<: d o t
H C -
D O T




OR** 95%  C l p-value
Success* 434 94.35 398 96.84 0.55 0.54 0.24-1.18 0.12
D ied 12 2.61 7 1.70 1.54 1.58 0.56-4.41 0.38
D e fa u lte r 7 1.52 6 1.46 1.04 1.06 0.36-3.06 0.91
F a ilu re 3 0.65 0 - - - - •
T ra n s fe r
o u t 4 0.87 0 - - - -
* Success is aen n ea  as com om ation o t completion and cure
** Odds ratio adjusted for sex, and age group
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655 and 642 patients for CDOT and HC-DOT areas were recruited in 2006-2007 two 
years after CDOT was implemented. No statistically significant difference was found for 
the treatment success rates between CDOT and HC-DOT areas (0R=1.26, 95%CI: 0.56- 
2.82, p=0.56). The treatment outcome was still very successful in both areas (97.1% for 
CDOT and 96.57% for HC-DOT). The death and defaulter rates were also similar (p=0.13 
for death and p=0.37 for default). See Table 6.
5.3.2 Comparison of treatment outcomes between CDOT and HC-DOT in year
2006-2007
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Table 6: Comparison of treatment outcomes among all TB patients by type of DOT
in year 2006-2007
Two years a fte r  th e  in te rv en tio n  (2006-2007)
H C -
C D O T D O T
T re a tm e n t Crude Adj 95%  Cl P-
ou tcom e No. % No. % O R OR** value
Success* 636 97.1 620 96.57 1.19 1.26 0.56-2.82 0.56
D ied 10 1.53 17 2.65 0.57 0.50 0.21-1.24 0.13
D e fa u lte r 6 0.92 3 0.47 1.96 1.94 0.44-8.61 0.37
F a ilu re 0 - 1 0.16 “ •
T ra n s fe r
o u t 3 0.46 1 0.16 2.95 3.36 0.34-33.43 0.29
♦Success is defined as com bination o f  completion and cure 
** Odds ratio adjusted for sex, age group and TB type
Comparing only new-smear positive TB, at two-years after CDOT was implemented, 
there was a borderline statistically significant difference in death rates in CDOT areas 
compared to HC- DOT areas after adjusting for sex and age (OR=0.33, 95%CI: 0.11-0 99 
p=0.05). However, the overall treatment success for smear positive did not differ between 
areas (OR=1.21, 95%CI: 0.51-2.86, p=0.66) (Table 7).
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Table 7: Comparison of treatment outcomes among new-smear positive TB patients
by type of DOT in year 2006-2007




C D O T D O T





95%  C l p-value
Success* 408 97.14 462 96.65 1.18 1.21 0.51-2.86 0.66
D ied 4 0.95 13 2.72 0.34 0.33 0 .1 1 -0 .9 9 0.05
D e fa u lte r 5 1.19 1 0.21 5.74 5.75 0.59-55.71 0.13
F a ilu re 0 - 1 0.21 - - -
T ra n s fe r
o u t 3 0.71 1 0.21 3.43 3.36 0.34-33.43 0.29
su ccess is denned 3s combination o t completion ¿md cure
** Odds ratio adjusted for sex, and age group
5.3 J  Comparison of treatment outcomes in CDOT areas by year of assessment 
Comparing treatment outcomes for the same CDOT areas over time, after adjusting for 
sex, age, and TB types, there was some evidence of a small non-sig„ifieant improvement 
in the treatment success rates from baseline to two-years after CDOT was implemented
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(OR=2.10, 95%CI: 0.95-4.62, p=0.06). Moreover, there was a statistically significant 
decline in death rate among all TB patients at two years after implementation of CDOT 
compared with the baseline (OR=0.37, 95%CI: 0.15-0.92, p=0.03) (Table 8)
Table 8: Comparison of treatment outcomes for all TB types in CDOT areas at the 
baseline and two-years after CDOT was implemented
T re a tm e n t
ou tcom e
C D O T  areas
Baseli
2






ars  a fte r 
D O T  
em ented 
6-2007)




OR** 95%  Cl
p-value
Success* 512 9 4 .2 9 636 97.1 2.03 2.10 0.95-4.62 0.06
D ied 17 3.13 10 1.53 0.48 0.37 0.15-0.92 0.03
D e fa u lte r 7 1.29 6 0.92 0.71 0.86 0.29-2.53 0.79
F a ilu re 3 0.55 0 " - -








3 0.46 0.62 0.83 0.19-3.56
0.80
** O d d s  ratio  adjusted for sex, age group and TB type
No statistically significant difference was found for treatment success rates for smear 
positive patients when analysed by CDOT areas before and after the intervention (OR=
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2.07, 95%CI: 0.86-4.99, p=0.10). However, there was a non-significant decrease in the 
death rate for smear positive TB at two year after CDOT was implemented compared 
with the baseline (OR=0.35, 95%CI: 0.10-1.12, p=0.08) (Table 9)
Table 9: Comparison of treatment outcomes for new-smear positive TB patients in 






Treatm ent Crude Adj p-value
outcom e No. % No. % OR OR** 95%  Cl
Success* 434 94.35 408 97.14 2.04 2.07 0.86-4.99 0.10
Died 12 2.61 4 0.95 0.36 0.35 0.10-1.12 0.08
Defaulter 7 1.52 5 1.19 0.78 0.77 0.24-2.49 0.66
Failure 3 0.65 0 ” •
Transferred 0.19-
out 4 0.87 3 0.71 0.82 0.83 3.56 0.80
** O dds ratio adjusted for sex, and age group
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5.3.4 Comparison of treatment outcomes in HC-DOT areas by year of assessment 
After adjusting for sex, age, and TB types, in HCs which implemented ambulatory DOT, 
there was no statistically significant improvement in treatment success (OR=0.90, 95%CI: 
0.45-1.81, p=0.77) or death rate (OR=1.35, 95%CI: 0.59-3.08, p=0.46). Table 10 shows
the result.
Table 10: Comparison of treatment outcomes for all TB types in HC-DOT areas at 
the baseline and two-years after the CDOT intervention
T re a tm e n t
ou tcom e
H C -D O T  a rea s
Baseline
2002-2003
2-years a fte r  
th e  C D O T 
in terven tion  
2006-2007




OR** 95% Cl P-value
Success* 507 96.76 620 96.57 0.94 0.90 0.45-1.81 0.77
D ied 11 2.1 17 2.65 1.27 1.35 0.59-3.08 0.46
D e fa u lte r 6 1.15 3 0.47 0.40 0.40 0.1-1.59 0.19
F a ilu re 0 - 1 0.16 • •
T ra n s fe r
o u t 0 - 1 0.16 -
♦Success is defined as com bination o f  com pletion and cure 
** O dds ratio  adjusted for sex, age group and TB type
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5.4 TB case-finding
Most of the patients registered in both CDOT and HC-DOT areas were new smear­
positive TB cases. At baseline (2002-2004) in the CDOT HCs, TB case-finding was very 
low at 348 cases in 2002, 861 cases in 2003 and 1139 cases in 2004 compared to the HC- 
DOT 614 cases in 2002, 998 cases in 2003 and 1245 cases in 2004. The average case 
finding rates under CDOT and HC-DOT areas were 25 and 30 patients respectively per 
year. After CDOT was implemented in 2004, TB case-finding continued to increase 
dramatically from 1431 cases in 2005 to 1611 cases in 2008. TB case-finding in HCs 
without implemented CDOT also increased, but the trend was much less from 1545 cases 
in 2005 to 1615 cases in 2008. Table 11 shows the total TB case-finding from 2002 to 
2008. Figure 14 illustrates the TB case-finding rate by year for both CDOT and HC-DOT 
areas.
Table 11: Number of total TB case-finding by HCs- CDOT and HCs-DOT from 
2002-2008
Year of reporting
2002 2003 2004 2005 2006 2007 2008
HCs with CDOT 348 861 1139 1431 1431 1475 1611
HCs-DOT areas 614 998 1245 1545 1458 1489 1615
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Figure 14: TB case-finding by year under both HCs with CDOT and without CDOT, 
2002-2008
However, further analysis of TB case-finding by using the difference-in-differences 
method shows that TB case-finding from HC with CDOT implemented and HC-DOT 
over time was equal. The TB case-finding between these two HCs was not significantly 
different (p-value: 0.547). This test shows that even though the trend of TB case-finding 
is seen to increase after the implementation of CDOT, the slopes were not significantly 
different.
5 .5  S u m m a ry :  k ey  f in d in g s  f ro m  th e  q u a n t i ta t iv e  s tu d y
CDOT tended to maintain high treatment success rates (97.1%) as did HC-DOT (96 57%)
with no significant difference between them (OR=1.26, 95%CI: 0.56-2.82, p=0.56) A
key finding of this study is that in CDOT areas, treatment success rates tended to show
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small non-significant improvements in treatment success rates from baseline to two-years 
after implementation (OR=2.10, 95%CI: 0.95-4.62, p=0.06). Death rates were 
significantly reduced (OR=0.37, 95%CI: 0.15-0.92, p=0.03). This difference reflects the 
selection of HCs for the CDOT program, which tended to be where treatment success 
rates were low and death rates were high, compared to areas not selected. The HCs 
selected for CDOT had poorer outcomes at baseline in terms of treatment su c c ess , death 
rates, defaulters and failures (although these differences were not statistically significant 
at the 5% level) and this was probably connected to the decision to implement CDOT in 
these centres (Tables 6 and 7). This situation is reversed for the comparisons after the 
introduction of CDOT (although again the differences are not significant) showing that 
the CDOT centres had more than made up their deficit in treatment outcomes and death 
rates (see Table 8 and 9).
The trend of TB case-finding at HCs with CDOT showed a dramatic increase overtime 
after the CDOT implementation, although not statistically significantly better than TB 
case-finding at HC-DOT (p=0.547) (Figure 14). However the further analysis of TB 
case-finding by using difference-in-differences method, shows that TB case finding from 
HC with CDOT implemented and HC-DOT over time were equal. The TB case-finding 
between these two HC groups was not statistically different (p=0.547). This test shows 
that even though the trend of TB case-finding is seen to increase after the implementation 
of CDOT, the slopes of increase were not significantly different.
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6 CHAPTER 6: Qualitative Methods
This chapter presents the methods of the qualitative study which aimed to explore the 
experiences of both CDOT and HC-DOT among patients, staff and DOT watchers.
6.1 Objectives
The specific objectives of study are:
a. To explore how HC-DOT and CDOT are functioning
b. To determine the strengths and weaknesses for each approach, and
c. To assess the acceptability of CDOT and HC-DOT to HC staff, TB patients and 
DOT watchers
6.2 Study population
Patients treated for TB in 2007 in both types of HCs included in the quantitative study 
were selected for the interviews. DOT watchers and health workers, who had experience 
supervising or watching patients taking medicines, were also interviewed, as were 
selected staff working at the TB section.
6.3 Methodology
The methods used were a combination of in-depth interviews and observations of new 
patients who were treated in 2009 and had taken medicines in the HCs and in the 
community with DOT watchers. In addition, the informal conversations between the
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author and patients or their families relating to the experiences of TB treatment were also 
noted for the analysis.
6.3.1 Sampling methods
In the qualitative study only two age categories were used, “young people” were defined 
as those between 18 to 40 years old because they were of reproductive ages. Those aged 
over 40 years were categorized as “old”.
Purposive sampling in qualitative research aims to find information rich cases (Patton 
2002), with a mixture of typical, extreme and political sampling. An “extreme” case 
would be someone who was very old, and a “typical” case would be a patient from a rural 
setting or an urban area. “Political sampling” would be of someone who was very old and 
from a very deprived area with known problems of access. Table 12 shows the sampling
matrix for the purposive sampling used in the study, sampling by rural and urban setting, 
gender and age.
Table 12: Sampling matrix for identified interviewee 
Interviewee Location Gender
Rural u * “  Müü ' t o *
<40 years >40 years <40 years >40 years
Patients 43 8 7 15 13 16
D O T  watchers 18 0 2 10 2 4
H eath s ta ff 21 6 13 11 2 1
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Patients were randomly selected by the author based on the sampling matrix stratification 
through the quantitative list. DOT watchers were identified through staff recommendation 
or were selected by the author. HC staff were selected for interview based on their TB job 
experience and their availability during the presence of the author. Methods and criteria 
for eligibility are shown in Table 13.
Table 13: Methods and criteria included for the interviews
In terv iew ee M ethods C rite r ia  fo r  elig ib ility
Patients •  In-depth interviews •  Smear positive, smear negative and extra
•  Observation taken o f pulmonary TB
new  patients treated in •  Treated for TB with CDOT and the
2009 am bulatory DOT in 2007
•  Included in the quantitative study
•  Cured, completed and defaulter patients
DOT w atchers •  In-depth interviews •  Experiences in distributing and watching
•  Observation during 
distributed and 
supervised m edicines to 
patients for current 
patients
patients taking m edicines
Health staff •  In-depth interviews •  W orking at the TB section in the HC
•  Observation during •  Experience in distributing and watching
distributed and 
supervised patients taken 
m edicines for current 
patients
patients taking m edicines
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6.3.2 Questionnaires for the qualitative study
The development of the topic guide for the interviews was informed by the pilot study 
and by issues raised in other qualitative research papers on the subject of adherence to TB 
treatment in other countries (Munro S, Lewin. S et al. 2007). The first such issue was the 
distance between the patient’s home and the HCs or DOT watcher’s home, including 
travelling time and availability of patient’s transportation. The second issue was the 
relationship between patients and treatment providers such as health staff or DOT 
watcher, as many studies reported that a patient’s relationship with DOT watchers was the 
factor that could influence patients’ adherence to treatment; for example poor follow-up 
by treatment providers (Nair.D, George.A et al. 1997; Watkins RE and Plant 2004) or 
carelessness of DOT watchers (Jaiswal A 2003; Greene 2004). The third issue was the 
issue of choosing treatment providers. The fourth issue was level of understanding of TB 
treatment among patients and DOT watchers. The last issue was support or the lack of 
support for patients during the treatment. These issues could all influence patients’ 
adherence to treatment.
The questionnaires were also designed to gather information about how HC-DOT and 
CDOT are working in Cambodia, which has a cure rate above the WHO target of 85%, 
and to find out the interaction between patients and treatment supervisors including health 
staff, and to obtain patients’ honest answers about satisfaction with their TB treatment.
6.3.3 Context for the qualitative interviews
The information sought by the qualitative study is outlined in the guide for in-depth 
interviews for staff (Appendix 10), for patients (Appendix 11) and for DOT watchers 
(Appendix 12) was:
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•  Information about the interviewee -  eg. sex, age, occupation, where they lived.
•  HC-DOT implementation including the arrangement and interaction between 
patient and staff
•  CDOT implementation including the arrangement and interaction between patient 
and DOT watcher, patient and staff,
•  Strengths and weaknesses of CDOT and HC-DOT, and
•  Perceptions of CDOT -eg. the views of implementing CDOT among staff at HC, 
DOT watchers and patients, and how patients feel about receiving treatment with 
someone other than staff at the HC.
6.4 Data collection methods
6.4.1 Interviews 
A. Formal interviews
All interviews were undertaken by the author, and carried out as agreed by the 
interviewee in terms of convenience of time and place. Most health staff preferred to be 
interviewed at the HC after 11.00 am in the morning because they were very busy in the 
early morning. Twenty four health staff were interviewed in the HC, and the other three 
staff at their home. Sixteen staff from HCs with CDOT were interviewed in this study, 
and the other eleven from the HC-DOT.
After identifying DOT watchers and patients from the quantitative list, the author asked 
health staff, village chief or heath volunteer for addresses and directions to the DOT 
watcher’s and patient’s home. A phone call was used when applicable to arrange the 
meeting time. From the experience of the pilot study, the author tried to avoid the
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research team being brought to the patient’s home by staff from the HC, because patients 
might then think that the research team was from the public sector. This would be likely 
to affect patients’ answers in the interviews.
Most patients and DOT watchers involved in the interviews were from rural areas, so 
interviews were conducted at their homes or in rice fields. Often, in rural areas interviews 
conducted at homes attracted the interest of more than one person. In particular family 
members and neighbors seemed interested and would sit with the interviewee during the 
interviews. However, we asked them to leave, and tried to find quiet private places for the 
interviews. Family members were sometimes called to assist when interviewees required. 
A total of 51 patients (28 CDOT patients and 23 HC-DOT patients) and 18 DOT watchers 
were interviewed in the study.
Participants interviewed received a sarong (Cambodian traditional skirt) from the author 
at the end of the interview for their contribution of time to this study. All interviews were 
conducted in Khmer language with no language barriers. Interviews were tape-recorded 
with verbal permission from the participants.
B. Informal discussions and feedback
Five interviews and discussions were held with patients’ relatives including wives and 
daughters o f patients receiving treatment at home where their treatment supervisors were 
their family members.
Many issues were discussed with family members, and health staff at the HCs and ODs
level throughout the entire data collection period, especially the practical issues for the
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implementation of DOT and CDOT approaches and what people in the community think 
about these approaches.
6.4.2 Observations
Observations on the interactions between new patients treated in 2009 and health staff, 
and between patients and DOT watcher were also made. However, these observations 
were only made for patients who were currently being treated for TB in 2009. Four 
interactions between patients and health staff were observed at the HC while another two 
interactions between patients and DOT watchers were observed at DOT watchers’ homes.
6.5 Ethical issues
Informed consent was agreed and consent forms signed before the interview (Appendix 
13).
6.5.1 Autonomy
The participant could refuse to participate at any point before or during the interview. 
Moreover, participants had the right to not answer any questions which they were not
happy answering. In this study, only one participant refused to finish the interview due to 
her health p r o b le m s .
6.5.2 Confidentially
All information received from the interviews was kept confidential. The interviews were 
carried out by the author and one assistant who was a note taker. To ensure 
confidentiality, the note taker was also asked to keep the information confidential. Only 
the author could have access to tape records and transcripts.
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6.5.3 Anonymity
To maintain the anonymity for participants involved in the interviews, no reference is 
made to the actual name of participants or to other circumstances that might identify the 
participants in the results.
6.6 Analysis
All interviews were taped and transcribed. The interviews lasted between one to one and 
a half hours. After interviews finished, the author was responsible for performing the 
transcription of interviews in Khmer language and then later translated them into English. 
Each transcription took between 5 to 6 hours to complete. Data analysis for this 
qualitative study was done in several steps using thematic content analysis (Daly J, 
Kellehear A et al. 1997). The thematic analysis method was selected to use in this study 
because it is a useful method to search for themes that emerge as being important to the 
description of the phenomenon (Daly J, Kellehear A et al. 1997).
The qualitative data analysis package NVivo 8 (NVivo 2008) was used for the initial 
stage of coding the themes, which allowed the author to indicate segments of the 
transcripts and make notes on particular themes. It also allowed complex searching and 
the ability to link research notes to coding. However, the NVivo package was only used 
to organise the themes and coding, but not for the data interpretation.
6.6.1 Finding general themes
The first step was to identify general themes regarding the structure of HC-DOT and
CDOT, experiences of TB supervision and treatment for both approaches, and perception
of TB care towards health staff, DOT watchers and patients. General themes for the
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structure of HC-DOT and CDOT included the number of TB staff in the HC, availability 
of TB tests in the HC, DOT treatment requirement, allocation of patients for treatment, 
especially place and DOT watcher for patients.
6.6.2 Identifying emergent categories
The second step was to identify the categories of effects of CDOT and HC-DOT 
approach. This was particularly important in identifying the various factors that could 
influence patients’ adherence to treatment for both treatment approaches.
6.7 Limitation of the data collection for qualitative method
Most patients selected in this study lived in rural areas where the infrastructure is very 
poor. In some areas the author and research team took more than two hours by car and 
walking from the HC to get to the patient’s home. Finding patients and DOT watchers’ 
homes was not easy as there are no house numbers and the road instructions given by 
DOT watchers, health villagers or staff at HC were often not very clear. The author tried 
to arrange meeting times with patients by phone, but not all patients had access to the 
telephone.
There were several other problems affecting the data collection; the first was migration;
some patients were not at home during the author’s visit since they worked in the city or
had moved to another province. The second problem was not finding the patient’s home.
The last problem was that a few selected patients had passed away due to other diseases.
When these problems occurred, the author interviewed the next patient on the list; this
was time consuming, so sometimes the author needed to select patients based on
recommendations from health volunteers or local villagers, to identify patients whose
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houses were easy to find or who lived close to the main road. This selection may have 
impacted on the study findings, as patients who lived closer to the main road or the HC, 
may have less difficulty travelling either to HC or a DOT watcher’s house; in particular 
they may have easier access to DOT information, TB education and treatment than those 
who lived farther or were more isolated from others in the community. In contrast to 
patients whose houses were easier to find, those not interviewed because the author could 
not get access to their houses, may have more negative experiences and face more 
problems during the treatment, including problems of transportation, difficulty in coming 
to the HC, the problem of follow-up by staff or DOT watchers, and the level of 
understanding of DOT and TB treatment may have differed. Furthermore; patients 
selected in the interviews based on the recommendation by staff or DOT watchers, may 
have better relationships and more successful treatment compared to those not selected. 
This may have influenced the findings on interaction between staff/DOT watchers and 
patients. It is not clear how this may have affected the results, but it is likely that “hard to 
reach” patients were more likely to benefit from CDOT rather than HC-DOT, as they 
would have greater transport problems, so to this degree, the benefits of CDOT may be 
under-reported
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Picture 9: Road from the health centre to patient’s house
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Picture 10: List of community health workers in the health centre
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7 CHAPTER 7: Qualitative results for the general
arrangement for implementation of DOT treatment in 
Cambodia
This chapter presents the results of DOT administration in both HCs in Cambodia. 
Results were based on analysis of the interviews, and where relevant, input from other 
sources such as observation and notes from informal discussion.
7.1 Characteristic of participants
7.1.1 HC staff
A total of 27 health staff (24 men and 3 women) were interviewed in the study. The ages 
ranged from 25 to 56 years old. Most of them were primary and secondary nurses; their 
positions were as directors of HC and persons responsible for TB units including 
consultation, TB health education, TB treatment or other activities related to TB disease. 
The majority of health staff participating in the interviews had been working at the HC 
for more than 10 years.
7.1.2 Patients
Twenty three patients from the 17 HCs treated with HC-DOT, and twenty eight patients
from 26 HCs treated with CDOT, were interviewed. Twenty nine patients were women
and the rest were men. The ages ranged from 22 to 68 years, and most of them were
married. Almost all patients had either no education or had only completed primary
school. Most were self employed such as farmers, motor bicycle repairers and
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housewives; five patients were primary school teachers. All patients lived in the rural 
areas and their incomes were less than 2000 Riel ($0.50) per day. The ethnicity of all
patients was Khmer.
Among patients interviewed in the study, 19 had finished their treatment within the last 
three months, and 14 others had completed the treatment between 3 to 6 months before 
the interview. Another 5 patients had not yet completed the treatment at the time of 
interviews; and the remaining patients had finished the treatment more than 6 months ago.
7.1.3 DOT watchers
A total of 18 DOT watchers were interviewed, twelve men and six women, aged from 29 
to 68 years. Most DOT watchers had completed primary or secondary school; and they 
could read and write Khmer. The majority were farmers and some were community 
health volunteers. All had worked as DOT watchers for more than two years.
7.2 DOT administration
7.2.1 Staff in TB unit
Generally two or three staff worked in the TB unit in each HC. They are responsible for 
finding suspect cases in the community, TB health education, taking sputum samples and 
sending them to the laboratory, and watching patients swallow medicines at the HC Their 
responsibilities were not only for TB but also for general consultation, PEV program, 
HIV/AIDS and maternity and child care.
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7.2.2 Identifying suspect cases
The first place where patients seek treatment is at the HCs and referral hospitals. Most 
patients were confident about the government health services, but a few patients went to 
private clinics, pharmacies or drug stores to buy medicines because of the waiting time in 
HCs, and would be referred back to HCs by private doctors or pharmacists for further TB 
tests if TB was suspected. One patient stated:
“F ir s t  I  w e n t  to  th e p r iv a te  c lin ic  n ea r  th e m arke t. D o c to r  g a v e  m e  a n  in je c tio n  f o r  2  
d a y s ... I  s t i l l  co u g h ed . Then d o c to r  to ld  m e  to  g o  f o r  th e  c h e s t X - r a y  a t  th e  h o sp ita l. ” (HC- 
DOT patient, male 51 years old)
Some TB cases were found during general consultations and medical check-ups at the 
HC. As mentioned by most staff and patients, only a few TB patients were referred to the 
HC by health volunteers or staff, and they were usually living in the same village as staff 
or close to staffs home. Quote: “7 f e l t  v e r y  s ic k  a n d  I  w e n t to  th e  H C  f o r  the  
c o n su lta tio n . ” (HC-DOT patient, female 52 years old)
Others involved in referring patients with TB symptoms included neighbors, relatives and 
friends. As this quote illustrates: "B e c a u se  I  h a d  s im ila r  sy m p to m s  a s  m y  n e ig h b o r  w h o  
j u s t  f in i s h e d  th e  TB tre a tm e n t, then  h e  to ld  m e  to  g o  f o r  TB te s ts  a t  th e  H C . ” (CDOT 
patient, female 59 years old)
7.2.3 TB te s ts
The most common TB test used was the sputum test. Patients were asked to give three
saliva samples over two days. Lung X-rays were not available at the HC level, but only in
the main referral hospitals in the city or in some private clinics. Some patients were
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referred for X-ray if the sputum tests were negative depending on the distance between 
the HCs and the referral hospitals and the staffs level of experience.
One staff member noted: “ W e h a v e  o n ly  th e  sp u tu m  te s ts  f o r  T B  in  o u r  H C . C h e s t X -r a y  
is  a v a ila b le  o n ly  in th e r e fe r r a l  h o s p ita l  w h ic h  is  f a r  f r o m  h ere .... B a s e d  on  m y  
e x p erien ce , p a t ie n ts  w h o  w e re  sm e a r  n e g a tiv e  b u t w e r e  v e r y  s ic k  a n d  h a d  th e  TB  
sy m p to m s;  s ta r te d  ta k in g  TB m ed ic in es  r ig h t a w a y . A  c h e s t X - r a y  w o u ld  d e la y  
trea tm en t. ” (Staff at HC- CDOT, male 40 years old)
All sputum samples need to be sent to laboratories at referral hospitals because the HCs 
do not have their own laboratories, microscopes and specialists. Sending samples to the 
laboratory could not be done every day, depending on the location of HC and the distance 
between HCs and the hospitals. Most HCs are located far from hospitals, some more than 
14 kilometers, which would take more than half an hour by motorbike. On average, 
samples are sent every 3 days if HC is close to the laboratory, but once a week or every 
two weeks if the HC is very far and transportation difficult.
Quote: "7 ta k e  th e  s a m p le s  f r o m  p a t ie n ts  a n d  s e n d  th em  to  the la b o r a to r y  a t  th e  r e fe r ra l  
h o s p i ta l  w h ic h  is  f a r  f r o m  h e re  s in ce  th e  H C  d o e s n ’t  h a ve  a n y  m ic r o s c o p e s  a n d  m a teria ls .
I  s e n d  th e m  o n c e  a  w e e k  b y  m y  m o to rb ik e , e v e r y  tim e  i t  ta k es  m e a b o u t 2 0  m in u te s  to  g e t  
to  th e  h o sp ita l. ” (Staff at HC-CDOT, male 41 years old)
Every HC receives $24 three monthly from the CENAT to send the tests to the laboratory.
This covers weekly transport costs. Some staff reported that if the samples needed to be
sent more than once a week, they had to pay from their own money. As one staff member
noted: “T he $ 2 4  g iv e n  b y  th e  C E N A T  a llo w s  u s  to  s e n d  s a m p le s  4  t im e s  a  m onth . I f  th ere
a r e  a  lo t  o f  s u s p e c t  c a s e s  a n d  w e  n e e d  to  s e n d  th e  s a m p le s  tw ic e  a  w eek , th en  o u r  s ta f f
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p a y  f r o m  th e ir  o w n  p o c k e t  f o r  th e  tra n sp o r ta tio n . ” (Staff at HC-CDOT, male 38 years 
old)
Results were picked up by staff within 1 or 2 weeks from when they sent the new 
samples. Most patients reported that they were asked to come back to the HC for 
treatment about 10 days after the sputum samples were taken. Others mentioned almost 
15 days before starting treatment, especially patients treated at HCs located far from the 
laboratory. One patient said: “I t was a lm o s t 3  w e e k s  f o r  m e u n til I  w a s  a s k e d  to  co m e  
b a c k  a t  th e  H C  f o r  tre a tm e n t b eca u se  s ta f f  to ld  m e th a t  m y  sp u tu m  w a s  s e n t to  the  
la b o r a to r y  w h ic h  is  f a r  f r o m  o u r  d is tr ic t. ” (CDOT patient, male 33 years old)
7.2.4 HIV/AIDS test
In some HCs, an HIV/AIDS test was required for TB patients before starting the TB. This 
test was available only for HCs with NGO funded TB and HIV programmes. Few patients 
interviewed in the study had this test.
“ T h is H C  r e q u ir e s  H IV  te s t  f o r  p a t ie n ts  tr e a te d  f o r  TB. I  k n o w  o n ly  m y  H C  a n d  tw o  o th er  
H C s  in  th is  O D  u se  c o m b in e d  H IV  te s t  w ith  TB p r o g r a m  b e c a u se  it  is  fu n d e d  b y  C H W  
( lo c a l  N G O ). The o th e r  H C s  d o n ’t  re q u ire  H IV  te s t  f o r  TB p a t i e n t s ." (Staff at HC-DOT, 
male 40 years old)
7.2.5 Direct observation treatment (DOT)
DOT was implemented at the HC level in 2002, for the long course treatment of 8
months; 2 months with staff at HC, and for the other 6 months patients took medicines at
home without DOT watcher. The short course treatment (6 months) was fully introduced
in 2004; some HCs implemented the ambulatory DOT (HC-DOT) where staff are the
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DOT watchers. Others implemented CDOT (DOT in community) where the DOT 
watchers included chiefs of villages, health volunteers, or family members. Some HCs 
implemented both types of DOT.
TB treatment, including medicines, is free for everyone within the country, although, 
patients pay around 4000 Riel (US$1) for the first consultation. " D u rin g  th e w h o le  
tre a tm e n t, I  p a i d  o n ly  4 ,0 0 0  R ie l a t  f i r s t  b e fo re  th e y  to o k  m y  sa m p le s , th e r e s t  I  d i d n ’t  p a y  
a n y th in g  b e c a u se  T B  m e d ic in e s  w e re  f r e e .” (CDOT patient, female 39 years old)
HCs do not treat relapse patients and multi-drugs resistance patients. These are referred to 
the referral hospitals or the TB hospital in Phnom Penh.
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8 CHAPTER 8: Qualitative results for specific implementation 
of CDOT
This chapter presents the results for the implementation of CDOT program including the 
structure, the weakness and strengths of CDOT in Cambodia. The acceptably of 
implementing CDOT program among staff, DOT watchers and CDOT patients are also 
presented in this chapter.
8.1 The implementation of CDOT program
The implementation of CDOT started between 2005 and 2006. This program was 
introduced and established by the CENAT in collaboration with other local and 
international organizations such as USAID, Japan International Cooperation Agency 
(JICA), Reproductive and Child Health Alliance (RACHA), Cambodian Health 
Committee (CHC), Partners for Health and Development (PFHAD), and Save Children 
Australia (SCA). The CDOT program was a part of the health promotion program 
activities funded by these organizations. Selection of HCs for implementation of CDOT 
depended on the availability of sponsored funding. “C D O T  is  p a r t  o f  h ea lth  a c tiv it ie s  
s u p p o r te d  b y  th e  R A C H A , b u t TB a n d  C D O T  a re  n o t th e f i r s t  p r io r i ty  f o r  them , b eca u se  
th e y  m a in ly  s u p p o r t  m a te r n ity  a n d  c h i ld  ca re , a n d  f a m i ly  p la n n in g  in  th e  H C . ” (Staff at 
HC-CDOT, male 40 years old)
While the CDOT program started at the end of 2005, its duration varied between HCs 
depending on the funding available from its sponsors, with most sponsors funding for 1 to 
2 years. During the study period, some HCs had already terminated the CDOT program;
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other HCs said that the program would finish in the near future due to lack of funding. 
One staff member reported: "M y H C  h a s  im p le m e n te d  th e  C D O T  s in c e  th e e n d  o f 2 0 0 5 . 
H o w e v e r , b y  th e  e n d  o f  th is  y e a r , th e C D O T  w il l  c e a se  in m y  H C  b eca u se  R A C  H A is  
g o in g  to  p u l l  o u t th e f u n d  f r o m  TB a n d  C D O T . I  th in k  th is  o rg a n iza tio n  run  o u t  o f  fu n d s  
f o r  C D O T  p r o je c t  b e c a u se  th e y  h a ve  m a n y  a c tiv i t ie s  su ch  a s  f a m i ly  p la n n in g , a n d  m o th e r  
a n d  c h i ld  ca re . T h ey  h a v e  to  d e c id e  w h ich  o n e  is  th e  f i r s t  p r io r i t y  f o r  them . ” (Staff at HC- 
CDOT, male 42 years old)
The implementation of CDOT differed from one HC to another, depending on the policy 
and program of the individual sponsor. For example, some sponsors such as RACHA, 
JICA, and USAID provided funds directly to HCs to run the CDOT program. Biannual 
reports of the number of new TB cases and treatment outcomes were submitted to the 
sponsors and time to time, inspection teams of the sponsors were assigned to follow-up 
on the registration, the operational activities and on the way of DOT watchers observe 
patients in the community.
Quote: "JICA h a s  p r o v id e d  m o n e y  d ir e c t ly  to  o u r  H C  to  im p lem e n t th e  C D O T  p ro g ra m .  
T h e y  w e r e  n o t in v o lv e d  in th e  tra in in g  a n d  th e s e le c tio n  o f  D O T  w a tch ers . T w ice  a  y e a r  
w e  n e e d  to  s e n d  th em  th e  r e p o r ts  o f  th e  n u m b er  o f  n e w  c a s e s  a n d  tre a tm e n t o u tc o m e s  f o r  
T B  a c tiv it ie s . S o m e tim e s  th e ir  in s p e c to r s  c o m e  to  c h e c k  th e  r e p o r ts  a t  th e  H C  a n d  th e y  
a ls o  g o  to  v is i t  p a t ie n ts  a n d  D O T  w a tc h e r s  in  th e  co m m u n ity  to  s e e  h o w  th e  C D O T  is  
p r a c t ic e d . " (Staff at HC-CDOT, female 36 years old)
Where the CDOT program was sponsored by CHC, PFHAD, and SCA organizations TB
staff of the HCs were only involved in the activities of providing training to DOT
watchers and follow-up of patients’ adherence to treatment. Other activities, such as the
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selection of DOT watchers, delivery of medicines to DOT watchers, and the incentives 
for DOT watchers were organized by the sponsors.
“ W e w e r e  in v o lv e d  o n ly  f o r  th e  TB  tra in in g  a n d  s o m e tim e s  g o  to  v is i t  p a t ie n ts  a n d  D O T  
w a tc h e r s  in  th e  com m u n ity . The C H C  s e le c te d  th e D O T  w a tc h e r s  f o r  th e  p ro g ra m ;  
e s p e c ia lly  th is  o rg a n iza tio n  p a i d  f o r  th e tra n sp o r ta tio n  f o r  D O T  w a tc h e r s  to  co m e  a t  the  
H C  to  c o l le c t  m ed ic in es . ” (Staff at HC-CDOT, male 40 years old)
HCs implementing the CDOT also used some ambulatory DOT. According to staff 20 to 
30% of patients were treated with ambulatory DOT.
8.2 Identifying suspect cases under the CDOT areas
Through the media and health education in the community by staff and health volunteers, 
patients may decide to seek TB consultation at the HC. The majority of suspect cases 
came for sputum tests by themselves especially those who live close to the HC. Patients 
who lived far from the HC were referred by DOT watchers, family, friends, or neighbors. 
For those who lived very far from the HC and had difficulty to come for the sputum 
check, DOT watchers were asked to bring the containers with patient’s sputum back to 
theHC.
“I f  p a t ie n t s  c o u ld n '/ c o m e  to  th e  H C , w e  a s k e d  D O T  w a tc h e r s  in th e  v il la g e  to  c o lle c t  
th e ir  sp u tu m  s a m p le s  a n d  b r in g  th em  b a c k  to  us. ” (Staff at HC-CDOT, male 26 years old)
8.3 The tr e a tm e n t procedures
In the same way as for HC-DOT, patients with results showing the existence of either TB
or extra-pulmonary TB were asked to come back to the HC. Contact was made through
staff at the HC, chief of the village, the DOT watchers, friends and their neighbors.
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Usually, the contact would be made by the same DOT watchers who referred patients for 
the sputum check at the HC in the first place.
For patients who could come to the HC, staff explained to them about the DOT including 
treatment duration, side-effect of drugs, time, place and name of the DOT watcher who 
would be responsible for watching them during the whole treatment, and especially the 
consequence of non-adherence to treatment. Patients were asked to sign the agreement 
form between patients and staff or DOT watchers, in which they agreed to take medicines 
regularly with DOT watchers for the whole period of treatment. For patients who could 
not come for their results, DOT watchers were asked to meet staff, who explained about 
the patient’s profiles including name and address, patient’s results, type of TB, and the 
medicines that patients needed to take for the initial and continuous phase: "A fter p a t ie n ts  
w e r e  s e le c te d  f o r  m e  to  ta k e  ca re , th e  d o c to r  a t  H C  p h o n e d  m e  to  t e l l  a b o u t  p a t i e n t ’s  
n am es, th e ir  TB re su lts , th e ir  a d d re sse s , a n d  m e d ic in e s  th a t p a t ie n ts  n e e d e d  to  ta k e  f o r  
th e  in it ia l  p h a se . ” (DOT watcher, male 55 years old)
8.4 Allocation of patients for the treatment under HCs which implemented CDOT
Patients were allocated to either the ambulatory DOT or CDOT based on staffs 
decisions. Most staff said that patients were allocated to treatment with the ambulatory 
DOT if  they lived less than 5 kilometers from the HC, except patients who were very 
sick, old, had no transportation, or had other reasons that made them unable to come for 
the treatment at the HC. The CDOT was used for patients who lived further from the HC 
or were unable to access the HC every day during the treatment. As a patient said: “1  
d i d n ’t  s e le c t  w h e re  I  w a n te d  to  ta k e  m e d ic in e s ;  th e  d o c to r  a t  th e  H C  a d v is e d  m e to  take
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m e d ic in e s  w ith  th e  D O T  w a tc h e r  in  m y  v il la g e  b e c a u se  h e  k n e w  th a t  1  d o n ’t  h a v e  a n y  
v e h ic le  to  g o  to  th e  H C . ” (CDOT patient, female 39 years old)
8.5 Places and DOT watchers for patients treated with the HC-DOT
Patients treated with HC-DOT came to take medicines with staff at the HC from Monday 
to Friday for the initial phase; during the weekend and national holiday patients were 
allowed to take medicines at home. During the continuous phase, most patients were 
allowed to take medicines at home without any supervisor; only a few of these patients in 
the study took medicines with DOT watchers for the continuous phase.
“/  w e n t  to  ta k e  m e d ic in e s  w ith  s ta f f  a t  the H C  e v e r y  m o rn in g  f r o m  M o n d a y  to  F r id a y  f o r  
th e  f i r s t  4 5  d a y s , a n d  th e  r e s t  o f  m y  tre a tm e n t I  to o k  m e d ic in e s  a t  h o m e b y  m y s e l f ” 
(Patient, male 69 years old)
The most important period for the TB treatment is the initial phase, when unpleasant side- 
effects are most likely, so patients are required to have DOT watchers for their adherence 
to treatment. For the continuous phase (usually the 3rd-6th months) patients tend to 
become more comfortable with medicines and they understand the treatment process; so 
they are allowed to take medicines at home if they could not come to the HC. As a staff 
reported: “ T he f i r s t  im p o r ta n c e  o f T B  tre a tm e n t th a t w e  n e e d  to  h a v e  so m e o n e  to  o b s e rv e  
p a t ie n ts  is  th e  f i r s t  tw o  m o n th s; a f te r  th a t  p a t ie n ts  k n o w  th e  tim e  o f  ta k in g  m ed ic in e s  a n d  
f e e l  c o m fo r ta b le  w ith  m ed ic in e s . T hen  w e  a l lo w e d  th em  to  ta k e  m e d ic in e  a t  hom e. ” (HC- 
CDOT staff, female 53 years old).
Most staff said that patients needed to sign a form to agree to take medicines every day at 
home until the treatment ended. The treatment cards were checked by staff whenever
patients came to refill medicines at the HC. Some staff mentioned that even though they 
allowed patients to take medicines at home, they still followed up the patients’ adherence 
to treatment by checking the treatment cards and visiting the patients at home.
8.6 Type of DOT watchers for CDOT patients
According to staff, there were two types of DOT watchers: permanent and temporary 
DOT watchers. However, the author found out that in practice family members were 
involved as DOT watchers for some CDOT patients.
8.6.1 The permanent DOT watchers
The majority of DOT watchers involved in the CDOT program were permanent DOT 
watchers. This type of DOT watchers was a village health volunteer or the chief of 
village. These people were involved in other health activities for HCs including mother 
and child care program, family planning, malaria, and HIV/AIDS. Generally, there were 
1 or 2 permanent DOT watchers in one village; they were selected by the staff and the 
sponsors of program. As note by a DOT watcher: “I  a m  a  h ea lth  v o lu n te e r  in  th e  v illa g e . 
1 a m  in v o lv e d  in  m a n y  h e a lth  p r o g r a m s  f o r  th e  H C . S in ce  2 0 0 5  I  w a s  a s s ig n e d  b y  s ta f f  
a n d  R A C H A  o r g a n iza tio n  to  w a tc h  T B  p a t ie n ts  ta k in g  m e d ic in e s  in  th e  com m u n ity . ” 
(DOT watcher, male 68 years old)
The selection of DOT watchers depended on their educational level, their experience
related to health activities, and the relationship between them and staff at the HC or the
sponsors. The basic requirement to become a DOT watcher is to know how to read and
write in the Khmer language, because they need to tick the patient’s treatment cards for
the follow-up patient’s adherence to treatment.
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DOT watchers received 2 to 3 days training with staff at the HC and/or staff from the 
sponsors before beginning work. The training included TB symptoms, TB educations in 
the community, definition of DOT treatment, the side-effect of medicines, how to follow­
up patients, the consequence of non-adherence to treatment, and how to deal with any 
problem that can happen during the treatment. However, DOT watchers mentioned that in 
the trainings TB was just one of many health activities including family planning, 
maternity and child care, HIV/AIDS, and malaria. One DOT watcher said: “/  h ave  
r e c e iv e d  th e  tra in in g  f o r  TB trea tm en t, TB s y m p to m s  a n d  h o w  to  f o l lo w - u p  p a t i e n t s ' 
a d h e r e n c e  to  trea tm en t. B u t th e  TB tra in in g  w a s  j u s t  o n e  s e s s io n  a n d  th e  r e s t  o f  th e  
tr a in in g  w a s  a b o u t  f a m i ly  p la n n in g , m a la r ia , v a c c in a tio n  a n d  H IV /A ID S. ” (DOT 
watcher, male 52 years old)
DOT watchers were asked to come back for a meeting at the HC every 2 or 3 months to 
review the TB training and to discuss any problems that they faced during their work. 
However, most DOT watchers said that the regular training happened only a few times at 
the beginning of the program; up to now they have been asked to come back for the 
training at the HC only once or twice a year because of the limitation of funds. “The  
r e g u la r  m e e tin g  f o r  T B  w ith  s t a f f  a n d  th e  N G O s  h a p p e n e d  o n ly  f o r  th e  f i r s t  6  m on th s, d u e  
to  la c k  o f  f u n d s  f r o m  th e  s p o n s o r  th e  m e e tin g  w a s  r e d u c e d  to  tw ic e  a  y e a r ” (DOT 
watcher, female 46 years old)
In addition, the family members of DOT watchers such as spouses and children were also 
involved in giving and watching patients take medicines when DOT watchers were busy 
or traveled during the treatment: “S o m e tim e s  w h en  h e  n e e d e d  to  a t te n d  th e  m ee tin g s  in
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th e  Clty’ h e  a s k e d  h ls  wif e  t0  b rin S  m e th e  m ed ic in e s  to  ta k e  a t  m y  h om e b e fo re  sh e  w e n t  
to  th e  m arket. ” (CDOT patient, male 63 years old)
DOT watchers involved in the study have worked in the CDOT program for more than 2 
years. Some DOT watchers have more experience because they have observed many 
patients, while others have observed only 2 to 3 patients. Most DOT watchers revealed 
that they could observe 3 to 4 patients at the same time; the number of patients for each 
DOT watcher was assigned by staff at the HC.
8.6.2 The temporary DOT watchers
Temporary DOT watchers were patient’s neighbors, friends or sometimes staff at the HC. 
They were asked to be involved as DOT watchers from time to time when the permanent 
DOT watchers were not available in the areas where patients lived. One patient said that- 
B e c a u se  th e  h e a lth  v o lu n te e r ’s  h o u se  in  th is  v il la g e  is  v e r y  f a r  f r o m  m y  house, so  I  to o k
m e d ic in e s  w ith  M rs ....(n a m e )  w h o  l iv e s  n ex t d o o r. S h e  is  j u s t  a  h o u s e w ife .” (CDOT 
patient, female 38 years old).
Temporary DOT watchers were also used for the continuous phase for ambulatory DOT 
patients who could not come to the HC and especially for those who did not have any 
family member living in the same household.
Some HC staff were also involved in giving medicines in the community, especially to 
those who lived close to staffs house and have difficulty to come to the HC “I  to o k
m e d ic in e s  w ith  D r., (n am e) w h o  l iv e s  a r o u n d  1 0  m in u te s  f r o m  h e r e  a n d  a lso  w o rk s  a t  the  
H C . ” (CDOT patient, female 67 years old)
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TB training sessions were also offered to temporary DOT watchers before they started 
their work. However, the training was only one day. “The tr a in in g  th a t  th e y  h a ve  
r e c e iv e d  f r o m  o u r  s ta f f  i t  w a s  j u s t  b a s ic  f o r  th e  trea tm en t. T h ey  w e r e  a s k e d  to  j o in  th e  
tra in in g  s e s s io n  o n ly  h a lfd a y . ” (Staff at HC-CDOT, male 41 years old)
8.6.3 Family members involved as DOT watchers
Most staff mentioned that employment of family members as DOT watchers for the initial 
phase was avoided in some HCs because it was not recommended by the NTP in the 
national guidelines, as it would be very difficult to control the patients’ adherence to 
treatment. “In  th is  H C , w e  d o n  V u se  f a m i ly  m e m b e r s  a s  D O T  w a tc h e r s  b e c a u se  p a t ie n ts  
m a y  n o t  b e  a f r a id  o f  th e ir  o w n  f a m i ly  m em b e rs;  e s p e c ia lly  f a m i ly  m e m b e rs  u s in g  a s  D O T  
w a tc h e r s  i s n ’t  r e c o m m e n d e d  in th e  g u id e lin es . ” (Staff at HC-CDOT, male 40 years old)
The involvement of family members as DOT watchers was applied only for the 
continuous phase of ambulatory DOT patients and some special cases, for example for 
patients who were very sick, unable to travel, and those who lived far from the HC and 
health volunteers’ house. As stated by one patient: “D o c to r  a s k e d  m y  w ife  to  w a tc h  a n d  
r e m in d  m e  a t  h o m e  f o r  th e  tim e  o f  ta k in g  m ed ic in e s  e v e ry  d a y  f o r  th e  w h o le  6  m on th s  
b e c a u s e  I  w a s  v e r y  s ic k  a n d  c o u ld n 't  g o  a n yw h ere . ” (CDOT patient, male 33 years old)
Family members who watched patients taking medicines were asked to meet with staff at 
the HC for briefing about the treatment procedures, patient’s medicines, the time to take 
medicines, how to tick the treatment card, some side-effect of medicines, and the 
consequence of patient’s non-adherence to treatment.
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Family members as DOT watchers for the CDOT patients were allowed by most HCs. 
Many CDOT patients mentioned that family members played a role as DOT watchers by 
giving and watching them take medicines when their DOT watchers were absent: “ W hen  
m y  D O T  w a tc h e r  w a s  busy, h e  g a v e  m e d ic in e s  to  m y  s o n  f o r  f e w  d a y s  a n d  a s k e d  h im  to  
o b s e r v e  m e  u n til m y  D O T  w a tc h e r  ca m e  b a c k  to  th e  v illa g e . ” (CDOT patient, female 67 
years old).
Even when family member were not assigned directly as DOT watchers they were 
involved in assisting and encouraging patients to complete the treatment. Family 
members were involved in reminding patients to take medicines, accompanying patients 
to DOT watcher’s houses, and going to collect medicines from the HC: “M y  d a u g h te r  
e n c o u r a g e d  m e to  co n tin u e  ta k in g  m ed ic in e s  w h e n e v e r  1 w a n te d  to  g iv e -u p  du e  to  s id e  
e ffe c t  o f  d ru g s. S h e  b o u g h t g o o d  f r u i ts  a n d  d e s s e r ts  f o r  m e  to  ta k e  a f te r  I  to o k  m ed ic in es. 
S o m e tim e s  w h en  I  w a s  v e r y  tired , sh e  h e lp e d  m e to  b r in g  m e d ic in e s  f r o m  D O T  w a tc h e r ’s  
h o u s e  a n d  a s k e d  m e  to  ta k e  th e m  a t  h om e. ” (CDOT patient, female 56 years old)
8.7 The selection of DOT watchers for CDOT patients
The DOT watcher for individual patient was selected by staff at the HC. It was also 
mentioned that sometimes DOT watchers and patients did not know each other before. 
One DOT watcher said that: “I  c o u ld n ’t  s e le c t  p a t ie n ts ;  th e y  w e r e  a s s ig n e d  b y  s ta f f  a t  the  
H C ; so m e tim e s  I  d id n  ’t  k n o w  th e se  p a t ie n ts  b efore . ” (DOT watcher, male 59 years old)
Some staff mentioned that patients could change their DOT watchers if they were not
satisfied with the selection. However, patients did not change their DOT watchers, even
though they were not satisfied because they thought that if they changed the DOT
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watchers, it could lead to trouble in the relationship between staff and patients during the 
treatment. “M y  D O T  w a tc h e r  w a s  a p p o in te d  b y  th e  d o c to r ;  I  d id n ' t  k n o w  h im  b efo re . We 
r a r e ly  ta lk e d  e v e r y  tim e  I  w e n t to  h is  house, w e  d id n  7 h a v e  a  g o o d  c o m m u n ic a tio n  d u r in g  
th e  trea tm en t. B u t I  w a s  a f r a id  o f  a sk in g  th e  d o c to r  to  ch a n g e  b e c a u se  I  d id n  7 w a n t to  
h a v e  a n y  tro u b le  e ith e r  w ith  th e d o c to r  o r  th e D O T  w a tch er . ” (CDOT patient, male 30 
years old)
When asking patients how satisfied they were with the selection of DOT watchers by 
staff, most said that they were happy because they have known each other before the 
treatment started. Especially, their DOT watchers were also the village health volunteers, 
so they could talk directly with them when they have any side-effects: “I  w a s  v e r y  h a p p y  
b e c a u s e  h e  is  a ls o  a  h e a lth  vo lu n teer . H e w a s  like an  u n cle  to  m e  b e c a u se  m y  f a th e r  a n d  
h im  a r e  v e r y  g o o d f r ie n d . ” (CDOT patient, female 21 years old)
8.8 The role of DOT watchers for the CDOT program
DOT watchers played an important role as educators and observers for the CDOT
program. They were responsible for finding and referring suspect cases to HCs for TB
tests. Their most important job was to give and observe patients taking medicines
regularly for the whole 6 months. DOT watchers needed to mark the treatment cards
every time the patients took medicines. DOT watchers were requested to report every
problem they faced during their work to staff at the HC. Some DOT watchers were
responsible for collecting patient’s medicines from HCs. As noted by one DOT watcher:
“I  n e e d  to  g iv e  m e d ic in e s  a n d  w a tc h  p a t ie n ts  ta k in g  i t  e v e r y  m o r n in g  u n til th e  tre a tm e n t
f in is h e d , l a m  a ls o  r e sp o n s ib le  f o r  f o l lo w - u p  p a t ie n ts  a n d  e n c o u r a g e  th e m  to  c o m e  ta k in g
m e d ic in e s  w ith  m e re g u la r ly . ” (DOT watcher, male 39 years old). Additionally, some
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DOT watchers were also responsible for collecting the sputum samples from patients and 
bringing them to the HC for the tests.
8.9 The role of HC staff in the implementation of CDOT
Staff at the HC were responsible for providing TB training including training in the 
guidelines for DOT treatment to DOT watchers at the beginning of their work; staff also 
needed to review and follow-up the activities of DOT watchers. Even though staff could 
not see the CDOT patients taking medicines every day, they were responsible for follow­
up of patients’ adherence to treatment, by going to visit DOT watchers and patients at 
home; and especially going to check the treatment cards for both patients and DOT 
watchers. Moreover, staff were also responsible for helping patients whenever they had 
any problems, such as side-effect of medicines during the treatment.
In some HCs, staff were responsible for transporting medicines to DOT watchers in the 
community: “M e d ic in e s  w e r e  b ro u g h t to  m e  b y  s ta f f  a t  th e  H C  tw ic e  a  m onth . ” (DOT 
watcher, female 46 years old). Moreover, staff were in charge of providing TB education 
and DOT treatment to people in the community; in particular they were also responsible 
for finding suspect cases and referring them for the TB tests at the HC.
8.10 The role of NGOs in the CDOT program
As mentioned above all the implementation of CDOT was funded by local or 
international NGOs. Most NGOs such as RACHA, USAID and JICA provided funds for 
health promotion which included the TB and DOT training. These NGOs provided funds 
directly to the TB staff at the HC in order to get more involved with staff for the CDOT 
program. For example, these NGOs provided the financial support including salary and
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transportation fees to staff at the HC for the monitoring and follow-up both DOT 
watchers and patients: "RA CH A s u p p o r ts  o u r  2  TB s t a f f  a t  th is  H C  w ith  U S $ 1 6  p e r  m onth  
f o r  tra in in g  a n d  m o n ito r in g  th e  C D O T  p r o g r a m  a n d  U S $4  p e r  m o n th  f o r  tra n sp o r tin g  
m e d ic in e s  to  D O T  w a tc h e r ’s  h ou se  in th e com m u n ity . ” (Staff at HC-CDOT, male 40 
years old)
Some NGOs including WRC and SCA put more effort into DOT watchers for the 
operation of CDOT program by giving rewards to DOT watchers and money for the 
petrol to collect medicines from the HC: "The N G O  p a i d  m e U S $ 2  p e r  p a t ie n t  w h o  
f in i s h e d  th e  tr e a tm e n t w ith  m e. ” (DOT watcher, female 23 years old).
A few NGOs such as CHC were directly involved in follow-up of the patients’ adherence 
to treatment, and sent their staff to visit patients and DOT watchers in the community to 
see whether patients have taken medicines regularly with DOT watchers: " S om etim es  
C H C  s e n t  th e ir  s ta f f  to  c h e c k  th e  tre a tm e n t c a r d s  f o r  C D O T  p a t ie n ts  a n d  to  s e e  i fp a t ie n ts  
r e a l ly  g o  to  ta k e  m e d ic in e s  w ith  D O T  w a tc h e rs . ” (Staff at HC-CDOT, male 42 years old)
8.11 Places of taking medicines for CDOT patient
The place and time of taking medicines for CDOT patients depended on the agreement
between DOT watchers and patients. Most staff said that the CDOT guideline required
patients to take medicines at DOT watcher’s house; however, they were flexible and
patients could also take medicines with DOT watchers at home or other places that were
convenient for both of them: "W e to ld  p a t ie n ts  to  g o  a n d  ta k e  m e d ic in e s  a t  D O T
w a tc h e r ’s  h o u ses , b u t th e y  c o u ld  ta k e  m e d ic in e s  a n y  p la c e s  th a t  w e r e  c o n v e n ie n t f o r  bo th
o f  p a t ie n ts  a n d  D O T  w a tc h e rs . " (Staff at HC-CDOT, male 39 years old)
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Some DOT watchers brought medicines to patient’s house every morning in the case of 
those who were very sick or unable to travel far from their houses: " M y D O T  w a tc h e r  
b ro u g h t m e d ic in e s  f o r  m e to  ta k e  a t  h om e e v e r y  m o rn in g  f o r  th e f i r s t  m on th  s in c e  I  w a s  
v e r y  sick . B u t th e  r e s t  o f  tre a tm e n t 1 w e n t to  ta k e  m e d ic in e s  a t  h is  h ou se. ” (CDOT patient, 
female 5 6  years old)
It was noted that not all CDOT patients lived close to the DOT watchers. Some patients 
lived more than 3 kilometers from the DOT watcher’s house. Many patients revealed that 
the distance from their house to the DOT watcher’s house and the HC was the same: "M y  
D O T  w a tc h e r ’s  h o u se  w a s n ’t  c lo s e  to  m y  h ou se . I t to o k  m e a r o u n d  15  m in u tes  b y  
m o to rb ik e  to  g e t  to  h is  h ou se. I  th in k  it  w a s  th e s a m e  d is ta n c e  f r o m  m y  h o u se  to  th e H C . ” 
(CDOT patient, female 23 years old)
8.12 The duration of taking medicines with DOT watchers for the CDOT patients
Most CDOT patients had treatment with DOT watchers for the initial and continuous 
phase. A few took medicines with DOT watchers only in the initial phase, while for the 
continuous phase they took medicines at home by themselves. There were other patients 
who lived far from the DOT watcher’s house, especially those who were very sick, for 
whom DOT watchers would bring medicines to their home and watch them taking it 
every day until their sputum control became negative at the end of second month: " I to o k  
m e d ic in e s  w ith  th e  D O T  w a tc h e r  f o r  o n ly  2  m on th s a n d  th e  r e s t  I  to o k  i t  b y  m y s e l f  a t  
h o m e  b e c a u s e  m y  D O T  w a tc h e r 's  h o u se  is  f a r  f r o m  h ere  a n d  I  h a d  d iff ic u lty  to  w a lk  s in c e  
I  lo s t  o n e  leg . ” (CDOT patient, male 69 years old).
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8.13 Methods of the delivery of medicines to DOT watchers
The transporting of medicines from HCs to DOT watchers in the community varied from 
one HC to another depending on the policy of the sponsor. Some sponsors paid HC staff 
to deliver medicines to DOT watchers while others paid transportation fees directly to 
DOT watchers to collect medicines from HCs: “I  w a s  p a i d  b y  th e  N G O s  f o r  g o in g  to  
c o l le c t  m e d ic in e s  f r o m  th e H C  o n ce  a  w eek ; I  r e c e iv e d  U S $ 7  p e r  m onth . ” (DOT watcher, 
female 23 years old).
Medicines were kept by DOT watchers rather than patients. Generally, medicines were 
delivered weekly for the initial phase and twice a month for the continuous phase 
depending on the availability of medicines in the HC. Most DOT watchers said that the 
delivery of medicines by staff was always on time, but sometimes DOT watchers needed 
to remind staff at the HC if medicines were nearly finished.
At some HCs, patients collected medicines from the HCs by themselves, or paid DOT 
watcher to collect medicines for them. One patient said: ‘‘S o m e tim e s  1 a n d  m y  w ife  w e re  
b u s y  a n d  w e  c o u ld n 't  g o  to  c o lle c t  m e d ic in e s  a t  th e  H C . I  p a i d  th e  p e tr o l  f o r  m y  D O T  
w a tc h e r  a b o u t  6 ,0 0 0  to  8 ,0 0 0  R ie ls . ” (CDOT patient, male 33 years old)
8.14 Follow-up the patients’ adherence to treatment for the CDOT patients
CDOT patients were required to have 3 treatment cards; one card for staff at the HC and
the other two for the DOT watcher and patient. Patients and DOT watchers needed to tick
the date on the cards every time patients have taken medicines. Both treatment cards were
verified by staff. Most staff and DOT watchers mentioned that staff went to check the
treatment cards once a week or every time they brought medicines to DOT watchers.
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During the visit by staff, medicines were checked and compared with the date on the 
cards to see if patients have taken medicines regularly: "S ta f f  c a m e  to  m y  h o u se  o n c e  o r  
tw ic e  a  w e e k  d u r in g  th e  c o n tin u o u s p h a s e  to  c h e c k  th e  p a t i e n t ’s  y e l lo w  c a r d  a n d  co u n t 
th e  m ed ic in es , to  s e e  w h e th er  I  g a v e  m ed ic in e s  to  p a t ie n ts  c o r r e c t ly  o r  n o t ." (DOT 
watcher, male 59 years old)
Some staff visited patients at home were dealt with based on whenever they passed by 
patient’s house to check treatment cards and the patient’s health status and to see if 
patients have any problem including side-effect of medicines. Visits by staff depended on 
the location of patient’s houses, the patient’s profile and the health status of each patient 
as reported by DOT watchers, and would be made more often for patients who often 
missed the treatment sessions with DOT watchers or who had very serious side-effects:
“D u r in g  m y  tre a tm e n t, s t a f f  c a m e  to  s e e  m e a t  h o m e o n ly  2  to  3  t im e s  b e c a u se  I  d id n  7 
h a v e  a n y  s id e -e f fe c t  o f  d ru gs. B u t d u r in g  th e tim e  o f  m y  f a t h e r ’s  trea tm en t, h e h a d  v e ry  
s e r io u s  s id e -e f fe c ts ;  s t a f f  c a m e  to  s e e  h im  a t  h o m e  e v e r y  3  to  5  d a y s  f o r  th e  f i r s t  m onth . ” 
(CDOT patient, male 25 years old)
Both DOT watchers and patients mentioned that the patients’ homes were visited by DOT
watchers the same day if patients did not show up for the treatment sessions in the
morning. In the absence of DOT watchers, medicines were given to patients by DOT
watchers’ family members. Most DOT watchers said that medicines were prepared by
them before being given to their family members. They taught the family members how
to observe and tick the date on the treatment cards. When asking them what made DOT
watchers believe that their family members did not make any mistakes related with
dosage and the number of medicines, most replied that their family members have already
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seen their activities in giving medicines to patients every morning, so they should not 
make any mistake. Patients also know the number and color of medicines since they took 
them every day: “I  le f t  m e d ic in e s  f o r  p a t ie n ts  w ith  m y  w ife  w h e n  I  w a s  b u sy  b e c a u se  I  
a l r e a d y  ta u g h t h e r  a b o u t m ed ic in es; e s p e c ia lly  th e p a c k a g e s  o f  m e d ic in e s  f o r  th e  
in d iv id u a l p a t ie n t  w e r e  p r e p a r e d  b y  m e. S h e h a s n e v e r  m a d e  a n y  m is ta k e  b e c a u se  sh e  
s a w  m e  g iv in g  m e d ic in e s  to  p a t ie n ts  e v e r y  m orn in g . " (DOT watcher, male 59 years old)
The DOT watcher was the first person patients sought for help whenever they had any 
problems including the side-effect of medicines. Most DOT watchers mentioned that 
minor side-effects were dealt with them based on their own experiences; severe side- 
effects of drugs would be reported to staff at the HC, and sometimes patients needed to go 
to see staff at the HC: “I  h a d  v e r y  b a d  s id e  e ffe c ts  o f  d r u g s  in  th e  f i r s t  w eek. 1  t o ld  m y  
D O T  w a tc h e r  a n d  sh e  to ld  m e  th a t  i t  w a s  j u s t  th e  r e a c tio n  o f  m e d ic in e s ;  sh e  a s k e d  m e  to  
d r in k  th e  c o c o n u t ju ic e  a f te r  1 to o k  m ed ic in es. S h e a lso  a s k e d  m e to  ta k e  so m e  v ita m in s; it  
h e lp e d . ’’ (CDOT patient, female 21 years old)
Most staff mentioned the government strategy to motivate and follow-up patients’
adherence to treatment, namely the gifts that patients receive during the treatment. The
gifts included 60 kg of rice, salt, dried fish and vegetable oils for TB patients treated with
DOT. These were provided by the government and the World Food Organization (WFO),
and given to patients twice during the 6 months treatment when patients completed the
first 3 months and at the end of treatment. They were both an incentive and an aid to
reco v e ry . P a tie n ts , w h o  m isse d  o r  in te rru p ted  trea tm en t, w e re  e x c lu d e d  fro m  th e  g ift list:
“A n o th e r  r e a so n  to  m a k e  p a t ie n ts  c o m p le te  th e  tre a tm e n t is  th e  g if ts  th a t  p a tie n ts  r e c e iv e
f r o m  th e  g o v e rn m e n t. I t  w o u ld  m o tiv a te  p a t ie n ts  to  f in is h  th e  tre a tm e n t. I f  th e y  d o n 't  take
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m e d ic in e s  r e g u la r ly  o r  g iv e  u p  th e  trea tm en t, th e y  w o u ld n  V r e c e iv e  th e se  g ifts . ” (Staff at 
HC-CDOT, male 41 years old)
8.15 The attitude of DOT watchers to CDOT patients
The hospitality of DOT watchers and their family members was mentioned by most 
patients. Most patients said that their DOT watchers never discriminated against them and 
they provided full supports including time and encouragement to patients during 
treatment. For example: "M y D O T  w a tc h e r  a n d  h is  f a m i ly  h a v e  n e v e r  d is c r im in a te d  m e  
b e c a u s e  o f  m y  d ise a se . H e  d e v o te d  h is  tim e  f o r  m e a n d  h e e n c o u r a g e d  m e to  f in is h  the  
tre a tm e n t. S o m e tim e s  he w a i te d  f o r  m e w h en  1 w a s  la te , h e n e v e r  g o t  a n g ry ; a n d  
s o m e tim e s  h e  w e n t  to  v is i t  m e  a t  h o m e w h en  I  d id n ' t  g o  to  h is  h o u se  in  th e  m orn in g . ” 
(CDOT patient, male 30 years old)
When asked if they worried about the disease being transmitted by patients to their family 
members, most DOT watchers mentioned that they did worry, and requested patients 
bring their own water to take medicines; they also asked patients to wear face masks and 
cover the mouth with a scarf when patients approached their residences: "I a s k e d  p a tie n ts  
to  w e a r  f a c e  m a sk s  a n d  c o v e r  th e ir  m o u th  w h en  th e y  c a m e  to  m y  h o u se ; e s p e c ia lly  w h en  
ta lk in g  to  m e o r  to  m y  fa m ily . ” (DOT watcher, male 52 years old).
8.16 The experience of TB stigmatisation and discrimination by CDOT patients
Many studies patients mention the stigma associated with TB. This stigma has existed in
C a m b o d ia n  cu ltu re  fo r m an y  y ea rs ; h o w ev er, n o w ad ay s  th ro u g h  th e  m ed ia  an d  TB health
education, the public have a better understanding about the cause and transmission of
disease, and so the problem of TB stigmatisation in the community has significantly
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decreased. Many patients in this study said that people in the community including their 
neighbors and friends never discriminated against them for being treated with TB: “I  
th in k  th a t  p e o p le  h ave  b e tte r  u n d e rs ta n d in g  o f  th is  d ise a se , s o  I  a n d  m y  f a m i ly  m em b e rs  
d i d n ’t  h a v e  a n y  e x p e rie n c e  o f  T B  s tig m a tisa tio n  d u r in g  m y  trea tm en t. M y  v il la g e r s  
in c lu d in g  m y  n e ig h b o rs  h a v e  kn ow n  m y  d ise a se  b u t th e y  n e v e r  d is c r im in a te d  a g a in s t  m e  
a n d  m y  fa m ily . In  co n tra s t, th e y  e v en  tr ie d  to  e n c o u ra g e  m e  to  f in is h  m y  m e d ic in e s  o n ce  
th e y  s a w  m e  h a v in g  s id e -e ffe c ts  o f  d r u g ." (CDOT patient, male 51 years old). Moreover, 
most patients said that they shared their experience of treatment with friends and people 
in the community in order to increase awareness of TB among people in the community.
However stigma was experienced indirectly by a few patients who felt that although other 
villagers understood about TB they still decided to isolate themselves in order to avoid 
the risk of TB transmission: “M y  f r ie n d s  a n d  n e ig h b o u rs  d id  n o t d isc r im in a te  a g a in s t  m e  
b u t  1 d i d  n o t  w a n t  to  tr a n s m it  th is  d is e a s e  to  th e m ...E v e ry  tim e  I  w e n t  to  th e  r ic e  f ie ld , I  
c o u ld  e a t  w ith  th em  a n d  I  k n e w  th a t  th e y  w o u ld n 't  s a y  a n y th in g .... B u t I  d e c id e d  to  take  
m y  m e a l a lo n e , b e c a u se  I  w a s  n o t su re  w h e th e r  th e y  w e r e  a f r a id  o f  m y  d ise a s e  o r  not. ” 
(CDOT patient, male 30 years old). Others experienced stigma from their C D O T  
watchers. As mentioned above most patients were requested by CDOT watchers to bring 
their own water to take medicines, and were asked to wear face masks and cover their 
mouths with scarves when approaching the DOT watchers’ houses. Whether this reaction 
should be classified as stigma or not is difficult to say. It could also be interpreted as a 
normal reaction to a serious and contagious disease, and the effect of this decreased 
stigmatisation in Cambodia is undoubtedly to increase the willingness to access diagnosis 
and treatment and thus limit the spread of the disease.
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8.17 Incentives for the involvement of DOT watchers in the CDOT program
Most DOT watchers received small incentives for their involvement in the CDOT 
program. The incentives for DOT watchers differed from one HC to another, again 
depending on the sponsors. Some DOT watchers received only material support such as 
T-shirt, clothes, bags, and bicycles, while others received money for their involvement in 
the training sessions: “S in ce  I  s ta r te d  m y  jo b ,  I  h a v e  r e c e iv e d  o n ly  o n e  b ic y c le  in  th e  
b e g in n in g  o f  m y  w o rk , i t  w a s  2  y e a r s  a g o  a n d  n o w  th e  b ic y c le  is  broken . ” (DOT watcher, 
male 59 years old).
Although DOT watchers received some money, the amount was very small and couldn’t 
support their costs: “I  w a s  p a i d  b y  th e N G O s  U S $ 2  p e r  p a t ie n t  b u t th is  a m o u n t w a s n ’t  
su ffic ie n t f o r  th e  tra n sp o r ta tio n s  f e e s  th a t I  h a ve  p a i d  f o r  th e  p e t r o l  to  g o  to  c o lle c t  
m e d ic in e s  f r o m  th e  H C . ” (DOT watcher, female 23 years old)
DOT watchers also received support in kind from the government. Consultation fees and 
the fees for delivery of baby at the HC or the referral hospital were free for DOT watchers 
and their family members: "B e c a u se  o f  m y  w o r k  a s  a  D O T  w a tc h e r , I  a n d  m y  fa m ily  
d o n ’t  n e e d  to  p a y  f o r  th e  c o n su lta tio n  f e e s  a t  th e  H C . ” (DOT watcher, male 29 years old)
Some DOT watchers received small gifts from patients such as fruits, vegetables, and 
meat; they rarely received money from patients: “S o m e  p a t ie n ts  w h e n  th e y  f e l t  be tter , 
th e y  g a v e  m e  s o m e  f r u i t s  o r  f o o d s  f o r  th e ir  thanks. " (DOT watcher, female 56 years old). 
Similarly, one patient said: “M y  D O T  w a tc h e r  h a s  n e v e r  a s k e d  m e  f o r  a n y  m on ey, b u t 
so m e tim e s  I  g a v e  h im  s m a ll  g if ts  su c h  a s  ch ick e n  o r  p o rk . I t  w a s  j u s t  m y  g ra titu d e . ” 
(CDOT patient, male 22 years old)
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8.18 “No-DOT” patients
Some patients in HCs where the CDOT was implemented took medicines at home 
without any supervisor for the whole treatment. Staff let patients take medicines at home 
without any supervisor for four reasons. The first reason is if patients were well educated 
and understood TB disease, such as the head of village, staff believed they were 
committed and able to complete the treatment: "I to o k  m e d ic in e s  a t  h o m e b y  m yse lf. I  
d id n 't  n e e d  a n yo n e  to  o b se rv e  m e b eca u se  1 u s e d  to  b e  a  h ea lth  v o lu n te e r  in th is  v il la g e  
a s  w e ll;  I  a lr e a d y  k n ew  th e tre a tm e n t p r o c e d u re . ” (Patient registered as CDOT patient, 
male 43 years old)
The second reason is the patient’s job; patients who did not have a permanent job in the 
village where they lived but travelled for work were allowed to take medicines at home or 
their work places, and needed to come to the HC at least once a month to meet staff and 
collect medicines: "In th e  p a s t ,  I  u se d  to  a l lo w  s e v e r a l  p a tie n ts  ta k in g  m e d ic in e s  a t  hom e  
w ith o u t a n y  D O T  w a tc h e r  b e c a u s e  o f  th e ir  c a r r ie r  backgrou n d . T h ose  p a t ie n ts  lik e ly  
w o r k e d  a s  c o n s tru c to r s ;  th e y  c a m e  b a c k  to  th e ir  h o m e to w n  w h en  th e y  w e r e  sick . I t w a s  
v e r y  d iff ic u lt  f o r  u s to  f o l lo w - u p  th em  d u e  to  th e ir  w o rk s;  th e y  m o v e d  a r o u n d  m o re  o ften  
f r o m  o n e  v il la g e  to  a n o th er . ” (Staff at HC-CDOT, male 42 years old).
The third reason is the patient’s health status and the availability of DOT watchers in the 
village where patients lived. Patients who were very sick and had difficulty in coming to 
the HC and a DOT watcher was not available in the areas where patients lived, would be 
allowed to take medicines at home: "I to o k  m e d ic in e s  a t  h om e, n o  D O T  w a tc h e r .. .I  w a s  
a l lo w e d  b y  th e  d o c to r  b e c a u s e  /  d i d n ’t  h a v e  a n y  v e h ic le  a n d  th e  D O T  w a tc h e r  in th is
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v il la g e  l iv e d  f a r  f r o m  m y  h ou se ."  (Patient registered as CDOT patient, female 62 years 
old).
The last reason is to do with the relationship between patients and staff at the HC. Staff 
allowed patients taking medicines at home when they knew each other well: " D o cto r  a t  
th e  H C  a n d  m y  uncle a re  g o o d  fr ie n d s . S o  he le t  m e ta k e  m e d ic in e s  a t  h om e in s te a d  o f  
g o in g  to  th e H C . ” (Patient registered as CDOT patient, male 28 years old)
Of the patients registered as CDOT patients and selected for interview in the study, most 
were “non-DOT” patients because they took medicines by themselves at home. The most 
usual reasons for this were lack of transportation, no availability of DOT watchers and the 
patient’s health conditions.
“Non-DOT” patients were followed up by staff at the HC; most staff mentioned that the 
patient’s home visits were made 3 to 4 time during the treatment, more for patients who 
had very serious side-effects and for those who lived close to staffs house: "W hen I  
s ta r te d  m e d ic in e s  f o r  th e f i r s t  2  w eek s, th e d o c to r  f r o m  the H C  ca m e  to  v is i t  m e  m o re  
o ften  b e c a u se  I  h a d  v e r y  b a d  s id e -e ffe c ts . ” (Patient registered as CDOT patient, male 55 
years old)
“Non-DOT” patients were asked to come to the HC for medicines four times per month 
for the initial phase and twice a month for the continuous phase. Family members of 
patients could also collect medicines at the HC.
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The involvement of family members in reminding patients to take medicines at home and 
encouraging patients to finish the treatment were mentioned by all “non-DOT” patients. 
One patient said: " W hen I  to o k  m ed ic in e s  a t  hom e, m y  so n  a lw a y s  r e m in d e d  m e e v e r y  
m o rn in g  b e fo re  h e w e n t o u t to  th e  r ic e  f ie ld . ” (Patient registered as CDOT patient, male 
66 years old)
8.19 Sputum controls for CDOT patients
The TB treatment guideline requires that the first sputum controls for smear positive 
patients be done at the end of the initial phase. Medicines for the continuous phase would 
be given to patients if the results were negative, otherwise patients needed to stay on the 
intensive phase medicines for one more month. The second controls are at the end of the 
fifth month before the treatment is finished.
Patients with DOT watchers in the community were asked by staff at the HC or DOT 
watchers to come for sputum control. Staff would remind DOT watchers in advance to 
tell patients when needed. A few staff contacted patients directly: “A w e e k  b e fo re  p a t ie n t  
n e e d e d  to  h a v e  th e  s p u tu m  c o n tro l;  J  r e m in d e d  D O T  w a tc h e r s  to  te l l  p a t ie n ts  on  w h a t  
d a te  sp u tu m  n e e d e d  to  b e  ta k e n  to  th e  H C . ” (Staff at HC-CDOT, male 26 years old).
Patients could also send their sputum samples to the HC through DOT watchers or family 
members. Containers for the sputum samples were left with the DOT watcher.
However, many patients disclosed that they had no sputum control during the treatment,
while a few patients only had one at the end of the initial phase. According to patients,
sputum controls were rarely done for two reasons; the first reason was that patients were
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not informed about the time for the sputum tests by staff or DOT watchers. Because most 
patients rarely visited the HC, patients could find out about the time for the sputum 
controls only through their DOT watchers: "1 d id n  7 h a v e  a n y  sp u tu m  c o n tro ls  d u r in g  m y  
tr e a tm e n t b e c a u s e  th e  d o c to r  a n d  m y  D O T  w a tc h e r  d i d n ’t  t e l l  m e  w h en  I  n e e d e d  to  
r e c h e c k  m y  sp u tu m . ” (Patient registered as CDOT patient, male 55 years old)
The second reason was the patients did not have sputum after they took medicines for a 
few months, because the mucus had disappeared: "/ d id n  7 h a v e  a n y  spu tu m  c o n tro l  
b e c a u se  I  f e l t  b e t te r  a n d  no m o re  m u cu s to  take. ” (CDOT patient, female 62 years old)
However, some patients who did not have the sputum control complained that they still 
had TB symptoms. Those patients were not sure if they were really cured of TB; some 
patients even asked for more medicines during the interviews: “/  am  n o t su re  w h e th e r  th e  
T B  in  m y  b o d y  w a s  c o m p le te ly  c u r e d  b e c a u se  I  f e e l  w e a k e r  th a n  b e fo re  a n d  1 c o u ld n  7 
w o r k  h a r d  a s  b e fo re . S o m e tim e s  I  c o u g h e d  w ith  b lo o d . I  a ls o  r e p o r te d  to  d o c to r  a t  th e  H C  
la s t  m o n th ; h e  t o ld  m e  th a t m y  T B  w a s  c u r e d  b u t i t  is  j u s t  th e  tra c e  o f  th e TB in  m y  lung. 
B u t 1 d o n  7 th in k  so , m a y b e  1  s h o u ld  ta k e  m o re  m ed ic in es . ” (Patient registered as CDOT 
patient, male 55 years old)
When the author asked staff what made them think that the patients were cured, since 
some of them did not have any sputum control, most said that they believed that if 
patients took medicines regularly for 6 months, TB would be cured because that is what it 
said in the DOT treatment guideline. Others mentioned that patients could have the 
symptoms such as cough or tiredness but it was just a trace of the TB that could appear 
sometimes when patients worked hard. "A fte r  th e  6  m o n th s  trea tm en t, p a t ie n ts  a re
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a lr e a d y  c u r e d  b u t s o m e  s ig n s  c o u ld  a p p e a r  w h en  p a t ie n ts  w o r k  h a r d  in  th e  r ic e  f ie ld . ” 
(Staff at HC-CDOT, male 41 years old)
8.20 TB education and promotion in the areas where the CDOT was implemented
TB education, including finding suspect cases and TB treatment itself, was done by staff 
and DOT watchers. Staff went into the community once a month to educate people about 
health activities including TB. For the HCs that have received support from the NGOs for 
the implementation of CDOT, staff have opportunity to go to the community more often 
to educate people compared to the ordinary HCs. Moreover, DOT watchers involved in 
the CDOT program also provided TB education, DOT information and case finding 
(finding new suspect case among the villagers). Most DOT watchers mentioned that they 
were often having meetings with the villagers to provide information about TB education 
and treatment; they particularly tried to find people with TB symptoms and encouraged 
them to go for TB tests at the HC.
8.21 Advantages of the implementation of CDOT program
There are several advantages that were raised by staff, DOT watchers and patients based 
on their experience of the CDOT program.
A. Staffs qualification
Some staff felt that one of the successes of the implementation of CDOT was the
capability of staff in providing sufficient TB training and education to DOT watchers.
Most staff mentioned that they have a lot of experience in TB training from both
government and NGOs, so they could provide this TB knowledge to DOT watchers and
guide them in its implementation in the community: “E v e n  th o u g h  w e  d o n ’t  w a tch
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p a t ie n ts  ta k in g  m e d ic in e s  e v e r y  d a y , w e  h a v e  tr a in e d  o u r  D O T  w a tc h e r s  b a s e d  o n  o u r  
e x p e rie n c e , h o w  to  g iv e  a n d  o b s e rv e  p a tie n ts , e s p e c ia lly  w e  g u id e  th em  w h en  th e y  h a v e  
p r o b le m s . " (Staff at HC-CDOT, male 40 years old)
B. DOT watchers motivation
The involvement of DOT watchers in the whole CDOT program, by referring new cases 
and giving and watching patients take medicines everyday in the villages, was felt to be 
the key success of CDOT. Most staff opined that even though the incentives for DOT 
watchers were very small, they were still involved in observing patients take medicines 
regularly and sometimes coming to collect medicines at the HC: "The g o o d  p o in t  is  th a t  
th e  D O T  w a tc h e r s  in o u r  H C  a r e  v e ry  a c tive . T h ey  h a v e  r e c e iv e d  o n ly  s m a ll  in c en tive s  
f r o m  th e  p r o g r a m  b u t th e y  s t i l l  w a n t to  b e  in v o lv e d  in th is  jo b .  T h ey  h e lp  us b y  r e fe r r in g  
s u s p e c t  c a s e s  a n d  o b s e rv e  p a t ie n ts  ta k in g  m ed ic in es. "(Staff at HC-CDOT, male 40 years 
old).
Patients liked the DOT watcher’s attitudes. Most patients were happy with their DOT 
watchers, because they were treated with respect and provided with emotional support to 
finish the treatment. Some DOT watchers and their family members also provided food or 
money to poor patients: “M y  D O T  w a tc h e r  w a s  v e r y  n ic e  a n d  helpfu l, he n ever  
d is c r im in a te d  m e  a n d  m y  fa m ily . H e  tr ie d  to  h e lp  m e b y  a s k in g  i f  I  h a v e  a n y  p r o b le m s  o r  
s id e -e ffe c ts . In th e  f i r s t  m o n th  w h e n  I  s ta r te d  m y  m ed ic a tio n , h e e n c o u r a g e d  m e  to  f in is h  
m y  m e d ic in e s  e v e r y  tim e  I  m e t  h im . ” (CDOT patient, male 22 years old).
Other patients mentioned that they appreciated the time DOT watchers devoted to patients
during the treatment. Patients revealed that the waiting time for taking medicines with
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DOT watchers at home was not an issue because DOT watchers were there when patients 
arrived. "1 l ik e d  to  ta k e  m ed ic in e s  w ith  m y  D O T  w a tc h e rs  b e c a u se  sh e  h a s  n e v e r  le t  m e  
w a it  f o r  h e r;  e v e r y  tim e  I  a r r iv e d  a t  h e r  house, sh e  w a s  th ere  a n d  w a it in g  f o r  m e. ” 
(CDOT patient, male 58 years old)
Another key factor that encouraged patients to take medicines with DOT watchers was 
the relationship between patients and DOT watchers. Some staff mentioned that some 
patients felt more comfortable in discussing any issue related to health problems (as well 
as other issues) with their DOT watchers than with staff at the HC. Patients felt they 
could talk openly and freely with DOT watchers since they may have known each other 
and may even live in the same village: “S o m e  p a t ie n ts  h a r d ly  s h a r e d  a n y th in g  w ith  o u r  
s ta f f  b e c a u s e  th e y  w e r e  a f r a id  o f  us. H o w e v er , th e y  w e r e  v e r y  h a p p y  to  ta k e  m ed ic in e s  
w ith  D O T  w a tc h e r s  in  the co m m u n ity  b e c a u se  th e y  c o u ld  sh a re  a l l  p r o b le m s  a n d  o th e r  
is su e s  in c lu d in g  e v e r y d a y  life  w ith  th e ir  D O T  w a tch ers . J f e l t  th a t so m e  p a t ie n ts  w e re  
m o re  c o m fo r ta b le  to  ta k e  m e d ic in e s  w ith  D O T  w a tc h e rs  th an  o u r  staff. " (Staff at HC- 
CDOT, male 26 years old).
C. The implementation of CDOT is convenient for patients
Most patients mentioned that taking medicines with DOT watchers in the community was 
less stressful because they were not required to wake up so early in the morning, and a 
convenient and flexible time schedule could be negotiated between patients and DOT 
watchers. Moreover, patients said that CDOT allowed them to engage with normal daily 
activities during the treatment: ‘7  w a s  v e r y  h a p p y  to  ta k e  m e d ic in e s  w ith  D O T  w a tc h e rs  
b e c a u se  I d i d n ’t  n e e d  to  g o  th e  D O T  w a tc h e r 's  h o u se  e a r ly  in  th e  m o rn in g  s in ce  h is  h ou se
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is  c lo s e  to  m y  house. I  c o u ld  s e n d  m y  k id s  to  s c h o o l  f i r s t  b e fo re  g o in g  to  take  m ed ic in e s  
w ith  him . ” (CDOT patient, male 33 years old).
D. The CDOT program saved patients’ expenditures
All patients, DOT watchers and staff agreed that the main advantage of CDOT was the 
reduction of cost and time to patients, as the costs of travelling were reduced: "I th in k  
th a t  ta k in g  m e d ic in e s  in th e co m m u n ity  s a v e d  m y  c o s ts  f o r  th e  tra n sp o r ta tio n . ” (CDOT 
patient, female 39 years old).
CDOT also saved patients from long waiting times for treatment at the HC, allowing 
more time to engage with other aspects of their lives: " / like  to  ta k e  m e d ic in e s  in the  
c o m m u n ity  b e c a u se  I  d id n 't  n e e d  to  w a i t  f o r  th e  a r r iv a l  o f  s ta f f  a t  th e  H C . E v e r y  m o rn in g  
1  s p e n t  o n ly  1 0  to  15  m in u tes  to  ta k e  m e d ic in e s  w ith  D O T  w a tch er , a f te r  th a t 1 c o u ld  g o  to  
w o r k  a s  usual. ” (CDOT patient, male 46 years old).
E. CDOT increased the patients’ adherence to treatment
The implementation of CDOT increased patients’ adherence to treatment because the 
time and place were convenient for patients, so they could take medicines regularly 
without any interruption: "B e c a u se  it  w a s  c o n v e n ie n t f o r  m e to  ta k e  m e d ic in e s  a t  D O T  
w a tc h e r ’s  h o u se  lo c a te d  c lo s e  to  m y  h ou se , I  w e n t to  ta k e  m e d ic in e s  e v e r y  d a y ..... I f  s ta f f  
a s k e d  m e  to  ta k e  m e d ic in e s  a t  th e  H C , 1  w o u ld  g iv e  u p  b e c a u se  1  d o n ' t  h a v e  a n y  veh ic le . " 
(CDOT patient, female 39 years old)
When asking patients how they felt taking medicines with DOT watchers who were not
medical professionals, most patients stated that they trusted them because they have
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known each other for long time; especially since most DOT watchers were village health 
volunteers, so they were the first person patients would go to seek for help whenever they 
had any health problems. “7 w a s  h a p p y  to  ta k e  m e d ic in e s  w ith  u n cle  D O T  w a tc h e r  
b eca u se  I  h a ve  kn o w n  him  s in c e  1 w a s  y o u n g  a n d  he w a s  l ik e d  m y  u n c le ." (CDOT patient, 
male 22 years old).
F. CDOT increased the TB awareness in the community
Another advantage of the CDOT was increased awareness of TB among people in the 
community; which could reduce the chain of TB transmission among villagers: "N ow  m y  
n e ig h b o r  h a d  c o u g h e d  f o r  2  w eek s , I  to ld  h er  to  g o  f o r  th e  sp u tu m  c h e c k  a t th e H C . I  to ld  
h e r  th a t  th e  tre a tm e n t is  e ffec tive  like  sh e  s a w  m e ta k in g  m e d ic in e s  w ith  th e  h ea lth  
v o lu n te e r  a n d  n o w  I  f e e l  b e tte r . ” (CDOT patient, female 56 years old)
The implementation of CDOT also helped to reduce TB stigmatization in the community 
by letting people understand that TB is an infectious disease that can be cured by taking 
medicines regularly for 6 months. One patient stated: " T akin g  m e d ic in e s  in  th e  
c o m m u n ity  c o u ld  le t  p e o p le  u n d e r s ta n d  m o re  a b o u t TB. The v il la g e r s  kn ew  th a t I  h a d  
T B .....b u t th e y  d id n ' t  d is c r im in a te  m e  a n d  m y  f a m i ly  b e c a u se  th e y  h a v e  u n d e r s to o d  th a t  
TB  isn  7 a n  h e r e d ity  d ise a se . ” (CDOT patient, male 30 years old).
G. CDOT is better than self-administration treatment
Some patients said that taking medicines with DOT watchers was better than taking
medicines at home without any supervision. Without the DOT watcher patients may not
take medicines regularly because they could forget the time or they could stop taking
medicines when they felt better. This could increase the risk of default and multi-drug
171
resistance in the future: "I th in k  ta k in g  m e d ic in e s  w ith  D O T  w a tc h e r s  is  b e tte r  than  ta k in g  
m e d ic in e s  a t  h o m e  a lo n e  b eca u se  w e  m a y  f o r g e t  to  take. ’’ (CDOT patient, male 25 years 
old)
8.22 Disadvantages of CDOT program
A. Lack of follow-up of CDOT patients by staff
However HC staff visiting CDOT patients in the community could be problematic, firstly 
due to time constraints. “M o s t p a tie n ts  g o  to  take  m e d ic in e s  w ith  D O T  w a tc h e rs  v e ry  
e a r ly  in  th e  m o rn in g , lik e  6  o  ’c lo c k  S o  I  c o u ld n 't  g o  to  s e e  e v e r y  p a t ie n t  b eca u se  I  n e e d  
to  s e n d  m y  k id s  to  s c h o o l  a n d  m y  w ife  to  th e m arket. ” (Staff at HC-CDOT, male 54 years 
old).
A further reason is the lack of money to allow follow-up of patients in the community; 
staff needed to pay for petrol from their own pockets if  they went more often to see 
patients in the community: “ W e c o u ld n ’t  g o  to  s e e  e v e r y  p a t ie n t  t r e a te d  in  th e  co m m u n ity  
b e c a u se  th e  a m o u n t o f  m o n e y  th a t w e  re c e iv e  f o r  tra n sp o r ta tio n  c o u ld n ’t  c o v e r  the p e tr o l  
to  s e e  e v e r y  p a t ie n t , a s  s o m e  p a t ie n ts  l iv e  v e r y  fa r .  S o m e tim e s  I  n e e d  to  p a y  f o r  the p e tr o l  
f r o m  m y  o w n  p o c k e t  i f  I  g o  to  s e e  p a t ie n ts  th ree  tim es  p e r  m onth . ” (Staff at HC-CDOT, 
male 42 years old)
It was also mentioned by patients that the visit by staff during the treatment was not 
enough especially during the first two months when most patients have very bad side- 
effects. “D u r in g  th e  tr e a tm e n t s t a f f  c a m e  to  s e e  m e  o n ly  4  tim es , 2  t im e s  f o r  th e  in itia l  
p h a s e  a n d  a n o th e r  2  t im e s  f o r  th e  c o n tin u o u s  p h a s e . I  w a n te d  h im  to  co m e  to  v is i t  m e
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m o re  o ften  d u r in g  th e in itia l p h a s e  b eca u se  I  h a d  v e r y  s e r io u s  s id e -e ffe c t o f  m ed ic in es . ” 
(CDOT patient, female 34 years old)
B. DOT watcher’s qualification
Many HC staff were concerned about the lack of knowledge among DOT watchers 
because they were not medical professionals. "H o n e s tly , I  d o n ’t  r e a lly  tr u s t  D O T  
w a tc h e r s  o b s e r v in g  p a t ie n ts  b eca u se  I  c o u ld n ’t  s e e  th e  in te ra c tio n  b e tw e e n  D O T  
w a tc h e r s  a n d  p a t ie n ts  e v e r y  day . S o m e tim es  I  w e n t  to  c h e c k  th e  tre a tm e n t c a r d  a n d  1 s a w  
d a y s  o n  th e  tr e a tm e n t c a r d  w e r e  m is s in g  b u t D O T  w a tc h e r s  r e s p o n d e d  th a t th e y  f o r g o t  to  
t ic k  b u t m e d ic in e s  w e re  g iv e n  to  p a tie n ts . ” (Staff at HC-CDOT, female 36 years old)
Some staff were also concerned that DOT watchers may not supervise strictly in the long 
term. They may allow patients to take medicines at their home without supervision, so it 
could lead to many problems such as non-adherence to treatment, drug overdose and 
MDRs in the future: “ W e a r e  w o r r ie d  th a t D O T  w a tc h e r s  m a y  a llo w  p a t ie n ts  ta k in g  
m e d ic in e s  a t  h o m e; th e y  c o u ld n ’t  w a tc h  p a t ie n ts  ta k in g  m e d ic in e s  reg u la r ly . I f  th is  
p r o b le m  h a p p e n e d  m o re  o ften , i t  c o u ld  be  in c re a s e d  th e n u m b er  o f  d e fa u lte rs  a n d  
M D R s. ” (Staff at HC-CDOT, male 26 years old).
This problem was also mentioned by many patients- DOT watchers allowed them to take 
medicines at home whenever patients requested, especially when DOT watchers were 
busy: “ W hen I  w e n t  to  p a g o d a  f o r  f e w  d a ys , m y  D O T  w a tc h e r  a l lo w e d  m e to  b r in g  
m ed ic in e s . S o m e tim e s  I  to o k  m e d ic in e s  a t  m y  h o m e to o  b e c a u s e  m y  D O T  w a tc h e r  w a s  
bu sy . ” (CDOT patient, female 67 years old)
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Further problems were mentioned by staff, for example that some patients missed 
medicines for a few days because of the absence of DOT watchers, or medicines ran out 
during the treatment but DOT watchers did not inform staff at the HC: "No m a tte r  h o w  
m u ch  e ffo r t  w e  p u t  to  D O T  w a tc h e r s  th e y  a re n  7 d is c ip lin e d  in  th e ir  jo b s .  A s  h a p p e n e d  in  
th e  p a s t,  s o m e  p a t ie n ts  m is s e d  m e d ic in e s  f o r  1 to  2  d a y s  b e c a u s e  D O T  w a tc h e rs  w e r e n ’t  
a t  hom e. S o m e tim e s  D O T  w a tc h e r s  d id n ' t  in form  us w h en  m e d ic in e s  f in ish e d . ” (Staff at 
HC-CDOT, male 40 years old)
Staff also mentioned that too low or an overdose of medicines could be given by DOT 
watchers. This was more likely to be done by DOT watchers who have received 
traditional medical background such as traditional healers; they may change the patient’s 
medicines without any discussion with staff at the HC because they think they have full 
knowledge of the medication. For example, some DOT watchers decided to reduce the 
number of pills for patients without any discussion or permission from staff when patients 
have side-effects of medicines: "In th e p a s t,  2  p a t ie n ts  to o k  m e d ic in e s  w ith  m e a n d  th ey  
h a d  v e r y  s e r io u s  s id e -e f fe c t  o f  d ru g s. I  d e c id e d  to  re d u c e  h e r  p i l l s  f r o m  8  to  4  ta b le ts  p e r  
d a y , a n d  I  g a v e  h e r  s o m e  m e d ic in e s  f o r  h e r  fe v e r . Then, I  s ta r te d  to  g iv e  h e r  b a c k  8  
ta b le ts  p e r  d a y  w h en  sh e  f e l t  b e tte r . ” (DOT watcher, male 68 years old)
C. Lack of incentives for DOT watchers
DOT watchers involved in the CDOT program were not paid for this job, so they could 
not devote their time only for TB patients and TB activities. One DOT watcher said: "The 
w e a k  p o in t  o f  C D O T  is  th e  la c k  o f  r e w a r d s  a n d  in c e n tiv e s  f o r  D O T  w a tc h e rs . I  d o n ‘t  e a rn  
a n y th in g  f r o m  th is  j o b ,  s o m e tim e s  I  n e e d  to  p a y  m y  o w n  m o n e y  f o r  th e  p e tr o l  w h en ev e r  I  
g o  to  v is i t  p a t ie n ts  a t  hom e. ” (DOT watcher, male 44 years old).
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Moreover, some DOT watchers resigned from the CDOT program: "Since 6  m o n th s  ago ,
I  r e s ig n e d  f r o m  the D O T  w a tc h e r  b e c a u se  1 am  v e r y  b u sy  w ith  o th e r  w ork . E s p e c ia lly  1 
d id n ’t  g e t  a n y  p a y  r o l l  o r  s a la r y  f r o m  th is  jo b . ” (DOT watcher, male 59 years old)
D. Insufficient DOT watchers for CDOT program
An inadequate number of health volunteers involved as DOT watchers for the CDOT 
program was reported by staff and patients. Normally, there were 2 or 3 health volunteers 
in one community; but one or two of them were selected to be DOT watchers because the 
program provided only small benefits. As mentioned by staff that sometimes DOT 
watchers needed to supervise 3 or 4 patients at the same time, so patients may select self­
administration as the treatment method: "I to o k  m e d ic in e s  a t  h o m e b y  m y s e l f  b eca u se  
D O T  w a tc h e r  w a s n  7 a v a ila b le  in m y  v illa g e . M y  v il la g e  u s e d  to  h a v e  one D O T  w a tc h e r  
b u t h e  p a s s e d  a w a y  a n d  th e  H C  h a sn  7 y e t  a p p o in te d  n ew  D O T  w a tch er . ” (Patient 
registered as CDOT patient, male 55 years old)
E. The environment of patients treated with the CDOT
Some staff believed that taking medicines with DOT watchers was not as strict as the HC 
because DOT watchers were not medical staff; in fact, sometimes they were good friends, 
so patients may not really listen to their advice. A similar issue was also raised by DOT 
watchers, that some patients didn’t listen to their advice and did not have the commitment 
to come for taking medicines. Some DOT watchers mentioned the irregularity of the 
patient’s visits to the DOT watcher’s house; some patients did not arrive on time while 
others did not show up: "In f a c t ,  i t  is  d iff ic u lt f o r  m e  to  d e a l  w ith  so m e  p a t ie n ts  w h o  
d id n  7 l is te n  to  w h a t I  sa id , f o r  e x a m p le  I  to ld  th em  w h a t  t im e  th e y  s h o u ld  co m e  to  take
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m e d ic in e s  w ith  m e. S o m etim es, I  n e e d e d  to  w a it  f o r  them  b e c a u se  th e y  a r r iv e d  la te  o r  th e y  
d id n  ’t  s h o w  u p  f o r  th e tre a tm e n t se ss io n s . ” (DOT watcher, male 59 years old)
Another complaint about the CDOT program was that some patients received insufficient 
information, and some patients felt that DOT watchers did not provide enough 
information regarding TB medicines, when and how long to take the medicines, and the 
date for the sputum controls: “I  d id n 't  kn ow  w h y  ¡ n e e d e d  to  ta k e  a  lo t  o f p i l l s  f o r  th e f i r s t  
2  m o n th s  b e c a u se  m y  D O T  w a tc h e r  n e v e r  to ld  m e. ” (CDOT patient, female 38 years old)
F. Lack of opportunity for selection of DOT watchers
Some patients complained that they did not have a choice in selecting their DOT watchers 
because DOT watchers were selected by staff. A few patients were not happy because 
their DOT watcher’s houses were further than the HC. "M y D O T  w a tc h e r ’s  h ou se  w a s  
fu r th e r  th a n  th e  H C . I t  w a s  th e  sa m e  r o a d  to  the H C  b u t it w a s  n e a r ly  1 m o re  k ilo m e te r  
f a r th e r  d o w n  f r o m  th e  H C . I  d i d n ’t  k n o w  w h y  s ta f f  w a n te d  m e  to  ta k e  m ed ic in e s  w ith  
her. ” (CDOT patient, female 21 years old)
G. Delay in getting the sputum controls for CDOT patients
Some staff revealed difficulty in getting sputum samples from some CDOT patients at the 
end of second and fifth month, and they were not sure about techniques that DOT 
watchers used to collect samples and transport them to the HC because DOT watchers 
were not really health professionals.
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H. Too few TB staff in the HC
Patients taking medicines with DOT watchers in the community still required staff at the 
HC to follow-up and check their adherence to treatment, but the numbers of TB staff at 
the HC was not enough. Because of this, the follow-up of patients in the community was 
reduced.
8.23 Perceptions of the implementation of CDOT among staff
When asking staff at the HC what they think about the implementation of CDOT based 
on their experiences, some were not really supportive of the CDOT program because they 
were concerned about the quality and effectiveness of CDOT. Staff recommended that the 
ambulatory DOT approach should be used for the initial phase for every patient who 
could come to the HC, because staff could see and follow-up patients taking medicines 
every day. However, CDOT could be applied during the continuous phase when the 
sputum controls become negative; also CDOT could be applied to some patients who are 
seriously sick or have difficulty to come to the HC every day: "1 th in k  e v e r y  p a t ie n t  w h o  
c o u ld  c o m e  to  th e  H C ; s h o u ld  co m e  to  ta k e  m e d ic in e s  w ith  us f o r  th e f i r s t  2  m on th s a n d  
th e  r e s t  4  m o n th s  th e y  c o u ld  ta k e  m e d ic in e s  w ith  D O T  w a tc h e rs  in th e  com m u n ity . 
H o w e v er , D O T  w a tc h e r s  c o u ld  a ls o  a s k  to  o b s e rv e  th o se  p a t ie n ts  w h o  h a v e  d iff ic u lty  to  
a c c e s s  th e  H C . ” (Staff at HC-CDOT, male 42 years old).
Staff were agreed that CDOT could reduce cost to patients and family but it could 
increase patients’ non-adherence to treatment if follow-up by staff and DOT watchers 
failed. Some staff were concerned that DOT watchers would not be supervised as strictly 
as staff at the HC and some patients may stop taking medicines when they felt better. 
Staff felt that taking medicines with staff at the HC is stricter than with DOT watchers
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because patients are afraid of staff. One staff opined: ‘7  am  n o t su re  i f  D O T  w a tc h e rs  
su p e r v is e  p a t ie n ts  a s  s tr ic t  a s  o u r  staff. I  am  a fra id  th a t th e n u m b er  o f  n o n -a d h eren ce  to  
tr e a tm e n t f o r  C D O T  p a t ie n ts  m a y  b e  in c re a s e d  i f  D O T  w a tc h e rs  f a i l e d  to  fo l lo w -u p  
p a t ie n ts  b e c a u se  p a tie n ts  m a y  s to p  th e ir  tre a tm e n t w h en  th e y  g e t  b e tte r . ” (Staff at HC- 
CDOT, male 54 years old)
As mentioned by staff, CDOT would be applied if the program had enough funds for both 
DOT watchers and staff. It could be done by providing more incentives and more benefits 
to DOT watchers, so it would allow them to devote their time to encouraging and 
watching patients complete the treatment. Moreover, the implementation of CDOT could 
not be done without supervision from staff at the HC; most staff suggested that providing 
enough money for transportation to staff at the HC would allow them to regularly visit 
patients and DOT watchers in the community: “I  th in k  i f  w e  r e a lly  w a n t to  fu l ly  
im p le m e n te d  C D O T , w e  n e e d  en ou gh  fu n d s  f o r  D O T  w a tc h e rs  a n d  o u r  staff. D O T  
w a tc h e r s  s h o u ld  r e c e iv e  m o re  b e n e fits  th a t w o u ld  a l lo w  th em  to  w o r k  h a r d  a n d  s tr ic tly  
s u p e r v is e  p a tie n ts . E sp e c ia lly , o u r  s ta f f  s h o u ld  h a ve  en o u g h  fu n d s  f o r  th e  tra n sp o r ta tio n  
th a t  w o u ld  a l lo w  us to  f o l lo w - u p  p a t ie n ts  in th e c o m m u n ity  m o re  often . ” (Staff at HC- 
CDOT, female 36 years old)
8.24 Perceptions of the implementation of CDOT among DOT watchers in the 
community
Most CDOT watchers strongly supported the CDOT program because they felt that the
implementation of CDOT could provide a lot of benefits to patients especially for those
who were very poor. They thought that patients treated in the community could save a lot
of time and money on the transportation. It was also useful for patients who were very
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sick and lacked transportation. Moreover, CDOT allowed patients to engage with their 
normal daily activities because the waiting time for taking medicines with DOT watchers 
was not a problem: I  th in k  th a t p a t ie n ts  ta k in g  m e d ic in e s  in th e  co m m u n ity  a re  h a p p y  
b e c a u se  th e y  d o n ’t  n e e d  to  g o  to  th e  H C  e v e r y  day , p a t ie n ts  c o u ld  sa v e  m o n ey  on  the  
tra v e llin g  ex p en ses . I t  is  a lso  m o re  c o n v e n ie n t f o r  th o se  w h o  a r e  v e r y  s ic k  a n d  d o n  7 h a ve  
a n y  v e h ic le s . ” (DOT watcher, female 56 years old).
When asking CDOT watchers how they felt about giving medicines and observing 
patients take them every day for the whole treatment; most responded that they were very 
happy to do these jobs because they felt that they could help to reduce the workload to 
staff at the HC, and more especially they could help people in the community to become 
free from TB: “I  am  v e r y  h a p p y  to  w a tc h  p a t ie n ts  ta k in g  m e d ic in e s  in  th e v il la g e  b eca u se  
I  c o u ld  h e lp  s t a f f  a t  th e H C , e s p e c ia lly  1 c o u ld  h e lp  m y  v illa g e rs . I  w a n t e v e ry o n e  in th is  
v il la g e  to  g e t  f r e e  f r o m  TB. ” (DOT watcher, male 55 years old)
However, some suggestions were made by many CDOT watchers about ways to improve 
the implementation of CDOT; the first is to increase of incentives for DOT watchers. 
CDOT watchers suggested that the program should give them more incentives such as a 
salary for DOT watchers and funds to cover the costs for going to visit patients at home 
or collect medicines from the HC: "I w o u ld  like  to  s u g g e s t  th a t  o u r  D O T  w a tc h e rs  s h o u ld  
re c e iv e  m o re  b en e fits , f o r  e x a m p le  s a la r y  f o r  D O T  w a tc h e r s .. . .I t  w o u ld  m ake us to  
m o tiv a te  in th is  j o b  b e c a u se  w e  w a n t to  h e lp  b u t w e  a ls o  n e e d  m o n e y  to  s u p p o r t  o u r  
f a m i ly  a s  w e ll. ” (DOT watcher, male 59 years old)
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Another suggestion was to increase the number of visits by staff to DOT watchers and 
patients in the community. Most DOT watchers proposed that staff from the HC should 
make more frequent visits to DOT watchers and patients at home, especially for the initial 
phase since most patients had very bad side-effects from the drugs. "I w o u ld  like  to  
s u g g e s t  th a t  s ta f f  s h o u ld  c o m e  to  v is i t  a n d  fo l lo w -u p  p a t ie n ts  in  th e  c o m m u n ity  m o re  
often . I  c o u ld  o n ly  o b s e r v e  p a t ie n ts  ta k in g  m e d ic in e s  b u t I  d o n ’t  k n o w  w h a t to  h e lp  
p a t ie n ts  f o r  th e  s id e -e f fe c ts  o f  d ru gs. ” (DOT watcher, male 44 years old)
The last recommendation by CDOT watchers was to receive more training and feedback 
from staff; most said that the training sessions which they received were not enough or 
were out- dated. Others mentioned that they would like to receive feedback from staff and 
NGOs regarding their work and TB treatment in the community.
8.25 Perceptions of the implementation of CDOT among patients
CDOT patients’ opinion of taking medicines in the community varied. Most patients 
agreed that CDOT was flexible and saved transportation costs, and allowed them to 
engage in their normal activity. Moreover, CDOT was very convenient for those who 
were seriously sick and had difficulty in travelling to the HC. Some patients mentioned 
that they got a lot of encouragement and support from their DOT watchers during the 
treatment; this motivated them to take the medicines regularly: "T hanks to  m y  D O T  
w a tc h e r  w h o  a lw a y s  g a v e  m e th e  e n c o u ra g e m e n t to  f in is h  m y  m ed ic in es . I  w a n te d  to  s to p  
th e  tr e a tm e n t b e c a u s e  th e  s id e -e ffe c ts , b u t h e tr ie d  to  e n c o u ra g e  m e  a n d  he a lso  g a v e  m e  
s o m e  m e d ic in e s  to  r e d u c e  it. " (CDOT patient, male 30 years old)
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However, many CDOT patients felt that follow-up by staff from the HC was not 
sufficient; especially TB education and the DOT information that they received through 
DOT watchers was not adequate compared to those treated at the HC: “1f e l t  th a t  m y  D O T  
w a tc h e r  d id n  't h a v e  en o u g h  e x p e r ie n c e  f o r  T B  tre a tm e n t b e c a u s e  e v e r y  tim e  I  a s k e d  h im  
a b o u t m e d ic in e s  a n d  s id e -e ffe c t  o f  d r u g s  h e  d i d n ’t  a n s w e r  m e  im m e d ia te ly  a s  h e n e e d e d  
to  a s k  s t a f f  a t  the H C . ” (CDOT patient, female 48 years old). All CDOT patients 
requested more regular visits by staff during the treatment.
Some patients said that CDOT would be better if staff allowed them to select their own 
DOT watchers. Even though CDOT patients were nearly always happy with the selection 
of their DOT watchers by staff, they still felt that staff should discuss with them first 
before making decision. Patients felt that as the TB treatment required patients taking 
medicines for 6 to 8 months, so patients preferred to take medicines with someone who 
has a good relationship with patients: “I  th in k  th a t  i f  1  n e e d  to  t r e a t  f o r  T B  aga in , I  w o u ld  
l ik e  to  s e le c t  m y  o w n  D O T  w a tc h e r  b e c a u se  I  d i d n ’t  h a v e  a n y  c h o ic e  to  s e le c t  m y  o w n  
D O T  w a tc h e r . I  th in k  i t  is  im p o r ta n c e  to  ta k e  m ed ic in e s  w ith  so m e o n e  w h o  y o u  a re  w e l l  
k n o w n  b e c a u s e  th e  T B  tr e a tm e n t is  v e r y  long. ” (CDOT patient, female 38 years old)
When asking patients who they would prefer to take medicines with during the treatment; 
the answer was mainly family members, because taking medicines with family members 
was convenient for most patients, since they did not then need to travel to another place. 
Patients revealed that although patients took medicines with DOT watchers during the 
treatment, family members were still involved in encouraging and motivating patients to 
come and take medicines every day. “I f  I  c o u ld  s e le c t  m y  o w n  D O T  w a tch er , I  w o u ld  
c h o o se  m y  w ife  b e c a u se  sh e  w a s  v e r y  g o o d  in re m in d in g  m e  f o r  tim e  to  ta k e  m ed ic in es.
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E sp e c ia lly , i t  w o u ld  b e  m o re  co n v e n ie n t f o r  m e  to  ta k e  m e d ic in e s  w ith  h e r  a t  hom e. ” 
(CDOT patient, male 58 years old).
There were similar responses from patients with self-administration treatment, they were 
happy to take medicines at their home rather than travelling to another house. They also 
mentioned that their family members were involved as DOT watchers as well as in giving 
medicines, collecting them from the HC, and reminding patients of when to take the 
medicines: “I  w a s  h a p p y  to  ta k e  m ed ic in e s  a t  m y  h o u se  b e c a u se  i t was c o n v e n ie n t f o r  m e. 
W hen I  to o k  m e d ic in e s  a t  hom e, m y  so n  o b s e r v e d  m e ta k in g  m e d ic in e s  e v e r y  day. ” 
(Patient registered as CDOT patient, female 52 years old)
In addition, patients who had the sputum controls before the treatment finished, were very 
happy about taking medicines in the community because they felt that the treatment was 
effective. In contrast, those who did not have any sputum checked during the treatment 
were still questioning their health and the effectiveness of treatment. They felt that the 
DOT watchers may have given them the wrong doses of medicines because some TB 
symptoms still persisted. A few patients thought that if they had been treated by staff at 
the HC from the beginning, they would be cured. One patient opined: "1f e l t  th a t I  am  n o t  
c o m p le te ly  c u r e d  f r o m  TB  b e c a u s e  I  s t i l l  c o u g h  b lo o d . I  th in k  m a y b e  m y  D O T  w a tc h e r  
d i d n ’t  g iv e  m e  th e  r ig h t  d o s e  f o r  m y  m ed ic in es . N o w  th in k in g  back , I  s h o u ld  h a ve  ta k en  
m e d ic in e s  w ith  s ta f f  a t  th e H C  b e c a u se  th e y  c o u ld  s e e  m e a n d  g iv e  m e th e  r ig h t  
m ed ic in e s . ” (CDOT patient, female 47 years old)
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8.26 Results from the observation
During the data collection, the author found that the real number of patients treated with 
CDOT in some HCs was less than the figures given in the register. The helping based on 
the number of CDOT patients, provided by sponsors or NGOs was the reason for the staff 
to increase the figures of number of CDOT patients in order to get more support. 
Moreover, there was a lot of self-administration patients among patients registered as 
CDOT patients.
CDOT patients rarely went back to the HC unless they had very serious side-effects. It 
was also disclosed by staff that they had never met some patients because they were 
registered through the DOT watchers. During the data collection, some patients were 
selected from the register by the author for the interviews; however, these names were not 
recognized by the villagers when the author visited.
Another problem found by the author was relapse of some CDOT patients and self­
administration patients in HCs which had implemented CDOT. Two patients selected in 
the interviews were relapse patients who had been treated for TB before. Both of them 
involved self-administration for the first treatment. “T h is  is  m y  s e c o n d  tim e  f o r  TB  
tre a tm e n t. I  s ta r te d  m y  f i r s t  tr e a tm e n t la s t  y e a r  b u t th a t  tim e  I  to o k  m e d ic in e s  a t  h o m e b y  
m y s e l f  ” (CDOT patient, female 47 years old)
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9 CHAPTER 9: Qualitative results for implementation of 
HC-DOT
HC-DOT, also known as ambulatory DOT, started in 2002 at most HCs in the study. 
Most patients treated with HC-DOT live within 5 kilometers of the HC. The m o s t  
common mode of transport to the HC is walking, by bicycle or by motorbike.
9.1 The treatment procedures
Most sputum positive patients were contacted to come for treatment by phone call, 
through health volunteers, the chief of village, neighbors or relatives, or HC staff if they 
lived in the same commune.
The DOT information including treatment duration, side effects of drugs, time, place and 
person responsible for watching patients, and the consequences of non-adherence to 
treatment were explained and discussed with patients on the day that treatment started. 
Interactions between staff and new TB patients were observed during the study, and 
patients were seen to be advised by staff to come to the HC every day to take medicines 
for 6 months; and the patients took medicines in front of staff. Side effects of the drugs 
were explained by staff before giving the medicines.
9.2 Flexibility in place of treatment for HC-DOT patients
Other DOT approaches such as DOT at home and CDOT were also used in the HCs
implementing ambulatory DOT, with assignment based on staffs decision. Staff allowed
patients to take medicines at home for the whole treatment if they were old, very sick,
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disabled or unable to come to the HC every day. Some patients were assigned to CDOT 
according to the availability of health volunteers in the village. For example: “7 w e n t to  
ta k e  m e d ic in e s  a t  th e H C  f o r  3  d a y s  a n d  th e  r e s t  I  to o k  m e d ic in e s  a t  m y  h o m e b e c a u se  the  
s ta f f  k n e w  th a t  I  h a d  d ifficu lt to  co m e  to  th e  H C  e v e r y  d a y  s in c e  m y  h o u se  is  f a r  a n d  I  l iv e  
a lo n e . ” (HC-DOT patient, female 28 years old)
9.3 Places and DOT watchers for patients treated with HC-DOT
Patients could take medicines while observed by any staff member in the HC because the 
TB medicines for each patient is prepared every morning. In contrast to the national TB 
guidelines for HC-DOT which requires patients to come for taking medicines at the HC 
supervised by staff for 6 months (MoH 2004), both staff and patients reported that 
patients came to take medicines at the HC only from Monday to Friday for the first two 
months for the initial phase, and for the other 4 months they were allowed by staff to take 
medicines at home. Furthermore, in the intensive phase patients were allowed to take 
medicines at home during the weekend and national holidays: " P a tien ts  a r e  r e q u ir e d  to  
ta k e  m e d ic in e s  w ith  u s  a t  th e  H C  o n ly  f o r  2  m o n th s  a t  th e  b e g in n in g  a n d  th e  r e s t  th e y  
c o u ld  ta k e  a t  h om e. D u r in g  th e tre a tm e n t w ith  us a t  th e  H C , w e  g iv e  th em  m ed ic in e s  to  
ta k e  a t  h o m e  d u r in g  th e  w e e k e n d  a n d  h o lid a y s  b e c a u se  n o b o d y  is  h ere. ” (Staff at HC- 
DOT, male 41 years old).
Some patients took medicines with staff at the HC for the continuous phase, especially 
those who lived close to the HC. For patients taking medicines at home, they were 
required to come back to the HC once or twice a month to restock with medicines.
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Most patients admitted that they rarely went back to the HC during the continuous stage, 
since their family members or friends helped them by collecting the medicines. Others 
mentioned that they went back to the HC either because staff asked them to go back or 
because they had other health problems, otherwise they took medicines at home for the 
remaining 4 months. One patient said: "After 2  m onth s, I  to o k  m e d ic in e s  a t  m y  h ou se; m y  
so n  h e lp e d  m e  c o lle c t  m ed ic in e s  f r o m  th e H C  e v e r y  M o n d a y . S in ce  th en  I  n e v e r  w e n t b a c h  
to  th e  H C . ” (HC-DOT patient, female 57 years old)
There was generally no DOT watcher to observe these HC-DOT patients taking 
medicines at home during the continuous phase. Almost all the patients and staff 
mentioned that, as patients become accustomed to taking medicines on a regular basis at 
the HC for 2 months and as their desire to be cured grew, there was no need for anyone to 
monitor them taking medicines at home for the rest of the treatment: "A t h om e n o  on e  
w a tc h e d  m e  ta k in g  m ed ic in e s , 1  to o k  m ed ic in e s  e v e r y  m o rn in g  b e fo re  g o in g  to  th e  r ic e  
f ie ld .  1 d i d n ’t  n e e d  a n yo n e  to  w a tc h  m e; I  kn ew  w h en  I  n e e d e d  to  take it. I ’v e  n e v e r  
f o r g o t te n  to  ta k e  m e d ic in e s  b e c a u s e  I  w a n te d  to  b e  c u r e d  a n d  g e t  b a c k  to  m y  re g u la r  
w o rk s. ” (HC-DOT patient, male 48 years old).
Although patients did not have anyone to observe them during the treatment at home, 
family members such as a spouse or children were involved in reminding patients of the 
time to take medicines. One patient said: "At h o m e m y  w ife  r e m in d e d  m e to  ta k e  
m e d ic in e s  b e fo r e  I  w e n t  to  w o r k  ’’ (HC-DOT patient, male 51 years old)
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CDOT was used in some HC-DOT for patients who had difficulty coming to HCs. Health 
volunteers and the chief of village were used as DOT watchers. These health volunteers 
did not receive any payment from the TB and DOT program as patients were not 
officially CDOT patients; they were paid from other program funds, such as the family 
planning program, or the malaria, mother and child care, and vaccination programs.
Staff were responsible for selecting health volunteers as DOT watchers for patients 
depending on the distance between the patients and the DOT watchers’ homes, especially 
the availability of health volunteers in the village where patients lived. One staff member 
stated: "F or p a t ie n ts  w h o  liv e  f a r  f r o m  th e  H C , I  n e e d  to  c h e c k  i f  th e re  is  a n y  h ea lth  
v o lu n te e r  a v a ila b le  in  th e ir  v il la g e s . I f  th e re  is, I  w i l l  s e n d  p a t ie n ts  to  ta k e  m e d ic in e s  w ith  
th e  h e a lth  v o lu n te e r s  in  th e v il la g e  in s te a d  o f  c o m in g  to  H C . ” (HC-DOT staff, female 42 
years old)
Patients treated with the CDOT revealed that they took medicines at a DOT watcher’s 
house everyday including the weekend and national holidays. Those responsible for 
watching patients taking medicines were not only health volunteers; but included their 
family members whenever health volunteers were busy. However, patients were still 
required to come to the HC once or twice a month to collect their medicines and leave 
them with health volunteers: “D o c to r  a s k e d  m e  to  ta k e  m e d ic in e s  w ith  M r ....w h o  is  
in v o lv e d  in  th e  h e a lth  a c tiv i t ie s  in  th e  H C . H e  l iv e s  c lo s e  to  m y  h o u se . I  w e n t to  take  
m e d ic in e s  w ith  h im  e v e r y  m o rn in g  in c lu d in g  S a tu r d a y  a n d  S u n d a y ." (Patient, male 55 
years old)
9.4 The CDOT used for HC-DOT patients
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Most patients who had treatment at home for the whole 6 months did not have any DOT
watcher observing them taking medicines, although a few patients were observed by their 
family members.
There are several situations where staff allowed patients to take medicines at home. First, 
if patients refused to have treatment if they were not allowed to take it at home, due to 
difficulty to travel to the HCs, and there was no availability of health volunteers in the 
village where patient came from. Second, during the period of flooding, patients were 
allowed by staff to take medicines at home because it was very difficult to access HCs. 
“T o  te l l  y o u  th e  tru th , w e  s t i l l  le t  p a t ie n ts  ta k e  m e d ic in e s  a t  hom e. We a s k e d  th e ir  fa m ily  
m e m b e r s  to  o b s e r v e  p a t ie n ts  a t  hom e. We d o n  7 h a ve  a n y  c h o ic e ...s in c e  o u r  H C  is  lo c a te d  
f a r  f r o m  th e  v i l la g e s  w h e r e  p a t ie n ts  live . S o m e  p a t ie n ts  c o m e  fr o m  v il la g e s  m o re  th a n  5  
km  f r o m  th is  H C . E sp e c ia lly , la s t  y e a r  o u r  H C  w a s  f lo o d e d  f o r  o v e r  5  m o n th s a n d  w e  le t  
p a t ie n ts  ta k e  m e d ic in e s  a t  h o m e  in s te a d  o f  c o m in g  to  th e  H C . ” (HC-DOT staff, male 41 
years old)
9.5 Non- DOT patients
Of HC-DOT patients interviewed in the study, almost half were “non-DOT”, because 
they had no supervisor, neither staff nor health volunteers at home, for the whole 6 
months. Reasons for not being observed daily by staff at the HC were distance from 
patient’s house to the HC, the difficulty of transport and the patient’s health conditions: 
“B e c a u se  m y  b o d y  h u r ts  a n d  m y  h o m e  is  v e r y  f a r  f r o m  th e  H C , 1  h a d  n o  s tre n g th  to  w alk. 
I  a s k e d  th e  d o c to r  to  ta k e  m e d ic in e s  a t  h o m e  in s te a d  o f  ta k in g  w ith  h e r  a t  th e H C  " (HC- 
DOT patient, female 40 years old)
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Many of these patients still went back to the HC weekly to collect medicines for the 
initial phase, and once a month for the continuous phase. Others said that they went back 
to see staff at the HC more often during the initial phase, in order to seek help for side 
effects. Most patients treated at home mentioned that their family members helped and 
reminded them to take medicines at home.
9.6 Follow-up of patients’ adherence to treatment for HC-DOT patients
Follow-up of patients’ adherence to treatment was by checking the patient’s treatment 
cards. Most patients mentioned they were told to tick the day in the treatment card every 
time they took medicines at the HC or at home. Those who took medicine at home needed 
to bring the card for staff to verify whenever they came for collecting medicines at the 
HC. Medicines were not given if any days of taking medicines were missing from the 
treatment card, and patients would be asked to come back to have treatment with staff at 
HC. One patient said: “T o a v o id  fo r g e t t in g  ta k in g  m e d ic in e s  a t  h om e, 1  w a s  to ld  b y  
d o c to r  to  t ic k  in  m y  tr e a tm e n t c a r d  e v e r y  t im e  I  to o k  m ed ic in es . I  n e e d e d  to  b r in g  th e  c a r d  
to  s h o w  h im  w h e n e v e r  I  w e n t  to  s e e  h im . ’’ (HC-DOT patient, male 49 years old)
When asked what made staff believe that patients were really taking medicines regularly 
at home, most answered that they believed in the patients’ desire to be cured and to avoid 
transmitting TB into the family. Several staff members commented that the family 
members were asked to observe and remind patients taking medicines at home. Staff also 
checked with the patient’s family to see and make sure if patients really took medicines 
regularly at home: " I in v e s t ig a te d  c lo s e ly  w ith  p a tie n ts . I  b e lie v e  th a t  th e y  m u st take  
m e d ic in e s  e v e r y d a y  b e c a u s e  e v e r y  p a t ie n t  w a n te d  to  b e  cu red , s o  t h a t ’s  w h y  th e y  ca m e  to  
s e e k  th e  tr e a tm e n t w ith  us. ” (HC-DOT staff, male 56 years old)
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If patients missed treatment for at least 2 days they were contacted by staff to come back 
to the HC, with the contact made through health volunteers, neighbors, and the chief of 
the village. Several staff stated that they went to visit at home those who missed treatment 
more than twice. However, most staff said that non-adherence rarely occurred; it only 
happened sometimes with patients who migrated to other places and those who died 
during the treatment.
9.7 Sputum controls for patients treated with HC-DOT
As with CDOT patients, smear positive patients were required to have sputum control 
twice during the treatment. In fact, these controls were rarely carried out due to two 
factors; the first was the difficulty in sending samples to the laboratory and delays in 
receiving back the results. Many staff at HCs revealed that the sputum controls were not 
necessary since the laboratory’s staff considered sputum samples for current patients as 
their first priority. That is why staff rarely asked patients for sputum controls unless they 
found patients still had some TB symptoms. " D e la y s  in  r e c e iv in g  th e  r e su lts  f o r  sp u tu m  
c o n tro ls  w a s  a lw a y s  h a p p e n in g  in  m y  H C . S ta f f  a t  th e la b o ra to r y  d o n ’t  c o n s id e r  the  
sp u tu m  c o n tro ls  a s  th e  f i r s t  p r io r i ty  s in c e  th e y  h a d  a  lo t  o f  sa m p le s  f o r  n e w  p a t ie n ts  to  
c h e c k  b e fo re  th e y  c o u ld  d o  th e  co n tro ls . Then 1 d e c id e d  to  g iv e  m ed ic in e s  to  p a t ie n ts  f o r  
th e  c o n tin u o u s  p h a s e  w ith o u t  w a i t in g  f o r  th e  r e s u lts  s in c e  I  k n e w  th e  s m e a r s  m u s t b e  
n e g a tiv e  a f te r  p a t ie n ts  to o k  m e d ic in e s  f o r  2  m on th s. H o w e v er , I  s t i l l  a s k e d  f o r  sm e a r  
c o n tro ls  f r o m  th o se  w h o  s t i l l  h a d  so m e  TB sym p to m s. ” (HC-staff, male 36 years old)
The second factor was that patients did not have any sputum because mucus had
disappeared after patients took medicines regularly more than 2 months. The same
reasons were given by most patients, that they did not have any sputum control during the
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treatment. “/  d id n ’t  h a ve  a n y  c o n tr o l  M y  sp u tu m  te s ts  w e r e  c h e c k e d  o n ly  a t  th e  
b eg in n in g . I  d id n 't  k n o w  th a t w e  n e e d e d  to  h a ve  th e  c o n tro ls  s in c e  s ta f f  d id n  7 a s k  f o r  it. " 
(HC-DOT patient, male 49 years old).
When asked what made them think that they were cured since they did not have any 
sputum control most patients mentioned that they felt better and all TB symptoms had 
disappeared after the treatment finished: “I  r e a lly  f e e l  b e tte r . I  d o n  7 h a ve  a n y  m o re  b lo o d  
w h en  1 cou gh . I  s ta r t  to  w o rk  a s  n orm al. B efo re  th e tre a tm e n t I  c o u ld  n o t w o r k  a n d  I  f e l t  
t i r e d  a l l  th e  tim e. L o o k  a t  m y  h e a lth  co n d itio n  now . ” (HC-DOT patient, male 51 years 
old). Others reported that they were told by staff at the beginning of treatment, that they 
would be cured when they took medicines every day for 6 months.
However, some patients, especially patients who took medicines at home and had no 
DOT watcher, questioned the effectiveness of TB medicines, because some TB symptoms 
remained. Some patients asked the author if they could continue to take more TB 
medicines; others said that they felt hopeless because their symptoms became more 
serious: “I  s t i l l  c o u g h  w ith  b lo o d , m y  h ea lth  d o e s n 't  g e t  b e tte r  s in ce  m y  tre a tm e n t  
f in is h e d . I  d o n  7 w a n t to  g o  b a c k  f o r  th e tre a tm e n t a g a in  s in c e  I  am  v e r y  o ld  a n d  I  am  
g o in g  to  d ie  o n e  day . ” (HC-DOT patient, female 55 years old).
9.8 TB education and promotion in the areas covered by HC-DOT
As for CDOT, TB education and health promotion activities in the villages, were done by 
staff at the HC and health volunteers, although due to lack of funding, they were rarely 
done from the TB education program, but combined with others health promotion,
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whenever they go to see people in the villages, and they ask health volunteers to help find 
suspect cases in the community and refer patients with TB symptoms to the HC.
Patients said they hardly saw staff from the HC come to do TB education in the villages. 
Rather they heard about TB symptoms and the DOT treatment through media such as TV 
and radio. “/  h a v e n 't  se e n  s ta f f  a t  th e H C  c o m e  to  ta lk  a b o u t TB in m y  v illa g e . I  h e a rd  
a b o u t T B  a n d  th e  tre a tm e n t th ro u g h  ra d io . ” (HC-DOT patient, male 51 years old)
9.9 Advantages of HC-DOT
A. Staff motivation
When asked about the key success of implementation of HC-DOT, answers differed. 
Most patients said that motivation and encouragement from staff at the HC caused them 
to complete the treatment. One patient expressed the idea: ‘7  c o n tin u e d  to  take  m ed ic in e s  
even  th o u g h  I  h a d  v e r y  b a d  s id e  e ffec ts  b e c a u se  o f  m y  d o c to r . H e  tr ie d  to  ex p la in  to  m e  
a n d  e n c o u ra g e  m e to  ta k e  m e d ic in e s  e v e r y d a y  w h en  I  s a w  him  a t  th e  H C. ” (HC-DOT 
patient, male 43 years old). Most patients mentioned that they were really happy and liked 
the treatment with HC-DOT because staff were very friendly and never discriminated 
against patients. A few liked the way staff were very flexible with patients who were very 
sick or lived far away from the HC by letting them take medicines at home.
Staff also saw encouragement as an important aspect of treatment. Most staff stated that 
they tried to find suspect cases in the community and to see patients at home if they 
missed treatment, even though they had to spend their own money for transportation: “I  
th in k  o n e  a d v a n ta g e  o f  H C -D O T  is  th e  s t a f f s  e n c o u ra g e m e n t to  p a t ie n ts  f o r  ta k in g
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m e d ic in e s  e v e r y  d a y ;  w e  a lw a y s  te l l  a n d  re m in d  th em  a b o u t th e  a d v a n ta g e s  o f  ta k in g  
m e d ic in e s  e v e r y  day. ” (HC-DOT staff, male 56 years old)
When “non- DOT patients” were asked what made them continue to take medicines 
regularly even though they have not been observed by anyone at home, most said that it 
was the encouragement of staff at HC to motivate and encourage them to take medicines 
every day. The effective TB treatment process and explanations by staff before started the 
treatment including the consequences of missing taking medicines, was a big influence. 
"I n e v e r  f o r g o t  to  ta k e  m ed ic in e s ;  I  cam e to  ta k e  m e d ic in e s  a t  H C  e v e r y  day. I f  I  h a d  a  
tr ip  f a r  a w a y  f r o m  m y  h o u se  I  a lw a y s  r e q u e s te d  m e d ic in e s  to  ta k e  d u r in g  m y  tr ip  b e c a u se  
I  k n e w  f r o m  s ta f f  th a t  i f  w e  d id n  7 take  m ed ic in e s  re g u la r ly , th en  m y  d ise a s e  w o u ld n  7 b e  
cu red . ” (HC-DOT patient, female 28 years old)
Staffs attitudes including their emotional support and help to reduce side effects of 
medicines; were key factors in helping patients stay in treatment until the end, even when 
they had serious side effects and were tempted to interrupt the treatment: ‘7  h a d  v e r y  b a d  
s id e  e ffe c ts  a f te r  I  to o k  m e d ic in e s  f o r  3  d a ys . I  w a n te d  to  s to p  ta k in g  m ed ic in es. B u t th e  
d o c to r  t o ld  m e  th o s e  p r o b le m s  w o u ld  g o  a w a y , a n d  h e  g a v e  m e  s o m e  m e d ic in e s  to  h e lp  
f o r  th o se  s id e  effec ts . I  f e l t  b e t te r  a f te r  that. I  am  th a n k fu l to  him. I f  1 d id n ’t  tr e a t  w ith  
him , I  w o u ld  g iv e  u p  f r o m  th e  b e g in n in g .” (HC-DOT patient, female 40 years old)
B. Staffs qualification
As with the CDOT program the staffs qualification and experience was one of the
advantages of the successful implementation of HC-DOT. Some patients felt more secure
taking medicines with staff at the HC because they have a lot of experiences in TB field,
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and are the best if something wrong appears during the treatment: “/ f e l t  sa fe r  w h en  1 to o k  
m e d ic in e s  w ith  th e d o c to r  a t  th e  H C  b e c a u se  h e c o u ld  w a tc h  m e  a n d  in terven e  a n y tim e  
w h en  I  h a d  s o m e th in g  w r o n g  in c lu d in g  s id e  effects. ” (HC-DOT patient, male 33 years 
old)
C. The environment in HCs
Some patients believed that the stricter environment of the HC was more likely to ensure 
their adherence to complete the treatment: "B eca u se  I  f e a r e d  h a v in g  a  b a d  r e c o r d  a t  the  
H C  f o r  m y  fa m ily . I n e e d e d  to  co m e  b a c k  a n d  ta k e  m e d ic in e s  e v e r y  d a y  in  th e  p r e s e n c e  o f  
th e d o c to r . ” (HC-DOT patient, male 40 years old)
Others mentioned that it was an advantage that the patients got clinical care beside TB, 
health education and encouragement and support from other patients: " E very  d a y  w h en  I  
c a m e  to  th e  H C , I  m e t  w ith  d o c to r s  w h o  g iv e  m e a n d  m y  f a m i ly  a d v ic e  a n d  su p e rv ise  
a b o u t g e n e r a l  h e a lth  e d u c a tio n . I  m e t w ith  o th e r  p a t ie n ts  w h o  ca m e  to  ta k e  m ed ic in es  a s  
w e ll;  th is  w o u ld  e n c o u ra g e  m e  to  d o  th e sa m e . ” (HC-DOT patient, female 30 years old)
D. TB medicines
Medicines being available and delivered on time from the top levels to the HC, were 
reported as a key factor in im p le m e n tin g  HC-DOT by most s ta f f  an d  p a tien ts . “/  lik e  to  
t r e a t  w ith  th e  H C - D O T  b e c a u se  e v e r y  tim e  I  co m e  to  ta k e  m ed ic in e s , d o c to r  a lw a y s  h a d  
m e d ic in e s  f o r  m e. ” (HC-DOT patient, male 51 years old)
All patients were very happy with the treatment because of the effectiveness of the
medicines, even though side effects were complained of by most patients.
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E. Involvement from the health volunteers in community
According to staff, the effective implementation of HC-DOT needs the involvement and 
effort from people in the community such as health volunteers and chiefs of the village, as 
well as family members in searching and referring suspect cases to HCs, and following- 
up and encouraging patients to complete the treatment. Even though most HCs 
implementing ambulatory DOT have not officially involved health volunteers as DOT 
watchers, health volunteers were still very much involved in TB activities including TB 
education in the community, referring patients and helping patients with transportation to 
the HC. One patient said: "I like  th e tre a tm e n t a t  th e H C  b e c a u se  th e y  h a ve  a  lo t  o f  
n e tw o rk s  in th e  v illa g e . D u r in g  m y  con tin u ou s p h a se , s o m e tim e s  I  d i d n ’t  n e e d  to  g o  to  
c o l le c t  m y  d ru g s  s in c e  th e  d o c to r  se n t th em  th ro u g h  M r ..w h o  w o r k s  a s  h ea lth  vo lu n teer. ” 
(HC-DOT patient, female 52 years old)
F. Ambulatory DOT is better than the hospital DOT
Few patients who had a family history of TB treatment under the hospital DOT, 
mentioned that treatment with the ambulatory DOT was much better since it did not 
require them to stay at the hospital during treatment. They still could stay in the family 
and work as normal people during the treatment: " la m  h a p p y  to  ta k e  m e d ic in e s  w ith  s ta f f  
a t  th e  H C  b e c a u s e  I  c o u ld  s ta y  w ith  m y  fa m ily . I t  w a s  b e t te r  th a n  m y  f a th e r ' s  tim e. H e  
n e e d e d  to  s ta y  a t  th e  h o s p i ta l  f o r  2  m o n th s; i t  w a s  d iff ic u lt  f o r  u s  to  g o  to  s e e  h im  in  th e  
h o sp ita l. ” “HC-DOT patient, male 25 years old)
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9.10 Disadvantages of HC-DOT
A. Problem of access to the HC
Patients and staff at the HC recognized that HC-DOT involved longer travel time and 
greater distance for patients. Therefore, the effort and time needed to attend the treatment 
at HCs everyday might affect patient’s adherence to treatment, especially for those who 
were very sick and had no transportation. " I f in d  i t  w a s  d iff ic u lt f o r  m e to  tra v e l  to  th e  H C  
e v e r y  d a y  d u r in g  the tre a tm e n t b e c a u se  I  n e e d e d  to  w a k e  u p  e a r ly  in th e m o rn in g  a n d  
w a lk  f r o m  m y  h o u se  to  th e H C . S o m e tim e s  I  w a s  v e r y  s c a r e d  o f  a  tra ffic  a c c id e n t b e c a u se  
I  n e e d e d  to  c r o s s  th e m a in  ro a d . ” (HC-DOT patient, female 68 years old)
The financial burden of transportation was complained of by most patients who regularly 
attended the HC in the initial phase. Travelling to the HCs every day cost patients a lot of 
money, especially those who were poor and lived far away from the HC: "G o in g  to  th e  
H C  e v e r y  d a y  h a s  c o s t  m e  a  l o t  o f  m on ey. I  l iv e  f a r  f r o m  th e  H C , I  h a d  o n ly  o n e  b icyc le . I  
h a d  to  b o r r o w  a  m o to rb ik e  o r  b ic y c le  f r o m  m y  n e ig h b o rs  w h en  m y  w ife  to o k  b ic y c le  to  th e  
r ic e  f ie ld .  S o m e tim e s  I  h a d  to  ta k e  a  m o to r  ta x i;  i t  w a s  v e r y  c o s t ly  to  m y  f a m i ly  b e c a u se  
w e  a r e  v e r y  p o o r .  ” (HC-DOT patient, male 40 years old)
B. Long waiting time at the HC
The inconvenient appointment times and long waiting times for treatment at the HC were
also reported by staff and patients. Most staff said that they asked TB patients to come for
medicines earlier in the morning before they have to see new patients. Patients have to
wait for staff to complete their duties before giving medicines to patients if they come
during the busy times: “I  w e n t  to  th e  H C  e v e r y  m o rn in g ; I  a r r iv e d  a t  th e  H C  a ro u n d  7
am . E ven  th o u g h  I  t r ie d  to  g e t  th e  H C  a r o u n d  th a t tim e  b u t I  s t i l l  h a d  to  w a it  f o r  the
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d o c to r  b e c a u se  s ta f f  w e r e n ’t  th e re  y e t. . .  o n ly  c le a n e r  w a s  th ere , so m e tim e  I  w a i te d  f o r  2 0  
m inu tes. ” (HC-DOT patient, male 49 years old)
C. No option for the alternative DOT
A few patients treated with the HC-DOT complained that staff did not give them a choice 
to decide where to take medicines. Decisions were made by staff at the HC, and choices 
were given only to patients who were friends or related to staff: “I  w a s  n o t h a p p y  w ith  
d o c to r ’s  d e c is io n ;  I  l iv e  v e ry  f a r  f r o m  th e H C  b u t d o c to r  s t i l l  a s k e d  m e to  co m e  f o r  ta k in g  
m e d ic in e s  a t  th e  H C . D u r in g  m y  tim e, 1  s a w  o n e  la d y  w h o  l iv e d  v e r y  c lo s e  to  th e  H C  b u t  
sh e  c o u ld  ta k e  m e d ic in e s  a t  h om e b e c a u se  sh e  is  th e s ta f f ’s  cou sin . ” (HC-DOT patient, 
female 53 years old)
D. Delay in getting the test results
Delaying in getting back the results from the laboratory and starting the treatment were 
mentioned by most staff and patients. Many patients reported that they tried to find 
alternative medical treatment such as traditional medicines or cultural Holy Spirit during 
the period of waiting for results from the HCs. Some patients needed to come back to the 
HCs several times in order to seek the results; it was very costly for them in transportation 
and time: ‘‘B e c a u se  I  h a v e n ’t  h e a r d  a n y  n e w s  f r o m  s ta f f  a t  th e  H C ...U  w a s  a lr e a d y  2  
w eek s . M y  w ife  a s k e d  m e  to  g o  to  th e  u n c le  w h o  is  a  fo r tu n e  te l le r  to  s e e  i f  so m e th in g  w a s  
w r o n g  w ith  m e  d u r in g  m y  w o r k  in th e  fo r e s t .  ” (HC-DOT patient, male 53 years old)
E. Lack of follow-up from HC staff during the continuous phase
Lack of follow-up from staff during the continuous phase was raised by nearly all patients
during the interview. Staff were more attentive to patients’ problems during the intensive
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phase. Most patients mentioned that staff never visited patients at home to see whether 
patients had any problems such as side effects of the new medicines: " I fe lt  th a t  s ta f f  o n ly  
c a r e d  f o r  p a t ie n ts  d u r in g  th e  f i r s t  tw o  m onth s. W hen I  to o k  m e d ic in e s  a t  hom e, h e  n e v e r  
c a m e  to  s e e  m e  o r  a s k e d  m e w h e th e r  I  s t i l l  h a d  a n y  s id e  e f fe c ts ." (HC-DOT patient, 
female 59 years old)
F. Lack of TB education and TB promotion in the community
Most patients treated with the HC-DOT felt that the TB education in their communities 
was not sufficient, because they rarely saw staff educate people about TB. Finding 
suspect cases in the community is not enough, since the HC’s network in the community 
is still weak. For example, there are not enough health volunteers involved in the TB 
activities including referral of suspect cases to the HC.
9.11 Perceptions of CDOT from people in HC-DOT
Staff and patients had differing perceptions towards CDOT.
A. Advantages of CDOT amongst people in HC-DOT
The majority of staff and patients recongnised that treatment with CDOT would save 
time, be more convenient for patients, and could reduce the financial burden on the 
patient’s transportation. CDOT was seen as a good method for those who have difficulty 
in coming to HCs during the treatment. One HC-DOT patient treated with CDOT 
asserted: “ W hen I  to o k  m e d ic in e s  w ith  m y  h e a lth  v o lu n te e r  in th e  co m m u n ity , i t  s a v e d  m e  
a  lo t  o f  tim e;  a n d  i f  I  w e n t  to  th e  H C  e v e r y  d a y , 1  w o u ld  p a y  a  lo t  o f  m o n e y  o n  th e  
tra n sp o r ta tio n . ” (HC-DOT patient, female 40 years old). Many patients reported that they 
would recommend CDOT to other patients and their relatives because it saves time and
198
money. Some staff mentioned that implementation of CDOT would reduce the workload 
for the HC and improve TB knowledge among people in the community.
B. Disadvantages of CDOT considered by people in HC-DOT
Both patients and staff saw advantages to CDOT, but were concerned about several issues 
relating to its implementation. The first issue was their lack of confidence in using health 
volunteers as DOT watchers. Most staff feared to let patients take medicines with health 
volunteers because they felt they did not have sufficient TB knowledge and training, 
especially in solving patients’ problems including managing side effects. Patients also 
commented that they would prefer taking medicines with staff at the HC. Health 
volunteers could not help them if patients had any problems during the treatment since 
they are not doctors and less experienced in TB training. One patient stated: “/  d o n  7 
w a n t to  ta k e  m e d ic in e s  w ith  h ea lth  v o lu n te e rs  in th e  c o m m u n ity  b e c a u se  th e y  a r e  n o t  
d o c to r s  a n d  l a m  a f r a id  o f  g iv in g  m e th e  w r o n g  m ed ic in es . " (HC-DOT patient, female 53 
years old)
The second issue was that staff were worried that health volunteers may not always 
supervise strictly in the long term, and so would affect patients’ adherence to treatment. 
Others mentioned that observing patients taking medicines every day by health volunteers 
may not be possible, because they have many jobs including their own job as well as 
other health activities in the community, and so they may not dedicate their time 100 per 
cent to DOT. For example, they may not sit and wait at home for patients to come to take 
medicines.
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The last issue was the lack of incentives for health volunteers as DOT watchers. Several 
staff who had experience in the implementation of CDOT mentioned that the success of 
CDOT implementation depended on giving incentives to DOT watchers. If DOT watchers 
get paid then they will do a good job in TB treatment such as watching patients take 
medicines, following-up patients’ adherence to treatment and referring the suspect cases 
to the HC. However, the implementation of CDOT could create more difficulty for 
patients and the HC if there was not enough financial support or incentives for DOT 
watchers. If DOT watchers were not paid, they would not pay attention enough to 
observing patients. It would then create difficulty for the HC by increasing the number of 
defaulters and multi-drug resistant patients.
As mentioned by one staff who had a bad experience with CDOT: "T w o  y e a r s  ago , w e  
t r i e d  to  im p le m e n t C D O T  f o r  th o se  w h o  l iv e d  f a r  f r o m  th e  H C  b y  a sk in g  h ea lth  vo lu n teers  
to  b e  D O T  w a tc h e rs . H o w e v e r , w e  d id n 't  g iv e  th em  a n y  f in a n c ia l  s u p p o r t  to  d o  th is  j o b ;  
o n ly  T -sh ir ts  a n d  b a g s . A t  f i r s t  th e y  h a v e  d o n e  a  v e r y  g o o d  j o b  b y  c o m in g  to  c o lle c t  
m e d ic in e s  f o r  p a t ie n t s  a n d  r e p o r te d  b a c k  to  th e  H C  i f  p a t ie n ts  h a d  a n y  p r o b le m s  
in c lu d in g  s id e  effec ts . B u t a f te r  a  w h ile  th e y  s to p p e d  c o m in g  to  th e  H C  b e c a u se  w e  h a d  n o  
m o re  T -sh ir ts  a n d  b a g s . T h en  p a t ie n ts  s ta r te d  to  c o m p la in  a b o u t  th e  a b se n c e  o f  D O T  
w a tc h e rs . W hen w e  c h e c k e d  w ith  p a tie n ts , w e  f o u n d  th a t  s o m e  m e d ic in e s  w e r e  n o t g iv e n  
th em . S in c e  th en  w e  h a v e  im p le m e n te d  o n ly  th e  a m b u la to r y  D O T  b e c a u se  w e  w e r e  a f r a id  
o f  le t t in g  p a t ie n ts  ta k e  m e d ic in e s  w ith  D O T  w a tc h e r s  in  th e  c o m m u n ity  - i t  c o u ld  ca u se  
th e  m u lti-d ru g  re s is ta n c e . ” (HC-DOT staff, male 42 years old)
Regarding the implementation of CDOT, most staff commented that CDOT should be
implemented during the continuous phase, where patients can take medicines at home.
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However, during the intensive phase, patients should come to take the medicines with 
staff at the HC because then staff can see patients’ adherence to treatment. Others 
mentioned that the CDOT would be appropriate for patients who are very sick and have 
difficulty to come to the HC: “I t is  g o o d  to  im p lem e n t th e  a m b u la to r y  D O T  f o r  the  
in te n s iv e  p h a s e  s o  s ta f f  c o u ld  fo l lo w -u p  p a t ie n ts  ta k e  m e d ic in e s  e v e r y  d a y , a n d  th e C D O T  
c o u ld  im p le m e n t in  th e  c o n tin u o u s p h a s e  w h en  p a t ie n ts  ta k e  m e d ic in e s  a t  hom e. ” (HC- 
DOT staff, male 36 years old)
“Non-DOT patients” mentioned that they were happy to take medicines at their home 
rather than to go to take them with anyone else, and if there is the requirement from the 
HC, they said family members are the best DOT watchers since they live in the same 
house: " W h y I  n e e d  to  g o  to  ta k e  m e d ic in e s  w ith  h e a lth  vo lu n te e rs . I a m  h a p p y  to  ta k e  a t  
m y  h o u se . B u t i f  th e y  r e q u ir e  m e  to  h a v e  D O T  w a tch er , I  c o u ld  a s k  m y  so n  to  w a tc h  m e; 
h e  w a s  th e  o n e  w h o  r e m in d e d  m e  ta k in g  m e d ic in e s  w h e n  I  t r e a te d  w ith  TB  la s t  tim e. ” 
(HC-DOT patient, female 59 years old).
Others said they would not be comfortable taking medicines with anyone beside staff at 
the HC, as they would feel a lack of privacy taking medicines with health volunteers: “/  
d o n ’t  w a n t  tre a tm e n t w ith  h e a lth  v o lu n te e rs  b e c a u se  i t  m a k e s  m e  f e e l  th a t e v e ry o n e  in the  
c o m m u n ity  w o u ld  k n o w  a b o u t m y  d ise a se . I p r e f e r  to  c o m e  f o r  ta k in g  m e d ic in e s  w ith  s ta f f  
a t  th e  H C . ” (HC-DOT patient, female 36 years old)
9.12 Results from the observation
From the observation during the interviews at the HC, the author found that more “no-
DOT” patients existed in the HC-DOT because most patients took medicines at home
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without any DOT watcher. Family members especially husbands and children helped 
patients by collecting medicines at the HC.
During the study the author found that six of twenty three patients were considered as 
relapse cases, because they still had TB symptoms such as coughing blood, lost weight 
and difficulty in breathing. All these patients were “no DOT’ because they took 
medicines at home and nobody observed them for the whole treatment.
During the informal meeting in the village, people complained about the lack of TB 
education and promotion in the community; they asked the author to bring this issue to 
the center in Phnom Penh. As stated by one family member: “I  h a v e  n e v e r  s e e n  s ta f f  
c o m e  to  d o  T B  p r o m o tio n  in o u r  v illa g e . M y  h u sb a n d  d i d n ’t  k n o w  a b o u t  h is  T B  sym p to m s. 
H e  w a s  v e r y  s ic k  f o r  m o re  th a n  2  m on th s. I  s p e n t  a  lo t  o f  m o n e y  b u y in g  d ru g s  f r o m  a  
p h a r m a c y  b e c a u s e  1  th o u g h t i t  w a s  j u s t  a  n o rm a l f lu . I  to o k  h im  to  th e  H C  w h en  h e  
c o u g h e d  b lo o d . I f  w e  k n e w  th a t  h is  s y m p to m s  w e r e  TB, w e  w o u ld  h a v e  g o n e  to  th e  H C  
r ig h t  a w a y . ” (Patient’s wife 38 years old)
Villagers suggested improving TB education and promotion activities in the community 
by creating a channel to find suspect cases with symptoms such as cough and referring 
them to the HC as soon as possible. Moreover, it can reduce the chains of transmission in 
the community; and this could be done by HC staff coming to educate people in the 
villages more frequently.
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9.13 Summary key findings of CDOT and HC-DOT from the qualitative study
The implementation of CDOT was recognized by staff, DOT watchers and patients as 
helping patients to reduce costs of travelling to the HC and saving patient’s time, which in 
turn would allow patients to engage in other economic activities. Patients treated by staff 
at the HC needed to spend more time in the HC for taking medicines compared to CDOT 
patients; and needed to spend money on the transportation fees for travelling to the HC 
every day. However, some staff and patients thought that patients who took medicines in 
the community may not be as strictly supervised as patients at the HC. CDOT patients felt 
that they received less regular health education compared to those treated at the HC.
Several problems including delays in getting the results from the laboratory, lack of funds 
for TB education and promotion in the community, lack of follow-up by staff, and lack of 
funds for staff and DOT watchers were apparent in both HCs with implemented CDOT 
and implemented ambulatory DOT. Moreover, neither CDOT patients nor ambulatory 
DOT patients had any choice of the place or person for their treatment. Self­
administration patients existed in both HCs and some still had TB symptoms.
The key finding from this part of the study was that there was significant involvement of 
patients’ family members in watching patients take medicines, reminding patients for the 
time, encouraging patients to complete the treatment, and helping patients to collect 
medicines from the HC. According to the national DOT treatment guideline, family 
members were not recommended to select as DOT watchers; however, in practice family 
members are involved in patient’s treatment more than DOT watchers. Most patients in 
both settings were very pleased with the care they received from their DOT watchers.
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10. CHAPTER 10: Discussion and Recommendations
The present study is the first of its kind to assess the existing CDOT program in 
Cambodia. The thesis examines CDOT compared to HC-DOT in the country in terms of 
treatment success and TB case notification. More specifically it aims to understand the 
implementation of CDOT and HC-DOT in the field especially in rural areas where the 
infrastructures are weak, and identifies gaps and issues related to their implementation 
based on the experiences of staff, DOT watchers and patients. The findings are important 
in designing and adopting TB control interventions that are relevant, sensitive and 
acceptable to the local people. This chapter discusses how the findings contribute to 
current implementation of the DOT approaches, makes suggestions as to how they could 
be improved, and finally makes recommendations for future studies
10.1 The effectiveness of CDOT compared to HC-DOT in the systematic review
It was clear from the systematic review that the effectiveness of CDOT in terms of 
success of treatment was the same or better when compared with HC-DOT. CDOT would 
therefore maintain roughly the same high treatment success for smear-positive TB as HC- 
DOT (RR= 1.05, Cl: 1.01-1.10).
10.2 The effectiveness of CDOT compared to family-DOT in the systematic review
Although family-DOT is not recommended in the national guideline in Cambodia, this 
approach has been used in different settings including Thailand, Nepal, India, and 
Tanzania. Based on the systematic review and analysis in this study, I have shown that
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the treatment success for smear-positive patients treated by CDOT is better than for 
family-DOT (OR=1.33, Cl: 1.20-1.48).
10.3 The effectiveness of CDOT in Cambodia
In 2005 CDOT was fully implemented in some areas in Cambodia, with the main goals 
being to maintain treatment success under the DOT program, to improve case finding, to 
improve the patients’ adherence to treatment, and to reduce the travelling costs for 
patients.
A. Treatment success rate under CDOT
The quantitative study in this thesis showed that the first goal of implementing CDOT in 
Cambodia has been successfully achieved, in that CDOT has proved to be as effective as 
HC-DOT in maintaining high treatment success rates of over 85%, in line with WHO 
targets.
The treatment success rate of all TB forms among patients treated with CDOT was 97.1% 
and that of HC-DOT was 96.57% (OR=1.26, 95% Cl: 0.56-2.82). The death rate from 
new-smear positive TB was small and decreased in the areas where CDOT was 
implemented compared to HC-DOT areas (OR=0.33, 95% Cl: 0.11-0.99). Moreover, this 
study showed that in the same CDOT areas, the death rate among all TB patients was 
reduced significantly after the implementation of CDOT (OR=0.37, 95% Cl: 0.15-0.92), 
and the treatment success rate slightly improved from baseline (2002-2003) to two years 
(2006-2007) after CDOT was implemented (OR=2.10, 95% Cl: 0.95-4.62).
Key Message: the first conclusion of the thesis is that the effectiveness of CDOT in 
Cambodia confirms the results of the systematic review of this study. The
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implementation of CDOT has maintained at least the treatment success rate of HC- 
DOT.
It is seen from the literature review that the cure rate of smear positive TB in Cambodia 
has remained high (95% in 2010) compared to the WHO target of 85%. However, the 
qualitative study found that most patients, for all TB forms in both DOT approaches, did 
not have sputum control at the end of treatment but, as patients who had completed the 
treatment informed the author, they were nevertheless registered as “cured patients” in the 
registration book at both HC and OD levels. This practice could impact the accuracy of 
data on cure and treatment completion rates within the country. In some cases, the actual 
cure rate of smear positive TB could be lower than the rate reported.
Key Message: the second conclusion of the thesis is that the lack of sputum control 
for patients in both CDOT and HC-DOT areas during treatment could bias the 
estimates of cure and treatment completion rates in Cambodia.
B. TB case-finding under CDOT
TB case finding for smear-positive in the CDOT program areas increased dramatically 
from 2002 to 2008, although this increase was not significantly greater than for HC areas 
without CDOT (p=0.547). The results from the quantitative study showed that TB case 
finding for smear-positive in HCs with and without CDOT increased every year from 
2002 until 2008; the improvement of TB case finding in both HCs could be the result of 
two factors. The first factor is the effectiveness of the DOTS strategy which includes a 
government commitment to sustain TB control activities, diagnosis by quality ensured 
sputum-smear microscopy, and standardized recording and reporting systems. Since 
adopting the DOTS strategy, the NTP has tried to put more effort into TB control
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activities by decentralizing the DOT program from hospital-based DOT to HC-DOT in 
every HC from 2002; so TB education and health promotion could more easily be 
disseminated to people in the community, especially to those who live in rural areas. The 
second factor is that the health care system, living conditions for people and Cambodian 
education have improved every year, so people in the community know more about 
hygiene, TB awareness and where to seek help when they are sick. This could increase 
the rates of TB case finding and reduce the death rate due to TB.
Based on the results of the qualitative study, there appear to be two reasons why the TB 
case finding is similar between HCs with and without implemented CDOT; the first 
reason is insufficient TB education and health promotion in the community. Even though 
HCs with implemented CDOT are supposed to have more TB activities in the community, 
such as DOT watchers finding and referring new suspect cases to the HC, this 
involvement from DOT watchers could not be carried out in every HC because of 
insufficient funding of the CDOT program from sponsors. Some sponsors gave incentives 
to DOT watchers to find and refer suspect cases for sputum checks at the HC, so these 
DOT watchers would be more actively involved in educating and finding new suspect 
cases in the community. However, in fact most new patients in both HCs came for TB 
tests at the HC by themselves and were not identified by the DOT watcher; more patients 
who lived far away and had difficulty in getting to the HC, were referred by DOT 
watchers or friends. This would indicate that TB education and health promotion in the 
areas with implemented CDOT is still weak. The involvement of health volunteers in HCs 
with only ambulatory DOT regarding the TB education and health promotion in the 
community, and in finding and referring new suspect cases for TB tests, was the same as 
DOT watchers involved in CDOT areas.
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Key Message: the third conclusion of the thesis is that the goal of implementation of 
CDOT in order to improve TB case finding has not yet successfully reached the 
target. In Cambodia, TB case finding has improved in both HCs since 2002 when the 
NTP decentralized the DOT system to the IIC level. Even though the CDOT 
approach has been implemented, the TB education and health promotion program 
in the community is still weak due to lack of funding.
C. Selection of HCs to implement CDOT
Since CDOT was introduced and piloted in Cambodia, from 2004 until the period of the 
study in 2008, not every HC within the country has implemented it. It was clear from the 
quantitative study that the selection of HCs to implement CDOT was based on where 
treatment success rates were low, and death rates were high, compared to HCs not 
selected for CDOT. Moreover, the qualitative results show that even though CDOT was 
introduced by the NTP, the implementation of this program depended heavily on the 
availability of sponsors or NGOs who could provide funds to support the CDOT; 
however, most of these sponsors did not put the CDOT program as their first priority as 
their main goals were focused on other health activities. During the study period, the 
implementation of CDOT was terminated in some HCs due to lack of funding from the 
sponsors. This confirmed the NTP report conclusions in 2007 that CDOT was withdrawn 
from 41 HCs because there were not enough funds from the NGOs (NTP 2007).
Key Message: the fourth conclusion of the thesis is that the implementation of 
CDOT program in Cambodia has depended on funding from sponsors. The NTP 
and CENAT have not had funds to implement CDOT in every HC in the country.
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10.4 Impact of the shortage of human resources for the implementation of the DOT
program
The numbers of TB staff at the HC is insufficient to cover the TB health activities, 
because staff also have responsibility for other health activities such as the PEV program, 
maternity and childcare, and general consultation. Generally, of the three or four staff 
who work at each HC, two or three work in the TB unit. The TB staff are overloaded, 
which means too little time for staff to go to the community for TB education, finding 
suspect cases, and follow-up of patients during the treatment period. Studies by Kabongo 
(Kabongo D and B 2010) and Wandwalo (Wandwalo E 2006) showed that CDOT can 
help to reduce the workload of health staff and free up more time to allow staff to provide 
quality services to other patients. In contrast, this study found that HCs which 
implemented CDOT still carried out the ambulatory DOT. So staff who work at the HC 
with implemented CDOT had more responsibilities for TB activities than the regular TB 
staff at the HC-DOT. It might explain why the large majority of patients in HCs with 
implemented CDOT said that the follow-up of patients in the community during the 
treatment was limited.
Key Message: the fifth conclusion of the thesis is that the shortage of TB staff at the 
HC could impact observation of patients’ adherence to treatment and TB education 
in the community. In particular, it would impact the implementation of CDOT, 
because of shortage of staff time to follow-up patients and DOT watchers in the 
community.
10.5 Impact of smear test implementation at the HC level
Most patients’ treatment was based on the results of a smear test, while other TB tests 
including chest X-rays were rarely done because of lack of facilities available at the HC.
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Few sputum negative patients were referred for X-rays at the referral hospital or private 
clinics before starting treatment, while others started treatment without any further tests. 
Decision-making about starting treatment for sputum negative patients was based on staff 
experience. This process could have advantages and disadvantages; the advantage is that 
if the staffs decision is correct, patients could start treatment immediately and it would 
reduce the chain of TB transmission in the community. However, if the patient had 
another disease, the TB patient could receive inappropriate treatment.
Another issue at the HCs is the delay in sending smear samples and in receiving the 
results back from the laboratory. This delays treatment and increases the TB transmission 
in the community; in particular it increases the patient’s costs including transportation 
fees and time. The results from the qualitative study showed that patients needed to travel 
several times to the HC to receive their diagnosis results.
Lack of sputum control before terminating treatment was clear from the qualitative study; 
half the patients interviewed in this study had no sputum control before their treatment 
finished; among these, were some patients who still had TB symptoms and who wanted to 
restart their treatment.
All staff interviewed mentioned that they wished to have their own laboratory in the HC 
because that would reduce the time to receive the results of smear tests, and in particular 
save travelling costs to staff transporting samples and going to pick up the results back 
from the laboratory, which was often done at their own expense.
Key Message: a sixth conclusion of the thesis is that there is a lack of sputum control 
and an issue of delay in sending the sputum samples and receiving the results back
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from the laboratory in both HCs with and without implemented CDOT. Few 
patients have sputum control during treatment. Without sputum control, it is 
difficult to make sure that patients are ready to proceed to the continuous stage of 
treatment, especially for those with smear-positive TB. This could create problems 
in the future by increasing multi-drug resistance for those who are not fully cured.
10.6 Impact of the shortage of financial support for implementation of the DOT 
program
Although the MoH and NTP have put great effort into the TB and DOT program by 
providing free treatment to every patient, the problem still exists of insufficient financial 
support for the implementation of DOT. It was evident from the qualitative interviews 
that most HCs did not have enough financial support from NTP to cover TB education 
programs in the community; and in particular there was not enough funding for staffs 
transportation fees to visit patients in the community, or to transport sputum samples.
These problems could be more serious for HCs with CDOT, as the CDOT program was 
based on the availability of sponsors, and some HCs have withdrawn the program because 
of the shortage of sponsor funding. The majority of staff said they could not go often to 
visit CDOT patients in the community because the financial support for transportation 
was limited; also the incentive for DOT watchers involved in the CDOT program was 
very small. The insufficient financial support caused discouragement of staff and DOT 
watchers involved in the program implementation. This may explain some of the 
problems raised by patients such as the lack of follow-up activity by HC staff, and in 
some cases the absence of DOT watchers during treatment, which could affect patients’ 
adherence to treatment. Moreover, the detriment to the CDOT program due to shortage of
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funds from sponsors could reverse the implementation of the program and harm people in 
the community; for this reason some patients have changed their treatment location from 
the community to the HC.
Key Message: the seventh conclusion of the thesis is that there is insufficient 
financial support for the implementation of both HC-DOT and CDOT in Cambodia. 
This could create several problems in the implementation of DOT such as: TB case 
finding not achieving the target, increasing patient’s non-adherence to treatment, 
and increasing the number of self-administration patients. In particular this 
problem is more serious for the CDOT program as it requires more follow-up and 
monitoring from staff at the HC level, as well as NGO funding for the DOT 
watchers.
10.7 The challenges of implementation of ambulatory DOT (HC-DOT)
Overall, the implementation of HC-DOT in Cambodia appears to be pretty successful in 
keeping the treatment success rate above the WHO target and in reducing the death rate 
due to TB. Based on the qualitative study, there were several factors, such as the 
involvement from staff and community health volunteers that played an important role in 
the achievements of this approach. Moreover, using health volunteers to observe patients 
taking medicines was also used in HC-DOT areas, especially for the continuous phase 
and for those patients who could not attend for treatment at the HC.
However, there were several issues relating to the implementation of HC-DOT found in 
this study. These issues were similar to those noted in previous studies in developing 
countries (Nair.D, George.A et al. 1997; Harper M 2003; Sanou A 2004). The first issue 
is that the HC-DOT treatment incurred travelling costs and time off work for patients who
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needed to attend the HC everyday for at least two months of treatment; for this reason the 
majority of patients treated with the HC-DOT came to take medicines with staff at the HC 
for only the initial phase; the rest of treatment they were allowed to take at home. This 
confirmed the results of studies in Pakistan ((Khan A 2000; Khan M 2005). The second 
issue is the long waiting time for taking medicines with staff at the HC. The third issue is 
the difficulty in attending the HC for patients who are very sick or unable to come to the 
HC every day due to lack of transportation. The last issue is the lack of flexibility and 
patient choice in selecting the location and the DOT watcher during the treatment.
In contrast to previous studies by Jaiswal (Jaiswal A 2003) and Greene (Greene 2004), 
this study found that staff at the HC did put considerable effort into supporting patients to 
complete the treatment; most patients were very happy with the staffs attitudes which 
also influenced patients to come to the HC every day; this difference might be due to 
differences in culture and settings between the studies.
Although the issues above relating to the implementation of HC-DOT were raised and 
recognized by most patients in the study, when the author asked if they wanted to change 
the mode of treatment by switching from the HC-DOT to CDOT approach for their future 
treatment, many of the respondents would not have wanted to change because they were 
happy to be treated by staff at the HC. They felt that HC staff could help in motivating 
them to complete the treatment; in particular staff could help them to reduce any 
problems with side-effects. Some patients appreciated the fact that there was flexibility 
around their attendances at the HC and medicines were allowed to be taken at home 
during the weekend, on public holidays and on the request of patients. Patients also said
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that they did not trust the qualification of DOT watchers as they were not medical 
professionals.
Key Message: the eighth conclusion of the thesis is that HC-DOT in Cambodia is 
flexible in some areas. Although there are some issues relating to the implementation 
of the program, it is generally acceptable to most patients. Satisfaction with the 
program was particularly high for patients who lived close to, or had easy access to 
the HC during treatment.
10.8 The challenges of implementation of CDOT
The main purpose of implementing the CDOT program in Cambodia was to remove the 
limitation and barriers caused by the ambulatory DOT as mentioned above. All 
interviewees in the qualitative study agreed that the CDOT program could help patients to 
cut their expenditures on travelling by reducing their visits to the HC; it could also help 
patients save time and allow them to engage with their normal daily activities, important 
for both patients and their families. Moreover, the CDOT program was seen to be very 
convenient for patients who were very sick, disabled or had difficulty accessing the HC. 
Results of this study confirm the results of previous qualitative studies by Wandwalo and 
Kabongo (Wandwalo E 2006; Kabongo D and B 2010). The level of adherence to 
treatment is increased for patients treated in the community because of convenience in 
terms of time and place. The study results also suggest that the CDOT program increased 
TB awareness and reduced TB stigmatization among people in the community, because 
people began to understand that TB is an infectious disease which can be cured by taking 
medicines regularly for 6 months, rather than being genetic.
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However, several limitations of the CDOT program are apparent from this study; the first 
problem is the lack of incentives for CDOT watchers, which could impact the absence of 
DOT watchers during treatment. The second issue is the question of DOT watchers’ 
ability; even though the majority of patients were happy to be treated by DOT watchers in 
the community, some patients complained that the information about treatment provided 
by DOT watchers was insufficient, compared to that of staff at the HC; in particular 
problems relating to side effects were not always dealt with effectively. Additionally, 
sometimes the dosage of medicines given to patients were incorrect since DOT watchers 
decided to reduce or increase the dosage without discussing this with HC staff. The third 
limitation is the lack of flexibility in selection of individual DOT watcher for or by 
patients. Many patients were not happy because HC staff had not allowed them to choose 
their own DOT watchers. The last limitation is that the environment for the CDOT 
program is not always as strict as the HC-DOT because of the more informal relationship 
between patients and DOT watchers. These problems have also been reported in other 
studies (Escott S 2005; Wandwalo E 2006; Kabongo D and B 2010; David K. Mafigiri, 
Janet W. McGrath et al. 2012).
A. Supporting the DOT watchers
The major weakness is the insufficient financial support for DOT watchers. As explained 
by Kironde (Kironde S 2002), for the success of CDOT program in the long term, the 
issue of sustainability of DOT watchers must be addressed; the most important issue is 
adequate financial incentives for DOT watchers and other community volunteers. 
Another review by Kangovi (Kangovi S 2009) showed that the CDOT programs which 
offered financial incentives to DOT watchers were likely to produce better outcomes, and 
to result in higher TB case finding. Providing proper financial support to the CDOT
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program could provide staff at the HC with an opportunity to monitor and support CDOT 
watchers through team meetings, and spot checks by staff at the HC, rather than simply 
requiring CDOT watchers to fill out treatment cards. Providing a financial incentive could 
also help to motivate CDOT watchers in their job to spend more time on TB education for 
people in the community, finding more suspect cases, and supervising patients more 
strictly. Another interesting point raised by Kangovi is that CDOT programs which do not 
provide financial incentives to DOT watchers tend to utilize a family member as the DOT 
watcher, often chosen by the patient.
Most CDOT programs are implemented in developing countries where resources are 
constrained, so financial support for CDOT watchers is almost always insufficient. 
However, it is noted that lack of resources does not always constitute a barrier to success 
in the implementation of CDOT program. Studies by Manalo in Manila (Manalo F 1990) 
and Walley in Pakistan (Walley J.D 2001) showed that their DOT watchers did not 
receive any financial incentive from CDOT programs, but still provided good services to 
CDOT patients; the defaulters and case detection rates were improved after 
implementation of CDOT. In my study, too, it was clear that many DOT watchers gave 
generous care well beyond their financial rewards. DOT watchers may be motivated not 
only by financial incentives, but there is also non-financial support such as provision of 
free health care to DOT watchers and their family as well as the feeling that they are 
helping fellow villagers in the community. Providing a non-financial incentive to DOT 
watchers could be a good strategy to supplement CDOT programs with scarce resources, 
like Cambodia. It was observed in this study that DOT watchers also operated in some 
HCs which implemented only ambulatory DOT, and also in some HCs where the CDOT 
program had been formally terminated, although they were not paid to do so.
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Key Message: the ninth conclusion of the thesis is that providing support for DOT 
watchers is the key to making the CDOT program successful in the long-term. Like 
other developing countries, Cambodia does not have enough financial resources to 
fully provide for DOT watchers, thus non financial support could be applied for 
CDOT program.
B. Providing proper training for DOT watchers
The issue of CDOT watchers’ ability could be addressed by providing them with proper 
training, regular updating and follow-up of their work. Most CDOT watchers mentioned 
that the information about TB training and treatment received from HC staff was not 
enough and out of date. Regular meetings occurred only at the beginning of their work 
and feedback from staff was rarely received. This could explain why the information and 
dosage of medicines given to patients by CDOT watchers were sometimes inappropriate. 
Results from the qualitative study showed that CDOT watchers were the first people 
CDOT patients would seek out for help during treatment. It is of the utmost importance to 
provide them with the correct information about DOT treatment.
Key Message: The tenth conclusion is that CDOT watchers should receive 
appropriate and up-dated training in order to address the problem of CDOT 
watchers’ capability in the CDOT program. Regular meetings, follow-up and 
feedbacks from staff should take place frequently in order to ensure that the correct 
treatment is given by CDOT watchers.
C. The selection of patients’ treatment supporters
The experience of the CDOT program in Swaziland reported by Escott (Escott S 2005) 
may be relevant to the setting in Cambodia; he reports that the successful implementation
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of CDOT requires many factors and the involvement from all parties including HC staff, 
DOT watchers, family members, and people in the community. The first factor is the 
patient’s flexibility and the choice of individual treatment supporter. This is confirmed in 
my study; some of both the ambulatory and CDOT patients in the study wanted to be 
involved in the selection of their own DOT watchers; and sometimes family members 
would be more likely to be selected by patients as their treatment supporters. This study 
showed that family members already play their role as DOT watchers and reminders, 
especially for self-administration patients by giving medicines, reminding patients to take 
medicines, collecting medicines from the HC, and motivating patients to complete the 
treatment.
In general, the discussion still continues as to whether family members are suitable for 
supervising patients for CDOT programs. The argument was made for using family 
members as DOT watchers because it may improve patients’ adherence to treatment; a 
study by MacIntyre (MacIntyre CR 2003) showed that the use of family members as DOT 
watchers resulted in worse adherence to TB treatment in a home-based DOT program. 
However that study was conducted in a developed country- Victoria, Australia.
Although in Cambodia family members are not recommended in the national guideline to 
be DOT supporters, in fact they have operated as such for both CDOT and HC-DOT 
patients. Moreover, this study found a lot of “non-DOT” (self administration) patients in 
both HCs; most of these revealed that their family members were their DOT watchers and 
reminders during their treatment. However, some of these patients still had TB symptoms 
and wanted to restart their treatment. Thus, the results from the qualitative study might 
partly explain the quantitative results as to why treatment outcomes in the CDOT
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program were similar to HC-DOT, as family supervision and self-administration occurred 
in both HCs, and could impact the treatment success of both DOT approaches.
However, other studies conducted in developing countries have shown that using family 
members as DOT supervisors in the CDOT program can lead to good treatment outcomes 
(Nyirenda TE, Harries A.D et al. 2003; Mafigiri D 2007; Thiam S. 2007), and good 
adherence to treatment (Manders A.J.E, Banerjee A et al. 2001; Wandwalo E 2006; 
Kabongo D and B 2010) and can be as effective as other DOT supporters (Banerjee A 
2000; Wright J 2004; Mathew A 2005; Newell JN 2006; Anuwatnonthakate A 2008). 
However it has also been shown in these studies that for the successful involvement of 
family members in CDOT program good training, monitoring and follow-up by staff at 
the HC are required.
Key Message: Based on the results of this study and experiences from various 
studies in different settings, family supervision could be applied to patients who are 
not able to come for the treatment at the HC, especially when no DOT watchers are 
available in the place where the patient lives. In order to avoid patients’ non­
adherence to treatment, staff need to put more effort in providing training, 
monitoring and frequent follow-up to family members employed as DOT watchers.
D. Selection of patients for CDOT program
The CDOT program may not be suitable for every patient; for example re-treatment 
patients, those who are too sick to walk to the DOT watcher’s house, and those who live 
near to the HC may not be suitable. In Cambodia, in some areas the CDOT program is 
sponsored by NGOs which provide relatively good financial support and incentives to 
staff at the HC or CDOT watchers, such as providing money for transportation fees; in
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these areas all appropriate patients could be registered by staff to have the treatment with 
the CDOT program. The qualitative study showed that the distance between some 
patients’ houses and the DOT watcher’s houses was further than the distance to the HC, 
while others said the distance between their home and the DOT watcher’s house was the 
same distance as their home to the HC, but patients were allocated by staff to take 
medicines with DOT watchers in the community although this was not their preference, 
nor the more appropriate setting. This study also identified three patients who were 
inappropriately treated with the CDOT, as they were re-treatment patients; these patients 
should have been treated at the HC or the referral hospital, because the re-treatment 
regimes should involve daily streptomycin injections for the first two months. The 
implementation of the CDOT program would be more successful if the program was 
targeted to the right group; for example, those who live far from the HC and do not have 
transportation, or those who have a good reason why they could not come to the HC 
every day during the treatment. The CDOT program may not be appropriate for those 
who live close to the HC, or those too weak to walk to the DOT watcher’s home who 
would be better having the treatment at home supervised by a family member who 
receives appropriate training from staff at the HC.
Key Message: the twelfth conclusion of the thesis is that identification of patients for 
whom community based care is appropriate must be clearly set out and 
implemented. The success of the CDOT program depends upon the implementation 
reaching the right targets and the right places.
10.9 The acceptability of implementing CDOT program in Cambodia
The CDOT program was well accepted by most CDOT and HC-DOT patients, DOT 
watchers and some staff in both HCs. They recognised that CDOT could remove or
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reduce many barriers such as inconvenience, and travelling costs to patients, and could 
allow patients enough time to engage with normal daily activities. CDOT is particularly 
convenient for those who are sick and have difficulty in coming to the HC every day. 
Most CDOT patients were satisfied and very happy to have DOT watchers in the 
community because their DOT watchers were known to them and helped and motivated 
them to complete the treatment.
In contrast many staff in HCs both with and without CDOT questioned the effectiveness 
of the CDOT program and DOT watchers’ capability in supervising patients in the 
community. Many of them expressed concern about the shortage of financial support for 
DOT watchers and lack of follow-up from staff at the HC, which could cause failure of 
the program. Most staff recommended the CDOT program as more appropriate for the 
continuous phase, when medicines are given to patients to take in the community.
On the other hand, the HC-DOT was considered satisfactory by some HC-DOT patients 
and staff, because they felt that the HC-DOT was already as flexible and convenient as 
the CDOT program and HC staff were the best people to advise and motivate them to 
complete the treatment. This may be because the implementation of HC-DOT in 
Cambodia is already very successful for most patients.
Key Message: The last conclusion of this thesis is that the two approaches are 
complementary rather than alternatives. Implementation of HC-DOT in Cambodia 
is generally considered to be successful by staff and patients, and the 
implementation of CDOT is also acceptable among most patients and DOT watchers 
in the community, especially where the HCs are located far from the patients’ 
houses. It is important therefore to identify the mix and criteria for offering each
221
option. Although this study did not aim to assess self care, evidence from the 
qualitative study suggested that this was more likely to result in serious problems of 
disease recurrence for non-DOT patients.
10.10 Limitation and strengths of the study 
A. Strengths of the study
The strength of this study is that it is the first such study in Cambodia conducted using 
both quantitative and qualitative methods to examine the effectiveness and acceptability 
of CDOT compared to the existing HC-DOT and to find out the gaps and issues in the 
implementation of both DOT approaches in the field by HC staff, patients, and DOT 
watchers. Moreover, before this study was conducted in Cambodia, the author carried out 
a meta-analysis of the effectiveness of CDOT programs compared to HC- DOT globally, 
to determine the comparative effectiveness of CDOT programs in different settings. The 
author also carried out a pilot study in four HCs, to assess the real design effects for the 
quantitative study, to examine the data quality, to pre-test the qualitative study tool, and 
to allow a better understanding of the complex environment of the HC and patients in the 
community. The pilot therefore strengthened the design and appropriateness of the main 
studies.
D e s p i te  th is  being a before-afier implementation study rather than a RCT, the coverage 
was broad as the HCs selected for the study were 81 HCs in 21 provinces out of the 24 
provinces in Cambodia, this representing the whole country. In particular, the HCs 
selected where the HC-DOT and CDOT were implemented were in the rural areas where 
the infrastructure as was very weak. The sample size of this study is 2700 patients, which 
is comparable to the previous study by Becx-Bleumink (Becx-Bleumink M 2001) (2353
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participants). All data entry was double-checked by two official statisticians. The analysis 
in this study was carried out separately for all types of TB and for new-smear positive TB 
and the comparison of treatment success was analysed before and after the introduction of 
the CDOT program as well as between areas where the program was and was not 
implemented.
Furthermore, the qualitative study provided wide ranging, detailed information about the 
strengths and weaknesses of each DOT option and how they operated in the field from the 
experiences of patients, staff and DOT watchers in the implementation of each approach.
B. Limitations of the study
The main design of the quantitative study is a before and after intervention study. This is 
a quasi-experimental study of before and after implementation of the program, in a group 
that received the intervention compared to a control group that did not. As this is not a 
randomised controlled trial it has some limitations such as: patients selected into the study 
were not randomised, the data are reliant on records from the HC registers to determine 
the outcomes, and external influences that may have induced changes in both areas could 
not be measured. However, to minimize these limitations, the comparison of baseline data 
in both areas were also analysed and differences from baseline data taken into account; 
the patient’s treatment cards were also verified by the researchers to determine whether 
the data were missing from the register. Additionally, to minimize the effect of missing 
data 10% was added for the sample size calculation. There was no difference in 
“missingness” between the groups.
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Another limitation of the quantitative study is selection bias of HCs into the study. Firstly 
the choice of HCs which implemented CDOT were almost certainly not random, as we 
know that these tended to be HCs with relatively poor baseline results. This again may 
result in an underestimate of the relative benefit of CDOT. There is another potential bias 
due to the fact that the selection of HCs which implemented CDOT in the study was 
based on the existing HCs where CDOT was ongoing; 41 HCs where CDOT was 
withdrawn in 2005 were excluded from this study as this would have involved a third 
group. This bias may have impacted on the estimation treatment success rates for CDOT 
areas; the odds ratio for treatment success for CDOT might be overestimated if CDOT 
was withdrawn due to unsatisfactory performance. However the outcomes may have been 
unaffected in the more likely cases where implementation of CDOT programs was 
discontinued because of failure of the program due to lack of funds.
A further limitation is the issue of selection bias and information bias in the qualitative 
part of the study. As discussed above, some patients were selected by convenience 
sampling and by recommendation of the DOT watchers or staff at the HC due to the poor 
road conditions, the migration of patients, and the absence of patients during the author’s 
visits. This bias could impact on the findings related to patients’ adherence to treatment, 
and as a result the findings on support by DOT watchers or staff to these patients would 
be overstated. Since some patients were selected based on their housing location, such as 
patients who lived close to the main road or the HC; so the level of adherence to 
treatment may be higher than those who lived in very remote areas and difficult to access 
to the HC. This may have understated problems for HC-DOT patients. Moreover, the 
author could not interview defaulter patients where they had moved out of the villages; it 
would be interesting to know the reasons why they did not complete the treatment.
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Although the author explained the study to participants, information bias could have 
affected the interviews, since participants may have thought that the study was conducted 
by the HC or the government. Participants may not have always answered questions 
honestly, since Cambodian people tend not to criticise public health services out of 
respect for staff from the government. This bias may lead to an overestimate of the 
positive aspects of the staff attitudes and the health service system. Participants may have 
provided only positive comments on the health service system and staffs behaviors.
Patients selected for interview in the qualitative study had mostly finished treatment more 
than six months ago; patients may not have recalled some information regarding the 
treatment and sputum control, or how many times they collected medicines from the HC, 
or how often staff came to visit patients in the community during the treatment. It may 
have introduced errors in information on systematic of DOT administration and treatment 
guideline provided by the NTP.
The last limitation is that this study does not assess the cost or cost-effectiveness of 
CDOT program in particular costs to the health care system for patient treated with 
CDOT and ambulatory DOT. This is due to limits of the time frame.
10.11 Recommendations
The evidence from both quantitative and qualitative studies showed that the effectiveness 
of both HC-DOT and CDOT were not significantly different; both were seen to maintain 
high treatment success rates and improved TB case findings over the period studies. Both 
HC-DOT and CDOT were generally working well and were acceptable among most 
patients, HC staff and CDOT watchers; most patients were happy with their DOT
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approaches. Findings of this study showed that CDOT was convenient for patients with 
disability or having difficulty to access the HC, or needing the time to work. Moreover, 
CDOT could not be implemented alone and should not replace the existing HC-DOT, 
both HC-DOT and CDOT are complementary and between them fulfil different needs. 
However, there are some major problems that need to be addressed with the current 
resources and with long term funding in order to maintain and improve both DOT 
approaches in Cambodia. These include the allocation of patients to ambulatory DOT or 
CDOT, the selection of DOT watchers, the need for up-to-date training for CDOT 
watchers, speeding up the process of sputum tests, providing incentives for CDOT 
watchers, and providing sufficient resources for HC staff to visit patients and educate 
people in the community.
A. Allocation of patients to ambulatory DOT or CDOT
Both DOT approaches would be more successful if the implementation reached the right 
targets and right places. CDOT would seem to be essential for people who are very sick, 
unable to come to the HC, patients living far from the HC, and patients who need to work. 
Ambulatory DOT would seem to be convenient for people who live close to the HC. 
However, HC staff should discuss more with patients where they want to be treated and 
reasons why they select that option before starting treatment.
B. The choice of selecting the individual DOT watcher
Because selection of DOT watchers may impact the patients’ adherence to treatment, 
patients for TB treatment should be allowed to play a part in selecting the DOT watcher. 
In this study, besides the community health volunteers, family members were found to be 
acceptable and appropriate for some patients. In Cambodian culture, especially in rural
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areas, family members have the obligation of taking care of sick people especially for 
chronic diseases such as hepatitis, HIV/AIDS and also TB. Family DOT should be 
employed for some patients who are really sick and where there is no availability of 
health volunteers where the patient lives. With the current situation of financial support 
for CDOT program in Cambodia, employing family DOT for some patients would reduce 
the financial burden of the program. However, using family members as DOT watchers 
would not be recommended for general patients since family DOT may not supervise 
patients as strictly as HC staff or CDOT watchers. The family members employed as 
DOT watcher would need to be properly trained and monitored by HC staff for TB 
education and the DOT treatment process.
C. Providing up to date training and feedback for CDOT watchers
The issue of the CDOT watchers’ ability could be resolved by HC staff providing 
sufficient training for them, including providing up-to-date information about DOT 
treatment, providing feedback and regularly following-up their work in the community. 
Providing more training and follow-up needs more funds, however, this training and 
feedback could be integrated with other health promotion activities when health 
volunteers come for training at the HC.
D. Speeding up the process of sputum tests
Delay in receiving the test results was a major problem in both HCs. Speeding up the 
sending and return of results for sputum tests would mean that treatment could be started 
earlier and indicate whether the intensive phase should continue or the continuous phase 
should stop and in particular it would give greater certainty as to whether a patient was 
cured or not. This could be achieved in several ways. Firstly given limited funds, the
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treatment card should have the date, month and year when patients need to come for the 
sputum test at the HC. Since the result of the tests take between one and two weeks, it 
would be necessary for patients to come for the control test one week before the intensive 
phase finishes. Both ambulatory DOT and CDOT patients should come for sputum tests 
by themselves where possible because this could avoid the effects of any poor technique 
of collecting sputum by CDOT watchers. Reminding patients of the date of the control 
test should be done by HC staff or CDOT watchers. Secondly, if funds were available, 
each HC could have at least one microscope for reading the sputum tests. Most TB staff 
mentioned in the study that they have been working in TB units for more than five years 
and some have experience as staff at the laboratory. However, training in reading the 
sputum test could be provided by the CENAT and MoH to TB staff at the HC. Having 
their own microscope at the HC could reduce the transportation costs involved in sending 
sputum to laboratory and would speed up the process of sputum results.
E. Incentives in kind for CDOT watchers
Maintaining and sustaining the motivation of CDOT watchers is the key to successful 
implementation of CDOT. With the limited resources available, providing free health care 
to CDOT watchers’ families like the current situation in Cambodia would be 
recommended; however, more incentives for CDOT watchers would be helpful in the 
long run. Providing sufficient funds for CDOT watchers to cover the transportation costs 
of collecting medicines and visiting patients at home should be considered, and this could 
possibly be discussed with sponsors before implementation of CDOT in every HC.
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F. Improve TB health education in the community
Based on this study, TB health education and promotion in the community needs to be 
improved. Health education is a key component in increasing the patient’s knowledge of 
TB and can motivate them to change their attitudes for TB treatment. This could be done 
through HC staff, health volunteers and CDOT watchers in the community. Providing 
sufficient resources for HC staff to visit and educate people in the village would be 
helpful also.
G. Feasibility of the CDOT program
The CDOT program is largely dependent on NGOs and available funding. There are 
several NGOs supporting CDOT, mainly USAID and the Global Fund, which have 
provided long-term funds normally between 3 to 5 years; as reported by the NTP at the 
end of 2010 the implementation of the CDOT program has expanded to 60% of HCs in 
Cambodia (MoH December 2010). This successful expansion of CDOT must come from 
the NTP putting more effort in looking for more sponsors including local and 
international NGOs. Although there are some problems with CDOT implementation 
where sponsors have withdrawn funding or given funds for limited period, the program is 
still pretty successful and could expand if the government sought more sponsors to 
implement the program.
H. Providing supports for patients
Continuation of the food gifts to patients during treatment is strongly recommended 
because it both encourages patients to complete their treatment and also improves their 
nutrition, which is likely to aid recovery. Poor nutrition is one of the key factors in 
increasing the risk of TB.
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I. Treatment guidelines
Treatment guidelines need to be clear, but more flexible in the interests of patients and 
HC staff. For example, they may need to be adjusted to acknowledge where patients can 
take medicines during weekends and holidays, because staff would not be present at the 
HC then. This flexibility is especially important in relation to the location where 
ambulatory patients can take medicines for the continuous phase, as there is a risk that 
many patients self administer at this stage.
J. Future research on the cost-effectiveness of CDOT program
Studies conducted in other settings have indicated that CDOT reduced costs and was cost- 
effective compared with HC-DOT (Floyd K 2003; Wandwalo E 2005). Considering 
future research, the author would strongly recommend assessing an integrated service 
together with a cost analysis. This would help policy makers determine how the CDOT 
programme should be funded nationally or whether they should look for further NGO 
funding. Similarly it would be useful to determine the role of “family DOT".
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Appendix 1: Combinations of search terms and concepts used to locate 
relevant studies in Pubmed, CINAHL, EMBASE and CENTRAL






2. Directly Observed 
therapy (DOT)
3. 1 & 2 V V V V
4. Health facility based 
DOT or (health center 
DOT)
5. 1 & 4 V V V V
6. Community based DOT
7. 1 & 6 V V V V
8. 1 & Community 
involvement
V V V •
9. 1 & patients’ adherence V V V -
♦ Search terms used in combination with the search strategy for retrieving trials: upper 
case MeSH or EMTREE: heading lower case: free text term.
Searches were conducted from 1995 until 2012 because DOT has been fully implemented 
only since 1994. The keys word tuberculosis and TB were combined with keywords 
about, using keywords “tuberculosis, directly observed therapy DOT, community based 
DOT, community involvement, health centre DOT, health facility based DOT, and 
patients’ adherence”. Hand search of the International Journal of Tuberculosis and Lung 
Disease was carried out from 1995 to 2012. Also searched were published bibliographies 
of related topics, and citations in articles which were included in this review.
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Appendix 2: Summary of included studies the effectiveness of CDOT compared to alternative DOT options
Y e a r  o f 
pu b lica ti 
on  o f 
s tu d y
C o u n try O bjectives Setting M ethods S am ple
size
F o rm  o f 
T B
T re a tm e n t
su p erv iso r
R esults
2000(Zw Cape Com pare the Suburb Unblinded 156 TB Adult aged Com m unity - There were no significant
arenstein Tow n , successful o f random ized patients over 15 health differences in successful
M  2000) South tuberculosis control, trial years, volunteer treatment rates across the
A frica treatm ent outcom e - 3 arm s were pulmonary three supervision (P=0.136)
rate betw een self assigned in the TB LHW  supervision
supervision, study. patients( outcomes, over all patients,
supervision by lay The first new and were not statistically
health  w orker group is self retreatment significantly superior to
(LH W ), and supervised ) either clinic DOT (17.2%,
supervision by which patients 95% CI:-0.1-34.5) o r to self
clinic nurse took medicines supervision (15%, 95%CI:-
at hom e and 3.7-33.6)
visited the - Clinic and se lf supervision
clinic once a outcomes were sim ilar to
week, or sent a each other (-2.2% , 95%CI:
fam ily member -21.5-17.1)
to  collect their - New patients benefit from
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drugs during 
the period o f  
treatm ent
- The second 






- The third arm 
is patients who 
received the 
supervise from 
s ta ff at the 
clinic
LHW  supervision (LHW  vs 
clinic nurse: risk difference 
24.2%, 95% CI:6-42.5, 
LHW  vs se lf supervision 
39.1%, 95%CI: 17.8-60.3) 
as do female patients (LHW  
vs clinic nurse 48.3%, 
95%CI:22.8-73.8, LH W  vs 
se lf supervision 32.6%, 
95%CI: 6.4-58.7)
2003(Fre K ilom bero - Evaluate the R ural/f Unmasked 522 TB New Com m unity - The cure rate for patients
d L /T anzania efficacy o f arm cluster- patients smear- volunteers under community-based
2003) com m un ity-based with random ized positive DOT was sim ilar to patients
vs institutional- low control trial pulmonary under health facility-based
based DOTS income - Intervention TB DOT
- Com pare the group is - Community-based DOT
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com m unity 
m em ber 
observed the 
patient daily 
during the first 
tw o m onth
may be a  viable alternative 
to health facility-based 
DOT
- Community-based DOT 
m ay be particularly useful 
in parts o f  the country 
where people live far from 
health facilities
2004(Eli 
ud W  
2004)
Tanzania Evaluate the 
effectiveness o f  
com m unity-based 







group is group 
o f  patients who 
were assisted 
by guardian or, 
in his/her 
absence, a 




All forms - Guardian was 
defmed as a 
family m em ber 




- Former TB 
patients
Success treatment 
outcomes for patients under 
community-based DOT and 
health facility-based DOT 
were similar: 85% and 83% 
respectively
- Percentage o f  patients felt 
to submit sputum at the end 
o f  treatment was high in 
community-based DOT 
(9.8%) com pared to once 
under health facility DOT 
(3.4%)
- Community-based DOT is
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as effective as health 
facility-based DOT and can 









effectiveness o f  
urban com m unity 







group who is 
received 
supervise by 

























- The proportion o f  total 
patients treated under 
community DO T increased 
significantly from  13% in 
2000 to 25% in 2002
- The treatment success rate 
among patients treated by 
community DOT was 
similar to  that among 
patients treated by health 
facility DOT (78%  vs 77%) 














- Governm ent 
health workers
- Treatment success rate 
treated by different DOT
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2005) problem s 
encountered by 
patients m anaged 
by different DO T 
providers in 
RN TCP
positive at prim ary providers w ere similar:
pulmonary health Anganwadi (80%),
TB institutions government outreach
(PHIs) workers (81%), community
- Governm ent volunteers (76%), PHI staff
outreach (76%)
workers Patients treated by
N on- community volunteers and
governmental PHI staff had high default
sectors: rate
Anganwadi (18% and 17%)
workers, - M onitoring TB activities
community report was poor among
volunteers supervision o f  Anganwadi 
and community volunteers 
while the government staff 
had a m onitoring activities 
through weekly review 
meetings
- Community volunteers 
and Anganwadi workers 
had a minimal training in
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health related issues and 












Evaluate the effect 
o f  lay health 
workers (LH W s) 
on tuberculosis 
control am ong 
perm anent farm  
workers and farm 











group is group 
o f  patients who 
w ere chosen to 
receive DOT 
from  the LHW, 
w ho has 
received the 
TB training 
from  the nurse 
at the clinic
- Control group 


















- The successful treatm ent 
completion rate in new 
smear positive adult TB 
patients was 18.7% higher 
on farms in the intervention 
group than on farms in the 
control group (P=0.042, 
95%CI:0.9-36.4)
- Case finding for adult new 
smear positive TB cases 
was higher on farms in the 
intervention group 












Establish w hether 
involving health 
extension w orkers 
(HEW s) in TB 
control improved 
sm ear-positive case 
detection and 
treatm ent success 












HEW s who 
w ere health 
w orkers and 
health 
volunteers, 
w ho received 
the training for 
TB education 
and DOT such 
as symptoms, 










-The m ean for case 
detection rate was higher in 
the intervention (122.2%  vs 
69.4%, p<0.001) and for 
the female patients (149% 
vs 91.6%, pO .O O l)
- The mean for treatm ent 
success rate for females 
was also high in the 
intervention than control 




to  collect, 
adm inister 












2001(Bee Sulaw esi, Com pare o f  TB Rural Before 2353 TB New 1998 the Com paring the case
X- Indonesia case notification and after study patients smear- comm unity notification between
Bleum in and treatm ent The base positive TB based TB villages with CBTP and the
k M results in a line was program non-CBTP villages, in 1998
2 0 0 1 ) com m unity based collected in (CBTP) was the rate more than tripled to
tuberculosis 1996-1997 introduced in 166 (51,68 in 1996 and
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program m e(C BTP) 
, before and after 
introduction o f  the 
program m e and 
betw een areas 
w here the 
program m e w as 
and w as not 
introduced.
before the 
introducing o f 




w as collected 
in 1998 when 




224 o f  the 772 1997) in the CB TP villages,
villages o f  tw o and increased slightly to  70
rural areas in (62, 60 in 1996 and 1997)
Sulawesi. in the non-CBTP villages.
Villages The sputum
which conversion results at the
implemented end o f the first 2 months,
CBTP, health for the base line (1996-
center need to 1997) the convention rate
provide health was higher in the CBTP
education and villages but the difference
information to was not statistically
the leaders significant. But in 1998 the
including the conversion rate was
village heads, significantly higher in for
religious patients treated in the
leaders and CBTP villages.
m em ber o f The treatm ent success
W om en’s rate (cure +  treatment
association completion) was higher in
group. the CBTP than in the non-




















m edicines at 
home
1996-1997 the difference 
was not statistically 
significant, but for 1998 the 
treatm ent success rate was 
significantly higher in the 
CBTP villages.
The decline in failure 
rate in both the CBTP and 
the non-CBTP villages was 
statistically significant.
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2002(K ir N orthern Explore the Rural/ Prospective 595 TB Pulmonary -Lay volunteers - There w as no significant
onde S Cape/ feasibility o f Urban cohort study patients TB for the difference in the treatm ent
and South com m unity The intervention success between
Kahirim b A frica participation in a intervention group community-based treatm ent
anyi high-burden group, patients - Clinic nurse supervision and clinic-
2002) Tuberculosis w ere treated for the control based D O T(P=0.367)
Control Program m e under group - Only 54% o f  retreatment
and establish how com m unity- patients has a  successful
supervision o f based DO T and treatment outcome
treatm ent by lay assigned to  lay compared to 70% o f  new
volunteers volunteers as patients. This difference
com pares with DO T was found to be statically
other m ethods o f supporters. significant (p<0.001)
tuberculosis D O T supporter - Alm ost 93%  o f  DOT
treatm ent deliveiy has received supporters were female.
the training 70% o f  DO T supporter
about were less than 45 years o f
supervising, age
recording and - The DOT supporters were
follow-up significantly more educated
patients from than the TB patients
nurse at the (X2=60.37, P <0.001)
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clinic
- The control 
group, patients 
w ere treated 
with the clinic- 
based DOT. 
Patients were 
asked to come 
to the clinic 
five days a 
w eek to  be 




also  carried out 






2003(De N orth A ssess the Rural - The study 128 New For the - The treatm ent completion
m issie M Ethiopia effectiveness o f used both patients smear- control group: was significantly better in
2003) “TB club”  in quantitative positive health facility’s the TB club group (68.7%)
im proving and qualitative pulmonary staff (X2=5.41, P<0.02)
com pliance w ith For the TB For the compared to the
TB treatm ent and quantitative, intervention comparison group (46.8%)
their im pact in prospective group: TB - The default rate was also
im proving societal cohort study is health workers significantly lower in the
attitudes associated used to T B  club group (12.5%
w ith T B com pare the (X2=11.57, P<0.001) than
treatm ent in the comparison group
outcom es (40.6%)
betw een the - However, the difference
intervention in the death rates was not
groups where statistically significant
patients (X2=1.09, p=0.29) died in
received the TB club (17.2% ) and
support from the comparison group
the “TB club”; (9.4%)
and the control According to  the
group where qualitative study, patients
patients treated treated w ith TB club have
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1 w ith regular 
TB care in 









better knowledge for TB 
education and treatm ent
2003(A ro N ew D eterm ine Urban Prospective 3127 TB All forms Community - Overall treatm ent success
ra  V .K D elhi/ feasibility, cohort study patients volunteers/ under community-bases
2003) India acceptability and neighbors DOT was significantly
efficacy o f better than the other
dom iciliary DOTS patients treated a t health
execution to  TB facility DOT
patients through - TB knowledge among
services o f patients treated under
com m unity DOTS community DO T was better
providers than once treated at health
facility
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- Com m unity DOT was 
able to  carry out o f  
successful in TB care and 



























w here patients 
receive the 
community- 














Association o f  







- Nurse or 
clinic s ta ff for 
the control area
- Community supervision 
had a better outcomes for 
both new patients (P<0.05) 
and retreatment 
patients(P<0.05)
- The cure rate for new 
smear positive patients on 
community supervision was 
higher than for patients on 
clinic supervision (72% vs 
46%); and the interruption 
rate lower (13%  vs 25% )
- For retreatm ent patients 
the cure rate was also 
higher (63%  vs 35% ) and 
the interruption rate lower 
in the intervention area
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(18%  vs 30% )
- Case finding in the 
intervention area was also 
higher than control area
2007(Khi 
eu  K 
2007)
Cam bodia Com pare the results 
o f  TB treatm ent 
betw een health 
center-D O T and 










com m unity 
-The control 
group: patients 






- For CDOT: 
community 
health workers
- For HC-DOT: 
staff
- There is no significant 
difference for cure rate 
between HC-DOT and 
CDOT (90.2% vs 92.5%) 
There is also no 
significant difference for 
completed treatm ent in 
patients w ith smear 
negative pulmonary TB and 
people with extra- 
pulmonary TB for both HC- 
DOT and CDOT, 
completed treatm ent was 
93.4% in HC-DOT and 
96.2% in CDOT
2007(C a R io de Com pare Urban/ A 1811 All TB - S taff a t the - Comparing the outcomes
valcante Janeiro com m unity-based City Retrospective patients forms clinic such as for slum residents, the
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s.c City, directly  observed cohort study
2007) Brazil treatm ent for 
tuberculosis using 
com m unity health  
w o rk e rs , w ith 
clinic-based DO T
w hich is 
com pared two 
w ays o f 
im plem enting 
D O T program 
- The clinic- 
based program 
w hich is called 
control
program , the 
treatm ent is 




supervised by a 











Com m unity 
health workers
overall success rates were 
higher for those treated 
with community-based 
DOT, followed by clinic- 
based DOT and self­
administration treatm ent 
(90.4%, 82.1% and 75.8%)
- The treatm ent success rate 
for all patients in the 
community-based DOT 
program was significantly 
higher than in the clinic- 
based DOT (90.4%  vs
78.2%, P<0.001)
- Treatment success rates o f 
new smear-positive TB and 
retreatment cases were also 
significantly higher among 
patients treated with 
community-based DOT
- The default rate was 
significantly lower in
program  or 
com m unity- 
based DOT, the 
treatm ent is 
taken place at 
the patient’s 




the comm unity 
health workers
community-based DOT 
compared to the clinic- 
based DOT (4.7%  vs 
12.7%, P<0.001)
- The acceptance o f  DOT 
was dram atically higher 
amongst patients treated 
under the community-based 
DOT (98.9% ) than for 
those treated in the clinic- 
based DOT (60% , P<0.001) 
Patients received 
comm unity-based DOT 
were more likely to  have 
successful treatment 
(OR=3, C l 1.9-4.8) than 
those who received clinic- 
based DOT (OR=1.5, C l 
0.9-2.4)
2009(Bo K ilim anjar A ssess the effect o f Rural A 2769 All TB - For CDOT: - Com pared to  patients
ogaard o/Tanzani the introduction o f and retrospective patients forms family under facility-based DOT,





allow s tuberculosis 
patients to  choose 
betw een 
com m unity and 
facility-based D O T 
-o n  treatm ent 
outcom es, and to  
analyze factors that 
contribute to  opting 
for com m unity 
D O T
w hich is 
com pared two 
w ays o f 
implem enting 
DO T program 
Intervention 
group is that 
patients treated 
w ith CDOT 
- Control group 





- For facility- 
based DOT: 
staff at the 
clinic
DOT w ere m ore likely to 
be female, aged<15 years 
or HIV positive
- Treatm ent success was 
more likely in patients 
under CDOT than in those 
under facility-based DOT 
(81% vs 70%), in patients 
with smear-positive 
pulmonary TB, and in 
patients who were HIV- 
negative
- Cure rates did not differ 
significantly between 
patients who opted for 
CDOT and those who opted 
for facility-based DOT 
(73%  and 72%, 






A ssess the 
outcom es o f  hom e-
Rural - Com bined 
m ethod o f
405
patients




- Overall, the treatment 





observed treatm ent 
(H B-D O T) versus 










w hich is to  




DO T and FB- 
DOT











nurses o r s ta ff 
at the HC
- The outcom e o f  treatm ent 
did not differ significantly 
between o f  HB-DOT and 
FB-DOT (p=0.45)
- The cure rate for patients 
with smear positive was 
also no different between 
HB-DOT and FB-DOT 
(p=0.48)
- However, health workers 
in the FB-DOT performed 
better in effort to trace 












-F B -D O T , 
patients were 
supervised by 
nurses at the 
health facility
201 l(A n K am pala/ Com pare the Urban -Prospective 107 TB Smear- -Com munity - There was no significant
dré P. U ganda treatm ent outcom es cohort study patients positive TB health difference in the treatment
Gabriel betw een the -T h e volunteers success rate between home-
2011) com m unity-based intervention: based DOTS and clinic-
D O T  w ith clinic patients treated based DOT (OR=0.29,







w ell JN 
2006)
N epal A ssess the success 






to  com pare two 
strategies- 
com m unity 
DO TS and 
fam ily-mem ber 
DOTS
Intervention 
group is group 
o f  patients who 
treated with 
fam ily-mem ber 
DOTS
- Control group 





Com m unity 










- There was no statistically 
significant difference in 
success rates (cure and 
treatment completion) 
between the intervention 
and control group (89% vs 
85%; OR= 0.67, 95% C l 
0.41-1.10)
- Estimated case-finding 
rates were 63%  with the 





treatm ent with 








com pare the 
effectiveness o f  
direct observation 
by com m unity 
health workers and 










- Control group 
was supervised 
by family 
m em bers or 
careers who 
nom inated by 
the patient and 
trained in
- 1353 for 
all TB 
forms





Com m unity 
health workers 
Fam ily 
m embers or 
carer
supervision
- There w as a non­
significant difference in the 
cure and com pletion rate 
between the two groups 
(P=0.52 ,0 :3 -7 )
- There w as a non­
significant difference in the 
cure and completion rates 
between female and male 
(P=0.06 ,0 :0 -1 0 )
- The overall cure rate for 
new sputum sm ear positive 
was 65%, this num ber 
increased to 70% when cure 
and treatm ent completed 
rates were combined
- For new sm ear positive,
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there was a significant 
difference between two 
groups for treatm ent 
success (cure +  treatm ent 
completion) (7%
difference, P=0.06)
« For new smear positive, 
there was a significant 
difference in cure rate 
between the two sexes 
(P=0.002, 12% difference, 
Cl: 5-20)
Patients who were 
supervised with CDOT and 
family DOT showed the 
same success in treatment 
outcomes. However, there 
was a significant increase in 
successful treatm ent
completion rates compared 







Thailand Evaluate the im pact 
o f  different DO T 
strategies on TB 




cohort study to 







fam ily member 
Patients 














- H ealth care 
worker (HCW ) 
Fam ily
member
- At the end o f  treatment, 
patients who received 
HCW  DOT were not 
significantly more likely to 
have treatm ent success 
compared with fam ily DOT 
patients (O R =1.1, Cl: 0.9- 
1.2)
- I f  the analysis restricted to 
evaluate the impact o f  DOT 
on only default at the end o f  
TB treatment, HCW  DOT 
was strongly associated 
with treatm ent success 
compared with family 
DOT.
- In patients that had 
treatment success or default 
a t the end o f  treatment, 
1,369(93%) o f  1477 HCW  
DOT patients had treatm ent
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2005(M a 





Com pare the 
com pletion rates o f  
the tw o
tuberculosis control 
program m es o f  the 























com pared two 




success com pared with 
3,130(89%) o f  3,529 family 
DOT patients (O R  1.5, Cl:
1.2-1.9)




is the village 
health workers
- There is a significant 
difference between the 
completion rates o f  both 
programme (P<0.05)
- The treatm ent completion 
rate o f  only 64.3%  in the
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Tum bagara, and to  
show that even in 
difficult areas, a 
DOTS program m e 




program m e 
- The control 
group where 
patients take 
the pills with 
fam ily member 
supervised, go 
to collect drugs 
at the clinic 
once a  month, 
and patients 
need to  pay for 
the drugs 
(w hich is called 
D O ST group) 
The
intervention 




who is trained 
by DO T 
supervisor from  
the hospital
DOST group, while that in 
the intervention group was 
89.2%
- There was a non­
significant difference in 
completion rates between 





Appendix 3: Summary and the reasons of excluded studies from this 
review
Y e a r o f publication O bjectives R eason fo r exclusion
1990(Manalo F 
1990)
Examine the treatm ent success by 
using comm unity-based short 
course treatment o f  pulm onary TB
Report only the treatm ent 
outcom es under supervised by 
com m unity health workers 
alone. N ot comparing with other 
alternative DOT
1996(D ickJ 1996) Evaluate the effectiveness o f  the 
group o f  volunteers in enhancing 
adherence o f  notified TB patients 
to  tuberculosis treatment
The main outcome was patient 
adherence to TB treatment. The 
treatm ent success was not given
1996(D ickJ 1996) Describes the perceptions o f  health 
team members regarding the 




M  R 1997)
Assess the treatm ent outcomes by 
using the community health worker 
as patient’s supervisor in phase 1: 
12 months treatment and phase 2: 8 
months oral regime
Report only the treatment 
outcomes under supervised by 
comm unity health workers 
alone. N ot com paring with other 
alternative DOT
1997(Dick J 1997) Describe and evaluate a lay worker 
project designed to enhance the 
effective control o f  tuberculosis in 
a rural/farm  setting
The treatm ent outcom es were 
not given in the report
1997(David W an d  
G eraint 1997)
Exam ine the successful use o f  
voluntary lay people and 
com m unity health  w orkers in the 
delivery o f  com m unity-based DOT
The treatm ent outcom es were 
not given in the report
2001(W alley J.D 
2001)
A ssess the effectiveness o f 
different package for TB treatm ent 
under operational conditions in
Intervention group is mixed 
between sta ff at the HC and 
com m unity health worker
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Pakistan
2001(M anders A .J.E , 
B anerjee  A  et al. 
2001)
M easure adherence to  trea tm en t o f  
patien ts on guardian-based D O T, 
health  centre-based D O T, and in­
patien t D O T  during  the in tensive 
phase o f  treatm ent
The outcom e m easure w as the 
adherence to  TB  trea tm en t
2002(P ungrassam i P 
2 002)
C om pare the trea tm en t ou tcom es 
betw een  tw o D O T  deliveries: 
hospital D O T and fam ily  D O T
N ot com m unity-based  D O T
2 002(B arker R .D  
2002)
Illustrate successes and d ifficu lties 
for the South A frican N ational 
T ubercu losis P rogram m e in a rural 
area
R eport only  the trea tm en t 
ou tcom es under supervised  by 
com m unity  health  w orkers 
alone. N o t com paring  w ith  other 
a lternative D O T
2 0 03(A da tu  F 2003) M easure the effectiveness and 
acceptability  o f  com m unity -based  
TB  care using the D O T  stra tegy  fo r 
TB  control
B efore and A fte r study  but no 
contro l group
2 0 0 3 (M iti S 2003) E valua te  the im plem entation  o f  the  
d irec tly  observed trea tm ent, short- 
course (D O T S) strategy as p a rt o f  
an  ex isting  H IV /A ID S h om e care  
p rogram m e, by  com paring  T B  
trea tm en t outcom es in an 
in tervention  population  
(C hipulukusu  com pound), w here  
im plem entation  o f  the  D O TS 
strategy  is an  in teg ra l part o f  the 
H IV /A ID S  hom e ca re  p rogram m e, 
and  in a  contro l popu la tion  
(T w ap ia  com pound) w ith  d istric t 
T B  services bu t as y e t w ith o u t 
coverage b y  th e  H IV /A ID S  hom e
C om m unity-based  D O T  






Assess the acceptability and 
effectiveness o f  traditional healers 
as supervisors o f  TB treatm ent in 
an existing directly observed 
treatment (DOTS)
The treatm ent outcomes were 
not given in the report
2003(Nyirenda TE, 
Harries A .D et al. 
2003)
Evaluate the impact on the 
Lilongwe district tuberculosis 
programme performance o f  
decentralisation o f TB services, 
including extending the range o f 
options for supervision o f  DOT 
during the initial phase o f  
treatment
-Com pared the treatment 
success between hospitalization 
DO T and other options 
- Involved with HIV/AIDS 
programme
2003(Salaniponi FM, 
Gausi F et al. 2003)
Determine the site o f  DOT during 
the initial phase o f treatm ent and 
the effectiveness o f the new 
regimen
Com pared the treatment 
regimen between 8 m onths and 
6 months o f  the treatment
2004(Senya S 2004) Describe the first community- 
based DOTS contribute to 





(THs) diagnostic and treatm ent 
practices for TB
- Understand health-seeking 
behavior for TB am ongst tribal 
groups
- Evaluate the acceptability o f THs 
to public health workers
- A ssess how  THs can collaborate 
with the TB program me
Qualitative study
2004(Kironde S and 
S 2004)
Describe and evaluate the 
involvem ent o f the tw o TB
The m ain outcom e was not the 
treatm ent success
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oriented NGOs working in the 
Northern Cape province
2005(Escott S 2005) Docum ent the experience o f people 
involved in the community-based 
TB
Qualitative study
2007(0kanurak  K., 
K itayapom  D. et al. 
2007)
To investigate patterns o f  drug 
administration for TB patients and 
to determine whether these patterns 
affect treatment success rates
Com pared the treatm ent success 
Detween health facility based 
DOT with family DOT and self- 
administrated treatment
2008(Egwaga S, 
Range N  et al. 2008)
Assess the burden o f the current 
treatm ent strategy, and opinions on 
a  proposed new strategy where 
patients are able to choose the 
place o f  treatm ent and the 
treatm ent supervisors, and receive 
treatm ent as a daily combination 
tablet
Qualitative study
2009 (W eiguo Xu, 
W ei Lu et al. 2009)
To improve treatm ent outcomes by 
understanding o f  particular barriers 
to  patient’s adherence
This study was to improve the 
patient’s adherence to TB 
treatm ent
2009 (Saidi Egwaga, 
A bdallah M kopi et 
al. 2009)
Com pare the treatm ent outcom es 
for patients who chosen home- 
based DO T treatm ent w ith those 
who chosen health facility-based 
DO T treatm ent
The m ajority o f DOT 
supervisors in the intervention 
were family members (76%)
2010(Sanneh AFNS 
and J I 2010)
Com pare the TB treatm ent and 
outcom es before and after the 
introduction o f  DOTS m edication 
and the perceptions/attitudes o f 
defaulters in the W estern Division 
o f  the Gam bia
This study was to compare the 
treatm ent regim en 3 tim es per 
w eek with daily treatm ent in the 
health clinics. It w asn’t 
compared the DOT approaches 
betw een CD OT and HC-DOT
201 l(A khtar S., Rozi Evaluate W HO defined This study w as compared the
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S. et al. 2011) tuberculosis treatment outcomes 
for patients under directly observed 
treatm ent at a health facility or at 
home DOT in urban Pakistan
treatm ent outcomes between 
health facility-DOT with 
family-based DOT, which the 
DOT watchers were family 
mem bers
2012((David K. 
M afìgiri, Janet W. 
M cG rath et al. 2012)
Examine modified community- 
based DOTS as “proof o f  concept” 
by identifying how the patients’ 
social support system may 
contribute to treatment seeking 
through task shifting in a high 




Appendix 4: Topic guide for the qualitative study
Patient
- How did you know that you had TB?
- What procedures did you take before starting the treatment?
- For what type of DOT are you treated?
- How did you select this treatment?
- Who was your DOT watcher?
- Where did you swallow medicines?
- How often did you go to take medicines with your DOT watcher?
- Did you have any problem during the treatment?
- Have you ever given anything (money, presents) to your DOT 
watcher?
- What do you like about DOT system (or TB treatment) in your 
HC?
- What do you dislike about DOT system in your HC?
- If you will be treated with TB again, would you be happy to be 
treated with the same type of DOT?
- Do you have any suggestions or recommendations to improve the 
DOT system in your HC?
DOT watcher
- What do you do for living?
- What is your education level?
- Why were you selected as a DOT watcher?
- Did you receive any training before started this job?
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- What are your responsibilities as a DOT watcher?
- Where did you see patients taking medicines?
- How often did you see patients?
-What do you do if a patient missed taken medicines?
- What problems do you face since you worked as DOT watcher?
- Are you paid for this job?
- What work related difficulties have you encounted?
- What do you like about implementing CDOT or HC-DOT in your 
village?
- What do you dislike about implementing CDOT or HC-DOT in 
your village?
- What would you recommend to improve CDOT or TB treatment 
in your HC?
- What do you think about the view of people in your village 
regarding the CDOT system?
Staff
-What is your position in this HC?
- How long do you work in this HC?
- What is you education level?
- What are your responsibilities in TB section?
- What do you do if you see a patient suspected with TB?
- What procedures does patient need to take for TB treatment?
- What types of DOT are implemented in this HC?
- Do patients have a choice where they want to be treated?
- Who is the DOT watcher in this HC?
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- How often do patients need to go to see DOT watcher?
- What happens if patient miss the treatment?
- Do you have any TB health promotion in the community?
- What work related difficulties have you encounted?
- What do you think are the strengths of DOT in your HC?
- What do you think are the weaknesses of DOT in your HC?
- What would you recommend to improve DOT or TB treatment in
your HC?
- What do you think of the CDOT approached?
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Appendix 5: Sample size calculation
Sample size estimate for cluster randomization design comparison of two proportion 
N= (Za/2  + ZP)21P,(1 - Pi) +_P2(1 - P?)l [1 + (m  - l)pl 
(P1 - P 2 ) 2
where:
N = required sample size
Za/2 =1.96: the z-score for alpha error, corresponding to the probability with which it is 
desired to be able to conclude that an observed change of size (P2-P1) would not have 
occurred by chance;
Zp = 0.84: the z-score for beta error, corresponding to the degree of confidence with 
which it
is desired to e certain of detecting a change of size (P2-  Pi), if one actually occurred.
Pi = 0.90: the estimated proportion at the time of the first survey
p2 = 0.945: the proportion at some future date such that the quantity
(P2- Pi) is the size of the magnitude of change it is desired to be able to detect
l+(m -l)p = 0.60: design effect which m is number of patients per cluster; m=50 patients
per two year
p= 0.017: Intra-cluster correlation
N=7.84f0.09+0.047)
0.0025
N= 605 patients per each group
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N  a fte r  10%  m issin g  va lu e  = 6 6 5  p a tien ts  p e r g roup  
N = 6 6 5 /2 5 ; N = 2 7  H C s p e r  g roup
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Appendix 6: Flowchart showing flow of selection clusters of HCs in the study
•  We continued with the same method until we got the total 27 clusters of HC for each 
group
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Appendix 8: The information on TB patient for quantitative study
ID Code#........................ date of data collection: DD/............ /MM......... 2008
9. tSR (Province) t..........................................................................
Id . [M n f l jR u n  ( ° D ) : ......................................................................................................................
m. HtWHJftJSfnn (Health center) :..............................................................
6 . iClJ8tMjitfdf1£iifntJ[U]ClJW8}Tlf1 (HC Register#) : ...........................................
g. tCtmgHntSti (Patient’s name) :.........................................................................
e). tfi9 (Sex) t (Male) 2.[M (Female)
tl. ffltlj (Age): .....................................................................................
cf. HlMtngiagm3S (Patient’s address):
t e u s t i s . . .......ÎÎH.................
V
..........................................U J ...........1 W .............. .......... I 8 R ...........n
its ÎSQIÜîfHflJltnCU (Date of start treatment):
l . t t s D D .......... iSMM... .......... /  2 0 0 2 2 . t t s D D . .V ........... /  Î 8  MM... .......... /  2 0 0 3
3 . Î Î 3 D D ..........*/• ../ ÎS MM... .......... /  2 0 0 6 4 . t t s D D . .%s .... /  Î 8  MM... .......... /  2 0 0 7
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90. ÎUÇÎUUîjS (TB Type):
i. fiSitüBMriîgBiaium (bk+) 2. fiSnuaMRHÎgtnsium (bk-)
3 . âSnuütLîrlMn(EP)
99 . tümsdtiîîSüfgnjltnCü (Type of patients):
1. § (New) 2. nnù (Relapse) B. tîmSïïEU (Transferred-in)
4. njltncuîtfntîîcusuü (Defaulter) 5.UnStU (Failure)
6. ÎÎÎJÜ9 (Other).................... 7. nt/JMÎÿnutl (MDR)
9lfl. RîtUÎMÜjtnumSîîîlGÎ (TB Suspect referred by) :
1. HR MU1RUS (DOT watcher in community) 2. 8S£)i3 (Self)
w
3. trtw ntr W 8m n (HC stafl) 4.ttjja5 WSUtmti (Other, please
specify) : ............................................................
9m. [Uif)9yRf5 (Type of DOT) :
1 . M nmtiaj (Hospital DOT) 2 . tiflMSWR (Ambulatory DOT)
3. RIBS! (DOT at Home) 4 . fiRtüMtimaâ (C-DOTS) 5. HSgRH (n0 DOT)
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9 6 .  gfiipH cufrm nju^m uti (d o t  watcher):
l.ymunHiujiiJMSinn (He staff) 2. gn fy (t%  (v iis g )
3.HfiSfi81v3 (neighbor) ^ h n iifm S S  (patient’ family)
9- MHUHTIR (Other, please specify) ....................................
91*. flJStJnjiSfninjltimj (Treatment outcomes): ,
(Cured) 2.umumjnptflnj (Completed)
3.WlU(Died) 4.ttn«utf (Defaulter)
S.UnSttf (Failure) 6. UmsranitLfri (Transferred-out)
G)S. nn/imtilijl miMt^nnttnwpyWBgSBl (Note/observation during the data
collection):................................................................................
pHfUBSBimffim (Collected by):...
tflfitfliBI /Itf (Signature/date)......... ITIRtfUSl (Signature/date) /I ti........
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Appendix 9: Check list on TB case-finding
1. tflITîoHn/liüftJSiTIfl ( H.C name )
2. BBSpt^tìatRUtìllBUQtìnUBHiUinJMSÌTimBS ( Population ).,
3. GSsgnàSitaattìnìtnsLMiìcìiìmtsIoaanjjtBMSfnmai <tb case-fmding)









Appendix 10: In-depth interview guide for staff
I understand that you are a staff at this HC and have been working for TB section; 
especially you have a lot of experiences in TB treatment. In my project, I would like to 
find out what were your experiences in doing this job, and to explore the strengths and 
weaknesses of implementing DOT as well as CDOT system in your HC. I would like to 
ask you some questions regarding the TB implementation in this HC. You have right to 
not answer any questions which you do not feel comfortable. If you don’t understand any 
questions please let me know, I will explain you more; and if you want to stop during the 
interview, please let me know then we can continue when you feel comfortable to 
continue the interview. If you are agree to participate in this interview, please sign the 
consent form then we can continue the interview.
I Back ground information
1. What is your name?
2. What is your current position in this HC?
Prompt: What degree qualification in medical field do you hold?
Prompt: Could you tell me about your works and job descriptions in TB section? 
Prompt: How many people work in TB section with you?
II Information about DOT treatment
1. Could you tell me about the TB treatment in your HC?
Prompt: What do you do when suspect patient come to see you?
Prompt: Where does the sputum test need to be done?
Prompt: In average how many days when the sputum results return to the HC? 
Prompt: What do you do when the test confirm patient having TB?
2. What kinds of DOT treatment implement in your HC?
Prompt: Where do patients take medicines during the whole treatment?
Prompt: Do patients have a choice to choose their own treatment?
279
A: For staff at HC-DOT
1. Could you tell me why patients need to take medicines with staff at the HC?
Prompt: Does it apply to all patients?
Prompt: Who are the exceptional cases? What kinds of criteria that applied to
those cases?
2. For patients take medicines at the HC, how often do they need to come to the HC? 
Prompt: What happens during the weekend or national holiday?
Prompt: What happens if patients miss their treatment?
Prompt: What do you do if you are busy?
3. How long do patients require to come to take medicines at the HC?
Prompt: What happens after the requirement?
Prompt: Do you give them a choice that where they want to treat after it?
Prompt: How do you follow-up with them?
4. For those are exceptional cases, where do patients take medicines?
Prompt: How do you manage with those patients?
Prompt: How do you select their DOT watchers?
Prompt: How often do you see them?
5. Could you tell me what do you or other staff do every time patients come to take 
medicines at the HC?
Prompt: Do you need to appoint one staff for one individual patient?
6. How do patients know they are completely cured?
Prompt: Do the sputum tests require for all patients?
Prompt: How do patients know when they need to come for the sputum control? 
Prompt: What happens when patients do not come for the sputum test?
7. I would like to ask you about the TB program in your HC. Do you have any TB 
health promotion programs in communities cover by your HC?
Prompt: What are those programs?
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Prompt: Who does support those programs?
B: For staff at CDOT
1. What kinds of DOT implement in your HC?
Prompt: What kinds of criteria for patients selected to be CDOT and patients 
selected to be HC-DOT?
Prompt: Do patients have a choice to select where they want to treat?
2. For patients treat with HC-DOT, where do they need to take medicines?
Prompt: Who is their DOT watcher?
Prompt: How often do they need to come to the HC?
Prompt: What do you or other staff do during they come to take medicines with 
you?
Prompt: What happens during the weekend or national holiday? Where do they 
take medicine?
Prompt: What do you do if you are busy?
Prompt: How long do patients need to come to take medicines at the HC?
Prompt: What happens after it?
Prompt: What happens when patients miss their treatment?
3. For patients treat with CDOT, where do they take medicines?
Prompt: Who is their DOT watcher?
Prompt: Do patients have the choice to select their own DOT watcher?
Prompt: How do you arrange for CDOT patients such as arrangement to collect 
medicines?
Prompt: How often do you need to see them?
Prompt: Why do you need to see them?
Prompt: How do you follow-up with them?
8. How do patients know they are completely cured?
Prompt: Do the sputum tests require for all patients?
Prompt: How do patients know when they need to do the sputum control?
Prompt: What happens when patients do not come for the sputum test?
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4. I would like to ask you about the TB program in your HC. Do you have any TB 
health promotion programs in communities cover by your HC?
Prompt: What are those programs?
Prompt: Who does support those programs?
DOT watcher
1. Now I would like to ask you about the DOT watcher in your HC. How do you select 
people to be a DOT watcher?
Prompt: What kinds of training do you provide them?
Prompt: What are their responsibilities in TB treatment?
2. How do you organize DOT watchers and patients such as how many patients
supervise per one DOT watcher?
Prompt: How do you follow-up their works?
Prompt: What would you do if they have any problems during their works?
3. Who does support the CDOT program in your HC?
Prompt: What kinds of support?
Ill Incentives 
Patients
1. In your HC, do patients need to pay for the TB treatment?
2. Do TB patients in your HC receive any support during the treatment?
Prompt: What are those supports?
Prompt: Does it apply to all TB patients?
Staff
1. Do you receive any incentives during your work in TB and DOT treatment in your 
HC?
Prompt: Who provides this support?
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DOT watcher
1. Does DOT watcher receive any incentive during their works?
Prompt: What types of incentive?
Prompt: Who provides these supports?
IV Strengths and weaknesses of DOT
From this question, I would like to ask you about your experiences and your ideas for 
implementing DOT in your HC that you have been faced during your works.
1. How do you feel about your works as TB staff in this HC?
2. Since you have a lot experiences in this HC relating to TB and DOT treatment, what 
difficulties have you faced?
Prompt: How do you deal with various difficulties that you mentioned?
3. What do you think the key factors or reasons for successful implementation of DOT 
program at your HC?
Prompt: Has the health centre archived its targets in the implementation of DOT 
program?
4. What would you recommend to improve the DOT or TB program in your HC?
V Perception of implementing CDOT and HC-DOT
A HC-staff
1. Have you ever heard about CDOT program?
Prompt: What do you think about this program?
2. In your opinion, how do you think the difference between CDOT and HC-DOT? 
Prompt: Would you implement this program in your HC in the future?
3. Is there anything else would you like to add?
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B CDOT staff
1. I understand that your HC implement both for CDOT and HC-DOT, what do you 
think about these two programs in term of their structures and their differences?
2. In your opinion, between these two programs which one is easier to manage? 
Prompt: Why?
Prompt: Which one is produced better results?
Prompt: Why?
3. Is there anything else would you like to add?
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I understand that you have assigned to be a treatment supporter (or DOT watcher) for TB 
treatment. In my project, I would like to find out what were your experiences in doing this 
job, and to explore the strengths and weaknesses of implementing CDOT as well as DOT 
system in your HC. I would like to ask you some questions regarding the TB 
implementation in this HC. You have right to not answer any questions which you do not 
feel comfortable. If you don’t understand any questions please let me know, I will explain 
you more; and if you want to stop during the interview, please let me know then we can 
continue when you feel comfortable to continue the interview, 
participate in this interview, please sign the consent form then 
interview.
I Background information
1. What is your name?
Prompt: Are you married?
Prompt: Do they live with you?
2. What do you do for living?
II Information about CDOT
1. I learned that you are selected to be a DOT watcher in your village, what it is like to 
be a DOT watcher?
Prompt: How did you become to be a DOT watcher in the first place?
2. Have you received any training before started this job?
Prompt: How do you feel about those training?
3. Could you tell me about your jobs as a DOT watcher?
Prompt: What are your responsibilities in this job?
Prompt: How your responsibilities with staff at the HC?
Appendix 11: In-depth interview guide for DOT watcher
If you are agree to 
we can continue the
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4. Could you describe what actions do you usually take after a patient be assigned to 
you?
Prompt: Who is arranged to collect medicines for patients?
Prompt: What do you do if the patient has a problem?
Prompt: What do you do if patient doesn’t come for medicines?
Prompt: What do you do if it runs out medicines?
Prompt: What do you do if you are busy?
5. Could you tell me what do you do every time the patient comes to take medicines 
with you?
Prompt: Do you have a choice to select patient to supervise?
6. How do you know if patients who you have b een  supervised are cured?
Prompt: Do patients need to check their sputum?
Prompt: How do you arrange the sputum control test?
7. Have you ever provided any support besides watching patient taking medicines?
Prompt: What are those?
g. How do you feel to have a contact with TB patients everyday?
Prompt: How about your wife or your children feel to have a contact with TB 
patient at your house?
I ll Incentive
1. Since you involve as a DOT watcher, do you get pay for this job?
Prompt: What do you receive from this job?
Prompt: Who give you this su p p o r t?
2. What do you think about those incentives?
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IV Strengths and weaknesses of implementing CDOT
From this question, I would like to ask you about your experiences and your ideas for 
implementing DOT, especially CDOT in your village that you have been faced since you 
have became a DOT watcher.
1. Since you have become a DOT watcher, what are works related difficulty that have 
encounter?
Prompt: What do you deal with those problems?
Prompt: Do you think those problems have been solved now?
2. What do you like about implementing CDOT in your village?
Prompt: Do you think those points achieved the goals which people in your 
village want?
3. What do you dislike about implementing CDOT in your village?
4. What would you recommend to improve CDOT or TB treatment in your IIC?
IV Perception of implementing CDOT
1. How do you feel to be a DOT watcher?
Prompt: What is your view about this job?
Prompt: What do you like about this job?
2. What are the views of people in your community regarding the CDOT system?
Prompt: What do they like about this implementation?
Prompt: What they don’t like about it?
3. Is there anything else you would like to add?
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Appendix 12: In-depth interview guide for patient
I understand that you have been treated for TB in the past. In my project, I would like to 
find out what you think of the TB treatment you have been experienced and how it could 
be improved. I would like to ask you some questions regarding the TB treatment in this 
HC. You have right to not answer any questions which you do not feel comfortable. If 
you don’t understand any questions please let me know, I will explain you more; and if 
you want to stop during the interview, please let me know then we can continue when you 
feel comfortable to continue the interview. If you are agree to participate in this interview, 
please sign the consent form then we can continue the interview.
I Background information
1. What is your name?
Prompt: Are you married?
Prompt: Do you have any children?
Prompt: Are they living with you?
2. What do you do for living?
3. Do you remember when did you have the TB treatment?
Prompt: How long you were on the treatment?
4. Where do you live?
Prompt: How far from your house to the HC?
II Information about DOT
1. Could you tell me how did you find out about your disease at the first place?
Prompt: Who referred you to go to the HC?
2. What did staff do when you told them about your symptoms?
Prompt: What kind of tests you took?
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3. What happened after you took the tests?
Prompt: How long did it take to get the results back?
4. When you knew about your disease, how did you feel?
5. What procedures did you need to take for the treatment?
Prompt: Who told you?
6. Where did you have the treatment?
Prompt: Who was your DOT watcher?
Prompt: How did you select this treatment?
Prompt: Did you have a choice to select where you wanted to treat?
For patient treated with HC-DOT
1. Where did you take medicines?
Prompt: Who was your DOT watcher?
Prompt: How long did you take medicines with your DOT watcher?
Prompt: What happened after it?
2. How often did you go to take medicines with your DOT watcher?
Prompt: What happened during the weekend or national holiday?
Prompt: What happened if your DOT watcher was busy?
Prompt: What happened if you were busy?
3. Could you describe what happened every time you went to take medicines with your 
DOT watcher?
Prompt: Do you know why you have to take medicines with your DOT watcher? 
Prompt: How were you received by your DOT watcher?
Prompt: Have your DOT watcher ever asked you for anything during the 
treatment?
4. Did you have any problems during the treatment?
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Prompt: What were those?
Prompt: How did you address those problems?
5. How do you feel after you finished the treatment?
Prompt: How do you know you are cured?
Prompt: Did you have your sputum check before finished the treatment?
6. Can you tell me during the treatment; have you ever received any supports?
Prompt: What were those?
Prompt: who else supported for your treatment besides your DOT watcher?
For patient treated with CDOT
1. Where did you take medicines?
Prompt: Who was your DOT watcher?
Prompt: How did you select your DOT watcher?
2. How long did you take medicines with your DOT watcher?
Prompt: What happened after it?
Prompt: How often did you go to take medicines with your DOT watcher?
Prompt: What happened if you were busy?
Prompt: What happened if your DOT watcher was busy?
3. Could you tell me about the arrangement between you and your DOT watcher 
including medicines collection from the HC?
Prompt: Who was arranging the place where you needed to take medicines? 
Prompt: How far from your house to the place where you took medicines?
Prompt; How did you get there?
4. Could you describe what happened every time you went to take medicines with your 
DOT watcher?
Prompt: Do you know why you needed to take medicines with your DOT 
watcher?
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Prompt: How were you received by your DOT watcher?
Prompt: Have your DOT watcher ever asked you for anything during the 
treatment?
5. How did you feel about taking medicines given by a DOT watcher instead of staff at
HC?
6. Did you have any problems during the treatment?
Prompt: What were those?
Prompt: How did you address those problems?
7. How often did you see staff at the HC?
Prompt: Why did you see them?
8. How do you feel after you finished the treatment?
Prompt; How do you know you are cured?
Prompt: Did you have your sputum check before finished the treatment?
9. Can you tell me during the treatment; have you ever received any supports?
Prompt: What were those?
Prompt: who else supported for your treatment besides your DOT watcher?
I ll Strengths and weaknesses of implementing CDOT and HC-DOT
1. Are you satisfied with the treatment which you have treated?
Prompt: Why?
2. From your experiences, how do you feel about the treatment that you received?
Prompt: What do you like?
Prompt: What you don’t like?
Prompt: What should be improved?
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For HC-DOT patient
3. Have you ever heard about CDOT?
Prompt: What do you think about this treatment?
Prompt: What do you think about the view of your village towards CDOT? 
Prompt: How do you feel about taking medicines given by someone rather than 
staff at the HC?
4. In the future if your family member or your friend has to treat with TB, what kind of 
treatment you would recommend them?
Prompt: Why?
5. Is there anything you would like to add?
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Appendix 13: Consent form for participants interview in the study
Informed consent form is for






This informed Consent Form has two parts:
Unformed Sheet (to share information about the study with you)
2.Certificate of Consent (for signature if you agree that you may participate)
You will be given a copy of the full Informed Consent Form
Part I. Information sheet
You understand that you are being asked to take part in a research conducted by The 
London School of Hygiene and Tropical Medicine and the National Tuberculosis Control 
Program. Your participation is voluntary and your employer will not know whether or not 
you decide to participate so your job will not be affected in any way by participating in 
the study.
PURPOSE OF THE STUDY
The purpose of this study is to evaluate the structured differences between community 
and health centre-based DOT, to evaluate the treatment success between these two 
programme and especially to assess their strengths and weaknesses. The study will ask for 
your opinion and advice about your treatment experience with these approaches and how 
we can improve TB treatment with DOT services in this area.
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PROCEDURES
If you volunteer to participate in this study, we would like you to participate in an 
interview. The maximum length of time of your participation in this study will be about 
1-1.5 hours. If you so wish, you may withdraw from the study at any time.
You will be interviewed in private where no one else can hear the questions or your 
answers. We will be either use tape recorder to record your answers and also write down 
your answers. The interview will take place here, at your place of work or at the place 
that is convenient for you.
POTENTIAL RISKS AND DISCOMFOTS
This study involves the collection of information and your opinions; there may be some 
discomfort, in responding to questions about disclosure of information and your 
expression of opinions. If some of the questions are found to be discomforting to you, you 
can stop any time.
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY
By telling us all about information you know and your shared experiences, we will learn 
about the advantage and disadvantage of implementing community and health centre- 
based DOT. As a result, this will help the NTP and the Ministry of Health in Cambodia to 
develop and improve TB treatment service in your area as well as in the whole country. 
You will benefit from this program and so does your community.
CONFIDENTIALITY
We will follow the strictest rules of privacy protection to insure your confidentiality. No 
one will have any way to connect your name with your results from the interviews
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind. You may also refuse to 
answer any questions you do not want to answer and still remain in the study.
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IDENTIFICATION OF INVESTIGATORS




Part II. Certificate of consent
I have read the foregoing information, or it has been read to me. I have been satisfactorily 
informed about this study with its possible risks and benefits. I have had the opportunity 
to ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntary to participate as a subject in this study and understand 
that I have the right to withdraw from the study at any time without in any way affecting 
my further medical care. I understand that I am free to quit at any time, even after signing 
this form.
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